<SEC-DOCUMENT>0001493152-22-011829.txt : 20220502
<SEC-HEADER>0001493152-22-011829.hdr.sgml : 20220502
<ACCEPTANCE-DATETIME>20220502171405
ACCESSION NUMBER:		0001493152-22-011829
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20220429
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220502
DATE AS OF CHANGE:		20220502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		22883197

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ABEO="http://abeonatherapeutics.com/20220429">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_ABEO_abeonatherapeutics.com_20220429 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20220429_20220429 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000318306 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityCentralIndexKey">0000318306</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abeo-20220429.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-29to2022-04-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-29</xbrli:startDate>
        <xbrli:endDate>2022-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20220429__20220429_z1m1KdB5X5ea"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO SECTION 13 OR 15(D) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_908_edei--DocumentPeriodEndDate_c20220429__20220429_zAh8JhGjHwC4"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April 29, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20220429__20220429_zoAB7VLwqVyc"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityRegistrantName">ABEONA
THERAPEUTICS INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220429__20220429_zsbqI9El9WS3"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20220429__20220429_zhmCge8ylH5c"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityFileNumber">001-15771</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20220429__20220429_zx3SRc6k48m"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityTaxIdentificationNumber">83-0221517</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20220429__20220429_zYZYKvccKDni"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityAddressAddressLine1">1330
Avenue of the Americas</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20220429__20220429_z4VmtgOPjvOc"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityAddressAddressLine2">33rd Floor</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20220429__20220429_zBTnQvlUHtD9"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20220429__20220429_zrra0Avczlae"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20220429__20220429_zLG1Y7quChv"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, of Principal Executive Offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--CityAreaCode_c20220429__20220429_z5b4944sBE3d"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:CityAreaCode">(646)</ix:nonNumeric></span>
<span id="xdx_90C_edei--LocalPhoneNumber_c20220429__20220429_zyMJ5uGKXffe"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:LocalPhoneNumber">813-4701</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--WrittenCommunications_c20220429__20220429_zfav10v68xS3"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--SolicitingMaterial_c20220429__20220429_z6xt6ZXRxzoe"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementTenderOffer_c20220429__20220429_zw03mt94f8uh"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20220429__20220429_zIgA34Nv1O7d"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act: </b>None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20220429__20220429_zHu1mZo2d3cd"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:Security12bTitle">Common
    stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20220429__20220429_zvCGLVat9fil"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" name="dei:TradingSymbol">ABEO</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_900_edei--SecurityExchangeName_c20220429__20220429_zAon3OA4yXGe"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Markets</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20220429__20220429_zlXUOucXYRs2"><ix:nonNumeric contextRef="From2022-04-29to2022-04-29" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span>
Emerging growth company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2022, Abeona Therapeutics Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Securities Purchase Agreement
(the &#8220;Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Investors&#8221;), pursuant to which the
Company agreed to issue and sell, in a private placement (the &#8220;Offering&#8221;), 1,000,006 shares of the Company&#8217;s Series
A Convertible Redeemable Preferred Stock, par value $0.01 per share (the &#8220;Series A Preferred Stock&#8221;), and 250,005
shares of the Company&#8217;s Series B Convertible Redeemable Preferred Stock, par value $0.01 per share (the &#8220;Series B Preferred
Stock,&#8221; and together with the Series A Preferred Stock, the &#8220;Preferred Stock&#8221;), at an offering price of $19.00 per
share, representing a 5% original issue discount (&#8220;OID&#8221;) to the stated value of $20.00 per share, for gross proceeds of approximately
$25.0 million in the aggregate for the Offering, before the deduction of discounts, fees and offering expenses. The shares of Preferred
Stock will be convertible, at a conversion price of $0.45 per share (subject in certain circumstances to adjustments), into shares of
the Company&#8217;s common stock, $0.01 per share (the &#8220;Common Stock&#8221;), at the option of the holders and, in certain circumstances,
by the Company. The Purchase Agreement contains customary representations, warranties and agreements by the Company and customary
conditions to closing. The Offering closed on May 2, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to call a special meeting of
stockholders to consider an amendment (the &#8220;Amendment&#8221;) to the Company&#8217;s Restated Certificate of Incorporation
(the &#8220;Charter&#8221;), to effect a reverse stock split of the outstanding shares of Common Stock by a ratio to be determined by
the Board of Directors of the Company within a range to be specified in the proposal put to the stockholders for approval of the Amendment
(the &#8220;Reverse Stock Split&#8221;). The Investors have agreed in the Purchase Agreement to not transfer, offer, sell, contract to
sell, hypothecate, pledge or otherwise dispose of the shares of the Preferred Stock until the Reverse Stock Split, to vote the shares
of the Series A Preferred Stock purchased in the Offering in favor of such Amendment and to vote the shares of the Series B Preferred
Stock purchased in the Offering in a manner that &#8220;mirrors&#8221; the proportions on which the shares of Common Stock (excluding
any shares of Common Stock that are not voted) and Series A Preferred Stock are voted on the Reverse Stock Split. The Reverse Stock Split
requires the approval of the majority of the votes associated with our outstanding stock entitled to vote on the proposal. Because the
Series B <span style="background-color: white">Preferred </span>Stock will automatically and without further action of the purchaser
be voted in a manner that &#8220;mirrors&#8221; the proportions on which the shares of Common Stock (excluding any shares of Common Stock
that are not voted) and Series A <span style="background-color: white">Preferred</span> Stock are voted on the Reverse Stock Split, abstentions
by common stockholders will not have any effect on the votes cast by the holders of the Series B Preferred Stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the Company will file certificates of designation (the &#8220;Certificates of Designation&#8221;) with the
Secretary of the State of Delaware designating the rights, preferences and limitations of the shares of Series A Preferred Stock and
Series B Preferred Stock. The Certificate of Designation for the Series B Preferred Stock will provide, in particular, that the Series
B Preferred Stock will have no voting rights other than the right to vote as a class on certain specified matters and the right to cast
15,000 votes per share of Series B Preferred Stock on the Reverse Stock Split proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of Preferred Stock will be entitled to
dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred Stock is convertible,
at the option of the holders and, in certain circumstances, by the Company, into shares of Common Stock at a conversion price of
$0.45 per share. The conversion price can be adjusted pursuant to the Certificates of Designation for stock dividends and stock splits,
subsequent rights offering, pro rata distributions of dividends or the occurrence of a fundamental transaction (as defined in the applicable
Certificate of Designation). The holders of the Series A and Series B preferred stock have the right to require the Company to redeem
their shares of preferred stock for cash at 105% of the stated value of such shares commencing after the earlier of the receipt of
stockholder approval of the Amendment and 60 days after the closing of the issuances of the Series A and Series B preferred
stock and until 90 days after such closing. The Company has the option to redeem the Series A preferred stock for cash at 105% of the
stated value commencing after the 90<sup>th</sup> day following the closing of the issuance of the Series A preferred stock, subject
to the holders&#8217; rights to convert the shares prior to such redemption.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds of the Offering will be held in an escrow account, along with the additional amount that would be necessary to fund the 105%
redemption price until the expiration of the redemption period for the Preferred Stock, as applicable, subject to the earlier payment
to redeeming holders. Upon expiration of the redemption period, any proceeds remaining in the escrow account will be disbursed
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Offering, on May 2, 2022, the Company and the Investors entered into a Registration Rights Agreement (the
&#8220;Registration Rights Agreement&#8221;), pursuant to which the Company is required to file a registration statement with the Securities
and Exchange Commission to register for resale the shares that are issued upon the potential conversion of shares of Preferred Stock.
The registration statement will be filed with the Securities and Exchange Commission on or before the later of 10 calendar days following
the date of the stockholder meeting held to seek approval of the Amendment and the 70<sup>th </sup>calendar day following the date of
the Registration Rights Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Offering, the Company agreed to pay A.G.P./Alliance Global Partners (the &#8220;the Placement Agent&#8221;) an aggregate
cash fee equal to $1.0 million and to reimburse the Placement Agent for certain of its expenses in an amount not to exceed $100,000,
as well as nonaccountable out-of-pocket expenses not to exceed $10,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Purchase Agreement, for a period of 60 days from the date of the Purchase Agreement, the Company and its subsidiaries are prohibited
from issuing or entering into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common
stock equivalents. Further, from the date of the Purchase Agreement until the earlier of (A) the date of which all shares of the Preferred
Stock are redeemed in accordance with their terms and (B) the date that is 180 days following the Reverse Stock Split Date, the Company
is be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common
stock or common stock equivalents (or a combination of units thereof) involving a Variable Rate Transaction, as defined in the Purchase
Agreement. Also, until the Reverse Stock Split Date, neither the Company nor any subsidiary may make any issuance whatsoever of common
stock or common stock equivalents. The above limitations on issuances of stock under the Purchase Agreement do not apply to Exempt Issuances
as defined in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summaries of the Purchase Agreement, the Registration Rights Agreement, and Certificates of Designation do not purport to be
complete and are subject to, and qualified in their entirety by, forms of such documents attached as Exhibits 10.1, 10.2, 3.1, and 3.2,
respectively, to this Current Report on Form 8-K, which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of
specific dates, were solely for the benefit of the parties to the agreements and are subject to limitations agreed upon by the contracting
parties. Accordingly, the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding
the terms of the Purchase Agreement and not to provide investors with any other factual information regarding the Company or its business
and should be read in conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the Securities
and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.03. Material Modifications to Rights of Security Holders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disclosure required by this Item and included in Item 1.01 of this Current Report is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The disclosure required by this Item and included
in Item 1.01 of this Current Report is incorporated herein by reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a press release announcing the Offering on April 29, 2022. A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-1.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Redeemable Preferred Stock</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-2.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Redeemable Preferred Stock</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement between Abeona Therapeutics Inc. and the investors thereto, dated April 29, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">Form of Registration Rights Agreement by and among Abeona Therapeutics Inc. and the investors named therein, dated April 29, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release of Abeona Therapeutics Inc. dated April 29, 2022, announcing the pricing of the Offering</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
                                            Therapeutics Inc.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 2, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brendan M. O&#8217;Malley</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Brendan M. O&#8217;Malley</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Senior Vice President, General Counsel</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZi00q3XRpURGrSCniNthRgm2mTOJPj+QtTVvEYWAY3vveE2ImNrQ2DTKcl2UBFbZdoz1CiVdktBcMjny7yyDcEm/GedbWj+8PzCkwGJh0rhY6CKP1aRzWGcg0lipOElAyW6Rw3Ito0HOyV1Oj9UY3oG0NR6aODXrN/ZRQ6TdZavux6oTsDNkM1FxO8gcSqRI40FO/iO8OiiIX0WycSGyYHt1Q83CeWlg12IYuN6H/jb4ULElD -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABEONA
THERAPEUTICS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF DESIGNATION OF PREFERENCES, </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIGHTS
AND LIMITATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
<FONT STYLE="text-transform: uppercase">a </FONT>CONVERTIBLE REDEEMABLE PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">PURSUANT
TO SECTION 151 OF THE </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">delaware
GENERAL CORPORATION LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Joseph Vazzano, does hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">He
    is the Chief Financial Officer of Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation is authorized to issue 2,000,000 shares of preferred stock, none of which have been issued.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following resolutions were duly adopted by the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Restated Certificate of Incorporation of the Corporation (the &ldquo;Certificate of Incorporation&rdquo;), provides for a class of
its authorized stock known as preferred stock, consisting of 2,000,000 shares, $0.01 par value per share, issuable from time to time
in one or more series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Board of Directors is authorized by resolution to provide for the issuance of preferred stock in one or more series, and to establish
from time to time the number of shares to be included in each such series, and to fix the designation, powers, privileges, preferences
and relative participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations or
restrictions thereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
it is the desire of the Board of Directors, pursuant to its authority as described above, to fix the rights, preferences, restrictions
and other matters relating to a series of the preferred stock, which shall consist of 1,000,006 shares of the preferred stock which the
Corporation has the authority to issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of preferred stock to be designated
&ldquo;Series A Convertible Redeemable Preferred Stock&rdquo; and does hereby fix and determine the designation, powers, privileges,
preferences and relative participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations
or restrictions thereof as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. For the purposes hereof, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Alternate
Consideration</U>&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Amendment</U>&rdquo;
means the amendment to the Corporation&rsquo;s Certificate of Incorporation to, after the date hereof, effect the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Authorized
Stockholder Approval</U>&rdquo; means approval of the Amendment by the holders of a majority in voting power of the then outstanding
shares of capital stock of the Corporation entitled to vote on the matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall have the meaning set forth in Section 6(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Buy-In</U>&rdquo;
shall have the meaning set forth in Section 6(c)(iv).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Change
of Control Transaction</U>&rdquo; means the occurrence after the date hereof of any of (a) an acquisition by an individual or legal entity
or &ldquo;group&rdquo; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal
or beneficial ownership of capital stock of the Corporation, by contract or otherwise) of in excess of 33% of the voting securities of
the Corporation (other than by means of the issuance, sale, conversion or exercise of Series A Preferred Stock or Series B Preferred
Stock), (b) the Corporation merges into or consolidates with any other Person, or any Person merges into or consolidates with the Corporation
and, after giving effect to such transaction, the stockholders of the Corporation immediately prior to such transaction own less than
66% of the aggregate voting power of the Corporation or the successor entity of such transaction, (c) the Corporation (and all of its
Subsidiaries, taken as a whole) sells or transfers all or substantially all of its assets to another Person and the stockholders of the
Corporation immediately prior to such transaction own less than 66% of the aggregate voting power of the acquiring entity immediately
after the transaction, (d) a replacement at one time or within a one year period of more than one-half of the members of the Board of
Directors which is not approved by a majority of those individuals who are members of the Board of Directors on the Original Issue Date
(or by those individuals who are serving as members of the Board of Directors on any date whose nomination to the Board of Directors
was approved by a majority of the members of the Board of Directors who are members on the Original Issue Date), or (e) the execution
by the Corporation of an agreement to which the Corporation is a party or by which it is bound, providing for any of the events set forth
in clauses (a) through (d) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Series A Preferred Stock pursuant to Section 2.1 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto and all conditions precedent to (i) each Holder&rsquo;s obligations to pay the Subscription Amount and (ii) the Corporation&rsquo;s
obligations to deliver the Series A Preferred Stock have been satisfied or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the Corporation&rsquo;s common stock, $0.01 par value per share, and stock of any other class of securities into
which such securities may hereafter be reclassified, converted or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Amount</U>&rdquo; means the Stated Value at issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 6(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A Preferred Stock
in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Escrow
Agreement</U>&rdquo; means the escrow agreement to be entered into concurrently with the Purchase Agreement, by and among the Corporation,
Wilmington Trust, National Association, and the other party thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Equity
Conditions</U>&rdquo; means, during the period in question, (a) the Corporation shall have paid all liquidated damages and other amounts
owing to the applicable Holder in respect of the Series A Preferred Stock, (b)(i) there is an effective registration statement pursuant
to which either (A) the Corporation may issue Conversion Shares or (B) the Holders are permitted to utilize the prospectus thereunder
to resell all of the shares of Common Stock issuable pursuant to the Transaction Documents (and the Corporation believes, in good faith,
that such effectiveness will continue uninterrupted for the foreseeable future), (ii) all of the Conversion Shares issuable pursuant
to the Transaction Documents (and shares issuable in lieu of cash payments of dividends) may be resold pursuant to Rule 144 without volume
or manner-of-sale restrictions or current public information requirements as determined by the counsel to the Corporation as set forth
in a written opinion letter to such effect, addressed and reasonably acceptable to the Transfer Agent and the affected Holder, or (iii)
all of the Conversion Shares may be issued to the Holder pursuant to Section 3(a)(9) of the Securities Act and immediately resold without
restriction, (c) the Common Stock is trading on a Trading Market and all of the shares of Common Stock issuable upon conversion of the
Series A Preferred Stock are listed or quoted for trading on such Trading Market (and the Corporation believes, in good faith, that trading
of the Common Stock on a Trading Market will continue uninterrupted for the foreseeable future), (d) there is a sufficient number of
authorized, but unissued and otherwise unreserved, shares of Common Stock for the issuance of all of the shares then issuable pursuant
to the Transaction Documents, (e) Authorized Stockholder Approval shall have been received and be effective, (f) the issuance of the
shares in question to the applicable Holder would not violate the limitations set forth in Section 6(d) herein, (g) <FONT STYLE="font-weight: normal; color: Black">the
shares of Common Stock have traded on the applicable Trading Market during a consecutive ten (10) day period at an average market price
per share greater than $2.00 (as adjusted for stock splits) and the average daily trading volume during such period is equal to or greater
than $2,000,000, (h)</FONT> there has been no public announcement of a pending or proposed Fundamental Transaction or Change of Control
Transaction that has not been consummated, (i) the applicable Holder is not in possession of any information provided by the Corporation,
any of its Subsidiaries, or any of their officers, directors, employees, agents or Affiliates, that constitutes, or may constitute, material
non-public information and (j) the Corporation shall have duly honored all conversions scheduled to occur or occurring by virtue of one
or more Notices of Conversion of the applicable Holder on or prior to the dates so requested or required, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Forced
Conversion Date</U>&rdquo; shall have the meaning set forth in Section 8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Forced
Conversion Notice</U>&rdquo; shall have the meaning set forth in Section 8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Forced
Conversion Notice Date</U>&rdquo; shall have the meaning set forth in Section 8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Fundamental
Transaction</U>&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
shall have the meaning given such term in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liquidation</U>&rdquo;
shall have the meaning set forth in Section 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Mandatory
Conversion</U>&rdquo; shall have the meaning set forth in Section 8(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Mandatory
Conversion Date</U>&rdquo; shall have the meaning set forth in Section 8(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Notice
of Conversion</U>&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Original
Issue Date</U>&rdquo; means the date of the first issuance of any shares of the Series A Preferred Stock regardless of the number of
transfers of any particular shares of Series A Preferred Stock and regardless of the number of certificates which may be issued to evidence
such Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Preferred Stock Purchase Agreement, dated as of April 29, 2022, among the Corporation and the original
Holders, as amended, modified or supplemented from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reverse
Stock Split</U>&rdquo; means the reverse stock split of the Corporation&rsquo;s Common Stock that is effected by the Corporation&rsquo;s
filing of the Amendment with and acceptance by the Secretary of State of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reverse
Stock Split Date</U>&rdquo; means the date on which the Amendment to effectuate the Reverse Stock Split is filed and accepted by the
Secretary of State of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
A Preferred Stock</U>&rdquo; shall have the meaning set forth in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
B Preferred Stock Certificate of Designation</U>&rdquo; means the Certificate of Designation of Preferences, Rights and Limitations of
the Series B Convertible Redeemable Preferred Stock of the Corporation, dated as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Share
Delivery Date</U>&rdquo; shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stated
Value</U>&rdquo; shall have the meaning set forth in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; shall mean, as to each Holder, the aggregate amount to be paid for the Series A Preferred Stock purchased pursuant
to the Purchase Agreement as specified below such Holder&rsquo;s name on the signature page of the Purchase Agreement and next to the
heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Corporation as set forth on <U>Schedule 3.1(a)</U> of the Purchase Agreement and shall, where applicable,
also include any direct or indirect subsidiary of the Corporation formed or acquired after the date of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Successor
Entity</U>&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Certificate of Designation, the Series B Preferred Stock Certificate of Designation, the Purchase Agreement,
the Registration Rights Agreement, the Escrow Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated pursuant to the Purchase Agreement, in each case as amended, modified or supplemented
from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust Company, and any successor transfer agent of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Designation, Amount and Par Value</U>. The series of preferred stock shall be designated as &ldquo;Series A Convertible Redeemable
Preferred Stock&rdquo; (the &ldquo;<U>Series A Preferred Stock</U>&rdquo;) and the number of shares of such series shall be <B>1,000,000
</B>(which shall not be subject to increase without the written consent of the holders of a majority of the then outstanding shares of
the Series A Preferred Stock (each, a &ldquo;<U>Holder</U>&rdquo; and collectively, the &ldquo;<U>Holders</U>&rdquo;)). Each share of
Series A Preferred Stock shall have a par value of $0.01 per share and a stated value equal to $20.00 (the &ldquo;<U>Stated Value</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Dividends</U>. Except for stock dividends or distributions for which adjustments are to be made pursuant to Section 7, Holders
shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock
basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares
of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid on shares
of Series A Preferred Stock. The Corporation shall not pay any dividends on the Common Stock unless the Corporation simultaneously complies
with this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Voting Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
For purposes of determining the presence of a quorum at any meeting of the stockholders of the Corporation at which the shares of Series
A Preferred Stock are entitled to vote and the voting power of the shares of Series A Preferred Stock, each holder of outstanding shares
of Series A Preferred Stock shall be entitled to a number of votes equal to the number of shares of Common Stock into which such shares
of Series A Preferred Stock are then convertible, disregarding, for such purposes, any limitations on conversion set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Except as otherwise required by the Delaware General Corporation Law or the Certificate of Incorporation (including this Certificate
of Designation), each share of Series A Preferred Stock shall be entitled to vote on each matter submitted to a vote of the stockholders
generally and shall vote together with the Common Stock and any other class or series of capital stock entitled to vote thereon as a
single class and on an as converted to Common Stock basis. Notwithstanding the foregoing, in addition, as long as any shares of Series
A Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding
shares of the Series A Preferred Stock, voting as a separate class, (a) alter or change the powers, preferences or rights of the Series
A Preferred Stock so as to affect them adversely, (b) amend the Certificate of Incorporation or other charter documents in a manner adverse
to the Holders, (c) increase the number of authorized shares of Series A Preferred Stock, or (d) enter into any agreement with respect
to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Section
5</U>. <U>Liquidation</U>. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &ldquo;<U>Liquidation</U>&rdquo;),
prior and in preference to the Common Stock, the Holders shall be entitled to receive out of the assets available for distribution to
stockholders an amount in cash equal to 105% of the Stated Value and no more. <FONT STYLE="font-weight: normal">The preference set forth
in this Section 5 with respect to distributions to the Series A Preferred Stock upon a Liquidation shall apply <I>mutatis mutandis </I>to
any distributions to be made upon the consummation of a Fundamental Transaction or Change of Control Transaction.</FONT> The Corporation
shall mail written notice of any such Liquidation, <FONT STYLE="font-weight: normal">Fundamental Transaction or Change of Control Transaction
</FONT>not less than 45 days prior to the payment date stated therein, to each Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
6</U>. <U>Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Conversions at Option of Holder</U>. Subject to Section 6(d), each share of Series A Preferred Stock shall be convertible, at any
time and from time to time only after the Reverse Stock Split Date, at the option of the Holder thereof, into that number of shares of
Common Stock determined by dividing the Stated Value of such share of Series A Preferred Stock by the Conversion Price. Holders shall
effect conversions by delivering to the Corporation a conversion notice in the form attached hereto as <U>Annex A</U> (a &ldquo;<U>Notice
of Conversion</U>&rdquo;). Each Notice of Conversion shall specify the number of shares of Series A Preferred Stock to be converted,
the number of shares of Series A Preferred Stock owned prior to the conversion at issue, the number of shares of Series A Preferred Stock
owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the
date the applicable Holder delivers such Notice of Conversion to the Corporation (such date, the &ldquo;<U>Conversion Date</U>&rdquo;).
If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be as of the close of business on the Business
Day that such Notice of Conversion is delivered to the Corporation, or if such day is not a Business day or if the Notice of Conversion
is delivered after regular business hours, the next Business Day. No ink-original Notice of Conversion shall be required, nor shall any
medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. The calculations and entries
set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. From and after the Conversion Date,
until presented for transfer or exchange, certificates that previously represented shares of Series A Preferred Stock shall represent,
in lieu of the number of shares of Series A Preferred Stock previously represented by such certificate, the number of shares of Series
A Preferred Stock, if any, previously represented by such certificate that were not converted pursuant to the Notice of Conversion, plus
the number of shares of Conversion Shares into which the shares of Series A Preferred Stock previously represented by such certificate
were converted. To effect conversions of shares of Series A Preferred Stock, a Holder shall not be required to surrender the certificate(s),
if any, representing the shares of Series A Preferred Stock to the Corporation unless all of the shares of Series A Preferred Stock represented
thereby are so converted, in which case such Holder shall deliver the certificate representing such shares of Series A Preferred Stock
promptly following the Conversion Date at issue. Shares of Series A Preferred Stock converted into Common Stock shall be canceled and
shall not be reissued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Conversion Price</U>. The conversion price for the Series A Preferred Stock shall equal $0.45, subject to adjustment herein (the &ldquo;<U>Conversion
Price</U>&rdquo;). In no event shall the Conversion Price be less than the Minimum Price defined in Nasdaq Listing Rule 5635(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Mechanics of Conversion</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
    of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days
    comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;<U>Share Delivery Date</U>&rdquo;),
    the Corporation shall deliver, or cause to be delivered, to the converting Holder the number of Conversion Shares being acquired
    upon the conversion of the Series A Preferred Stock, which Conversion Shares shall be free of restrictive legends and trading restrictions.
    The Corporation shall use its reasonable best efforts to deliver the Conversion Shares required to be delivered by the Corporation
    under this Section 6 electronically through the Depository Trust Company or another established clearing corporation performing similar
    functions. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
    of Trading Days, on the Corporation&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
    of the Notice of Conversion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Failure
    to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as
    directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation
    at any time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall
    promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly
    return to the Corporation the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Obligation
    Absolute; Partial Liquidated Damages</U>. Subject to Section 6(d), the Corporation&rsquo;s obligation to issue and deliver the Conversion
    Shares upon conversion of Series A Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective
    of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery
    of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination,
    or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged
    violation of law by such Holder or any other Person, and irrespective of any other circumstance, which might otherwise limit such
    obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares; <U>provided</U>, <U>however</U>,
    that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such
    Holder. In the event a Holder shall elect to convert any or all of the Stated Value of its Series A Preferred Stock, the Corporation
    may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged
    in any violation of law, agreement or for any other reason, other than pursuant to Section 6(d), unless an injunction from a court,
    on notice to Holder, restraining and/or enjoining conversion of all or part of the Series A Preferred Stock of such Holder shall
    have been sought and obtained, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the
    Stated Value of the Series A Preferred Stock which is subject to the injunction, which bond shall remain in effect until the completion
    of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains
    judgment. In the absence of such injunction, subject to Section 6(d), the Corporation shall issue Conversion Shares and, if applicable,
    cash, upon a properly noticed conversion. If the Corporation fails to deliver to a Holder such Conversion Shares pursuant to Section
    6(c)(i) by the Share Delivery Date applicable to such conversion, other than pursuant to Section 6(d), the Corporation shall pay
    to such Holder, in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated Value of Series A Preferred Stock
    being converted, $50 per Trading Day (increasing to $100 per Trading Day on the third Trading Day after the Share Delivery Date and
    increasing to $200 per Trading Day on the sixth Trading Day after the Share Delivery Date) for each Trading Day after the Share Delivery
    Date until such Conversion Shares are delivered or Holder rescinds such conversion. Nothing herein shall limit a Holder&rsquo;s right
    to pursue actual damages for the Corporation&rsquo;s failure to deliver Conversion Shares within the period specified herein and
    such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation,
    a decree of specific performance and/or injunctive relief. The exercise of any such rights shall not prohibit a Holder from seeking
    to enforce damages pursuant to any other Section hereof or under applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation
    for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the Holder,
    if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant
    to Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market
    transaction or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
    of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such
    Share Delivery Date (a &ldquo;<U>Buy-In</U>&rdquo;), then the Corporation shall (A) pay in cash to such Holder (in addition to any
    other remedies available to or elected by such Holder) the amount, if any, by which (x) such Holder&rsquo;s total purchase price
    (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares
    of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at
    which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option
    of such Holder, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A
    Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the
    number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements
    under Section 6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover
    a Buy-In with respect to an attempted conversion of shares of Series A Preferred Stock with respect to which the actual sale price
    of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under
    clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide
    the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the Corporation,
    evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to
    it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
    to the Corporation&rsquo;s failure to timely deliver the Conversion Shares upon conversion of the shares of Series A Preferred Stock
    as required pursuant to the terms hereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation
    of Shares Issuable Upon Conversion</U>. From and after the Reverse Stock Split Date and until no shares of Series A Preferred Stock
    remain outstanding, the Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued
    shares of Common Stock for the sole purpose of issuance upon conversion of the Series A Preferred Stock as herein provided, free
    from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of
    the Series A Preferred Stock), not less than the aggregate number of shares of the Common Stock as shall (subject to the terms and
    conditions set forth in the Purchase Agreement) be issuable (taking into account any adjustments under Section 7) upon the conversion
    of the then outstanding shares of Series A Preferred Stock. The Corporation covenants that all shares of Common Stock that shall
    be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fractional
    Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series A Preferred
    Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation
    shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
    by the Conversion Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent
    with the provisions of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from converting
    fractional shares of Series A Preferred Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transfer
    Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of the Series A Preferred Stock shall be made without charge
    to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion
    Shares, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved
    in the issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares
    of Series A Preferred Stock and the Corporation shall not be required to issue or deliver such Conversion Shares unless or until
    the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established
    to the satisfaction of the Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for
    same-day processing of any Notice of Conversion and all fees to the Depository Trust Company (or another established clearing corporation
    performing similar functions) required for same-day electronic delivery of the Conversion Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Beneficial Ownership Limitation</U>. Notwithstanding anything to the contrary set forth herein, the Corporation shall not effect any
conversion of the Series A Preferred Stock, and a Holder shall not have the right to convert any portion of the Series A Preferred Stock,
to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with
such Holder&rsquo;s Affiliates, and any Persons acting as a group together with such Holder or any of such Holder&rsquo;s Affiliates
(such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)) would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series A Preferred
Stock with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable
upon (i) conversion of the remaining, unconverted Series A Preferred Stock beneficially owned by such Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation
subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, the Series
A Preferred Stock) beneficially owned by such Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding
sentence, for purposes of this Section 6(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(d) applies, the
determination of whether the Series A Preferred Stock is convertible (in relation to other securities owned by such Holder together with
any Affiliates and Attribution Parties) and of how many shares of Series A Preferred Stock are convertible shall be in the sole discretion
of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&rsquo;s determination of whether the shares
of Series A Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates and Attribution
Parties) and how many shares of the Series A Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation.
To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice
of Conversion that such Notice of Conversion has not violated the restrictions set forth in this Section 6(d) and the Corporation shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation&rsquo;s most recent periodic or
annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or (iii) a more
recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the
written or oral request (which may be via email) of a Holder, the Corporation shall within one (1) Trading Day confirm orally and in
writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Series A
Preferred Stock, by such Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder
prior to the issuance of any shares of Series A Preferred Stock, 9.99%) of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon conversion of Series A Preferred Stock held by the applicable
Holder. A Holder, upon notice to the Corporation, may increase or decrease the Beneficial Ownership Limitation provisions of this Section
6(d) applicable to its Series A Preferred Stock; provided, that the Beneficial Ownership Limitation shall not in any event exceed 9.99%
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
conversion of this Series A Preferred Stock held by the Holder and the provisions of this Section 6(d) shall continue to apply. Any such
increase will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Corporation and shall only apply to
such Holder and no other Holder. The Beneficial Ownership Limitation shall not be waived by the Corporation or the Holder and upon issuance
of the Series A Preferred Stock by the Corporation, and the purchase thereof by the Holder, in accordance with the Purchase Agreement,
each of the Corporation and the Purchaser shall be deemed to acknowledge such limitation and to agree not to waive it. The provisions
of this Section 6(d) shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section
6(d) to correct this Section (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this Section shall apply to a successor holder of Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
7</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while the Series A Preferred Stock is outstanding: (i) pays
a stock dividend or otherwise makes a distribution or distributions that is payable in shares of Common Stock on shares of Common Stock
or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation
upon conversion of, or payment of a dividend on, the Series A Preferred Stock), (ii) subdivides outstanding shares of Common Stock into
a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller
number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the
Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. Notwithstanding
the foregoing in no event may the Conversion Price be less than the par value per share of Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of Common Stock or any class thereof (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete conversion of such Holder&rsquo;s Series A Preferred Stock (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Distributions</U>. During such time as the Series A Preferred Stock is outstanding, if the Corporation declares or makes any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of the Series A
Preferred Stock (without regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be
held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while the Series A Preferred Stock is outstanding, (i) the Corporation, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation
(and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders
of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by
the holders of at least 50% of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly
or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent conversion
of the Series A Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable
upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section
6(d) on the conversion of the Series A Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation
or of the Corporation, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which the Series A Preferred
Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion
of the Series A Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of
Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall
be given the same choice as to the Alternate Consideration it receives upon any conversion of the Series A Preferred Stock following
such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving
entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the
Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&rsquo; right to convert such preferred
stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation
is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Corporation under
this Certificate of Designation and the other Transaction Documents in accordance with the provisions of this Section 7(d) pursuant to
written agreements in customary form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for the Series
A Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
the Series A Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of the Series A Preferred Stock
(without regard to any limitations on the conversion of the Series A Preferred Stock) prior to such Fundamental Transaction, and with
a conversion price which applies the conversion price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such conversion price being for the purpose of protecting the economic value of the Series A Preferred
Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for
(so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other Transaction
Documents referring to the &ldquo;Corporation&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation and the other Transaction
Documents with the same effect as if such Successor Entity had been named as the Corporation herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice of Holders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustment
    to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation shall
    promptly deliver to each Holder by facsimile or email a notice setting forth the Conversion Price after such adjustment and setting
    forth a brief statement of the facts requiring such adjustment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
    to Allow Conversion by Holder</U>. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on
    the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
    (C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase
    any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required
    in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any
    sale or transfer of all or substantially all of the assets of the Corporation (and all of its Subsidiaries, taken as a whole), or
    any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation
    shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each
    case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of the Preferred
    Stock, and shall cause to be delivered by email to each Holder at its last email address as it shall appear upon the stock books
    of the Corporation, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a
    notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
    warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
    dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
    merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
    of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property
    deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver
    such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be
    specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
    regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file such notice with the Commission pursuant
    to a Current Report on Form 8-K. The Holder shall remain entitled to convert the Conversion Amount of the Preferred Stock (or any
    part hereof) during the 20-day period commencing on the date of such notice through the effective date of the event triggering such
    notice except as may otherwise be expressly set forth herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
8</U>. <U>Mandatory Conversion and Forced Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Mandatory Conversion</U>. Notwithstanding anything herein to the contrary, subject to Section 8(c), on the Reverse Stock Split Date
or, if all of the Equity Conditions are not satisfied on the Reverse Stock Split Date, on the first such date after the Reverse Stock
Split Date, if and only if such date is within and no later than fifteen (15) Trading Days after the Reverse Stock Split Date, that all
of the Equity Conditions are satisfied (unless waived in writing by a Holder with respect to such Holder) (the &ldquo;<U>Mandatory Conversion
Date</U>&rdquo;), the Corporation may deliver written notice of the Mandatory Conversion to all Holders on the Mandatory Conversion Date
and, on such Mandatory Conversion Date, the Corporation shall convert all of each Holder&rsquo;s shares of Series A Preferred Stock (the
&ldquo;<U>Mandatory Conversion</U>&rdquo;) into Conversion Shares at the then effective Conversion Price on the Mandatory Conversion
Date, it being agreed that the &ldquo;Conversion Date&rdquo; for purposes of Section 6 herein shall be deemed to be the Mandatory Conversion
Date. The Mandatory Conversion hereunder shall not be effective, unless all of the Equity Conditions are met (unless waived in writing
by a Holder with respect to such Holder) on the Mandatory Conversion Date through and including the Share Delivery Date and the actual
delivery of all of the Conversion Shares to the Holders. For purposes of clarification, a Mandatory Conversion shall be subject to all
of the provisions of Section 6, including, without limitation, Section 6(d) and the provision requiring payment of liquidated damages.
If any of the Equity Conditions shall cease to be satisfied at any time on or after the Mandatory Conversion Date through and including
the actual delivery of all of the Conversion Shares to the Holders, a Holder may elect to nullify the Mandatory Conversion as to such
Holder by notice to the Corporation within three (3) Trading Days after the first day on which any such Equity Condition has not been
satisfied (provided that if, by a provision of the Transaction Documents, the Corporation is obligated to notify the Holders of the non-existence
of an Equity Condition, such notice period shall be extended to the second Trading Day after proper notice from the Corporation) in which
case the Mandatory Conversion shall be null and void, ab initio. Subject to the other terms hereof, the Corporation covenants and agrees
that the Corporation will honor all Notices of Conversion that are tendered by the Holder on or after the Mandatory Conversion Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Forced Conversion</U>. At any time after 120 days following the Mandatory Conversion Date, the Corporation may deliver a written notice
to all Holders (a &ldquo;<U>Forced Conversion Notice</U>&rdquo; and the date such notice is delivered to all Holders, the &ldquo;<U>Forced
Conversion Notice Date</U>&rdquo;) to cause each Holder to convert all or part of such Holder&rsquo;s Series A Preferred Stock (as specified
in such Forced Conversion Notice) pursuant to Section 6 (a &ldquo;<U>Forced Conversion</U>&rdquo;), it being agreed that the &ldquo;Conversion
Date&rdquo; for purposes of Section 6 shall be deemed to be the Forced Conversion Notice Date (such date, the &ldquo;<U>Forced Conversion
Date</U>&rdquo;), provided that the Corporation shall not deliver a Forced Conversion Notice more than once in any 60 day period. The
Corporation may not deliver a Forced Conversion Notice, and any Forced Conversion Notice delivered by the Corporation shall not be effective,
unless all of the Equity Conditions have been met on the Forced Conversion Notice Date through and including the later of the Forced
Conversion Date and the Trading Day after the date that the Conversion Shares issuable pursuant to such conversion are actually delivered
to the Holders pursuant to the Forced Conversion Notice. Any Forced Conversion Notices shall be applied ratably to all of the Holders
based on each Holder&rsquo;s initial purchases of Series A Preferred Stock hereunder, provided that any voluntary conversions by a Holder
shall be applied against such Holder&rsquo;s <U>pro rata</U> allocation, thereby decreasing the aggregate amount forcibly converted hereunder
if less than all shares of the Series A Preferred Stock are forcibly converted. For purposes of clarification, a Forced Conversion shall
be subject to all of the provisions of Section 6, including, without limitation, the provisions requiring payment of liquidated damages
and Section 6(d) on Beneficial Ownership Limitation on conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Notwithstanding the terms of Sections 8(a) and 8(b) above, if the Corporation exercises its right to cause the conversion of Series A
Preferred Stock pursuant to Sections 8(a) or 8(b), then, within two (2) Trading Days following the receipt of a Mandatory Conversion
Notice or Forced Conversion Notice, each such Holder shall be entitled to Deliver a Redemption Notice to the Corporation to cause the
Corporation to redeem its shares of Series A Preferred Stock otherwise subject to conversion, only to the extent the right to cause such
redemption would otherwise be available to such Holder, pursuant to the terms of Section 9(a) below. In the event a Holder delivers a
Redemption Notice pursuant to this Section 8(c), any conversion contemplated by the applicable Mandatory Conversion Notice or Forced
Conversion Notice shall be null and void, ab initio, and the Corporation shall be obligated to redeem such Holder&rsquo;s Series A Preferred
Stock pursuant to Sections 9(a) and 9(b) below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
9</U>. <U>Redemption</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
(i) After the earlier of (1) the receipt of Authorized Stockholder Approval and (2) the date that is 60 days following the Original Issue
Date and (ii) before the date that is 90 days after the Original Issue Date, each Holder shall have the right to cause the Corporation
to redeem all or part of such Holder&rsquo;s shares of Series A Preferred Stock at a price per share equal to 105% of the Stated Value
(the &ldquo;<U>Redemption Consideration</U>&rdquo;) other than any shares that have theretofore been called for redemption by the Corporation
pursuant to Section 9(c) below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Subject to the terms of Section 9(a) above, to cause the Corporation to redeem all or part of its shares of Series A Preferred Stock,
each Holder shall deliver written notice to the Corporation (each, a &ldquo;<U>Redemption Notice</U>&rdquo;) setting forth the number
of shares of Series A Preferred Stock that each such Holder wishes to redeem. The Corporation shall redeem the shares of Series A Preferred
Stock in accordance with the Redemption Notice, no later than 5 days after the date on which the Redemption Notice is delivered to the
Corporation (such date of redemption, the &ldquo;<U>Redemption Date</U>&rdquo;). Upon receipt of full payment in cash for a complete
redemption, each Holder will promptly submit to the Corporation such Holder&rsquo;s Series A Preferred Stock certificates, if any, and
such redeemed shares shall no longer be deemed to be outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
At any time after the date that is 90 days after the Original Issue Date, the Corporation shall have the option to redeem any or all
shares of Series A Preferred Stock (other than any shares referenced in a Redemption Notice, the redemption of which shall be subject
to Section 9(a) and 9(b), or any shares referenced in a Notice of Conversion) at a price per share equal to the Redemption Consideration,
subject to the terms and conditions set forth in this Section 9(c). If the Corporation exercises its option to redeem any such shares,
it shall effect such redemption on the date specified in a notice, which date shall be at least five (5) Business Days after delivery
thereof (the &ldquo;<U>Call Date</U>&rdquo;), that shall be sent to each Holder whose shares are to be so redeemed by the Company pursuant
hereto (the &ldquo;<U>Call Notice</U>&rdquo;). The Call Notice shall state (i) the Call Date and the number of shares of Series A Preferred
Stock to be redeemed by the Corporation pursuant to this Section 9(c) on such date and (ii) that the Holder is to surrender to the Corporation,
in the manner and at the place designated in the Call Notice, such Holder&rsquo;s certificate or certificates, if any, representing the
shares of Series A Preferred Stock to be redeemed pursuant to this Section 9(c). On the Call Date, the Corporation shall redeem the shares
of Series A Preferred Stock subject to the Call Notice for the Redemption Consideration. Upon receipt of full payment in cash of the
Redemption Consideration for a complete redemption, each Holder will promptly submit to the Corporation such Holder&rsquo;s Series A
Preferred Stock certificates, if any, and such redeemed shares shall no longer be deemed to be outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
If on the Redemption Date or Call Date, as applicable, the Redemption Consideration for the shares of Series A Preferred Stock to be
redeemed on the Redemption Date or the Call Date, as applicable, has been paid to the Holders, then, notwithstanding that any certificate
representing any share subject to redemption pursuant to this Section 9 has not been surrendered to the Corporation for cancellation,
on the Redemption Date or the Call Date, as applicable, all shares so submitted or called for redemption shall be cancelled, and all
rights with respect to such shares shall forthwith on such Redemption Date or Call Date, as applicable, cease and terminate, except for
the right of the Holders to receive the Redemption Consideration therefor, without interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
Notwithstanding the terms of Sections 9(c) or Section 9(d) above, if the Corporation exercises its option to redeem shares of Series
A Preferred Stock pursuant to Section 9(c), then each such Holder shall continue to be entitled to deliver a Notice of Conversion to
the Corporation to cause the Corporation to convert its shares of Series A Preferred Stock otherwise subject to redemption in accordance
with Section 6 at any time prior to the Call Date and only to the extent the right to cause such conversion would otherwise be available
to such Holder pursuant to the terms of Section 6. In the event a Holder delivers a Notice of Conversion with respect to any of its shares
of Series A Preferred Stock pursuant to this Section 9(e), any redemption by the Corporation of such shares contemplated by Section 9(c)
shall be null and void, <I>ab initio</I>, and the Corporation shall be obligated to convert such Holder&rsquo;s Series A Preferred Stock
pursuant to Section 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
10</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Conversion, shall be in writing and delivered personally, by facsimile or email attachment, or sent by a nationally
recognized overnight courier service, addressed to the Corporation, at 1330 Avenue of the Americas, 33<SUP>rd</SUP> Floor, New York,
NY 10019, Attention: Joseph Vazzano, Chief Financial Officer, email address jvazzano@abeonatherapeutics.com, or such other email address
or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 10. Any
and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally,
by email attachment, or sent by a nationally recognized overnight courier service addressed to each Holder at the email address or address
of such Holder appearing on the books of the Corporation, or if no such email address or address appears on the books of the Corporation,
at the principal place of business of such Holder, as set forth in the Purchase Agreement. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered
via email attachment at the email address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next
Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address set
forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt
by the party to whom such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Lost or Mutilated Preferred Stock Certificate</U>. If a Holder&rsquo;s Series A Preferred Stock certificate shall be mutilated, lost,
stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated
certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series
A Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such
certificate, and of the ownership hereof reasonably satisfactory to the Corporation (which shall not include the posting of any bond).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Severability</U>. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate
of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain
applicable to all other Persons and circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Next Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Headings</U>. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Status of Converted or Redeemed Preferred Stock</U>. Shares of Series A Preferred Stock may only be issued pursuant to the Purchase
Agreement. If any shares of Series A Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares may not
be reissued and shall automatically be retired and cancelled and shall resume the status of authorized but unissued shares of preferred
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*********************</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have executed this Certificate this ___ day of April 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Vazzano</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNEX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF CONVERSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(To
be Executed by the Registered Holder in order to Convert Shares of SERIES A Preferred Stock)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby elects to convert the number of shares of Series A Convertible Redeemable Preferred Stock indicated below into shares
of common stock, par value $0.01 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of Abeona Therapeutics Inc., a Delaware corporation
(the &ldquo;<U>Corporation</U>&rdquo;), according to the conditions hereof, as of the date written below. If shares of Common Stock are
to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto.
No fee will be charged to the Holders for any conversion, except for any such transfer taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
calculations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date to Effect Conversion: _______________________________________________</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Preferred Stock owned prior to Conversion: _______________</FONT>___</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Preferred Stock to be Converted: ________________________</FONT>__</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stated Value of shares of Preferred Stock to be Converted: ____________________</FONT>__</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Common Stock to be Issued: ___________________________</FONT>__</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable Conversion Price:____________________________________________</FONT>__</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Preferred Stock subsequent to Conversion: ________________</FONT>__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery: ______________________</FONT>__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Or</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
DWAC Instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker no: ___________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account no: ___________</FONT>__</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOLDER</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ex3-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABEONA
THERAPEUTICS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF DESIGNATION OF PREFERENCES, </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIGHTS
AND LIMITATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
<FONT STYLE="text-transform: uppercase">B </FONT>CONVERTIBLE REDEEMABLE PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">PURSUANT
TO SECTION 151 OF THE </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">delaware
GENERAL CORPORATION LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Joseph Vazzano, does hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">He
    is the Chief Financial Officer of Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation is authorized to issue 2,000,000 shares of preferred stock, none of which have been issued.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following resolutions were duly adopted by the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Restated Certificate of Incorporation of the Corporation (the &ldquo;Certificate of Incorporation&rdquo;), provides for a class of
its authorized stock known as preferred stock, consisting of 2,000,000 shares, $0.01 par value per share, issuable from time to time
in one or more series;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Board of Directors is authorized by resolution to provide for the issuance of preferred stock in one or more series, and to establish
from time to time the number of shares to be included in each such series, and to fix the designation, powers, privileges, preferences
and relative participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations or
restrictions thereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
it is the desire of the Board of Directors, pursuant to its authority as described above, to fix the rights, preferences, restrictions
and other matters relating to a series of the preferred stock, which shall consist of 250,005 shares of the preferred stock which the
Corporation has the authority to issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of preferred stock to be designated
&ldquo;Series B Convertible Redeemable Preferred Stock&rdquo; and does hereby fix and determine the designation, powers, privileges,
preferences and relative participating, optional or other rights, if any, of the shares of each such series and the qualifications, limitations
or restrictions thereof as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. For the purposes hereof, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Alternate
Consideration</U>&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Amendment</U>&rdquo;
means the amendment to the Corporation&rsquo;s Certificate of Incorporation to, after the date hereof, effect the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Authorized
Stockholder Approval</U>&rdquo; means approval of the Amendment by the holders of a majority in voting power of the then outstanding
shares of capital stock of the Corporation entitled to vote on the matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall have the meaning set forth in Section 6(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Buy-In</U>&rdquo;
shall have the meaning set forth in Section 6(c)(iv).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Change
of Control Transaction</U>&rdquo; means the occurrence after the date hereof of any of (a) an acquisition by an individual or legal entity
or &ldquo;group&rdquo; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal
or beneficial ownership of capital stock of the Corporation, by contract or otherwise) of in excess of 33% of the voting securities of
the Corporation (other than by means of the issuance, sale, conversion or exercise of Series A Preferred Stock or Series B Preferred
Stock), (b) the Corporation merges into or consolidates with any other Person, or any Person merges into or consolidates with the Corporation
and, after giving effect to such transaction, the stockholders of the Corporation immediately prior to such transaction own less than
66% of the aggregate voting power of the Corporation or the successor entity of such transaction, (c) the Corporation (and all of its
Subsidiaries, taken as a whole) sells or transfers all or substantially all of its assets to another Person and the stockholders of the
Corporation immediately prior to such transaction own less than 66% of the aggregate voting power of the acquiring entity immediately
after the transaction, (d) a replacement at one time or within a one year period of more than one-half of the members of the Board of
Directors which is not approved by a majority of those individuals who are members of the Board of Directors on the Original Issue Date
(or by those individuals who are serving as members of the Board of Directors on any date whose nomination to the Board of Directors
was approved by a majority of the members of the Board of Directors who are members on the Original Issue Date), or (e) the execution
by the Corporation of an agreement to which the Corporation is a party or by which it is bound, providing for any of the events set forth
in clauses (a) through (d) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Series B Preferred Stock pursuant to Section 2.1 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto and all conditions precedent to (i) each Holder&rsquo;s obligations to pay the Subscription Amount and (ii) the Corporation&rsquo;s
obligations to deliver the Series B Preferred Stock have been satisfied or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the Corporation&rsquo;s common stock, $0.01 par value per share, and stock of any other class of securities into
which such securities may hereafter be reclassified, converted or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Amount</U>&rdquo; means the Stated Value at issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 6(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock
in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Escrow
Agreement</U>&rdquo; means the escrow agreement to be entered into concurrently with the Purchase Agreement, by and among the Corporation,
Wilmington Trust, National Association, and the other party thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Equity
Conditions</U>&rdquo; means, during the period in question, (a) the Corporation shall have paid all liquidated damages and other amounts
owing to the applicable Holder in respect of the Series B Preferred Stock, (b)(i) there is an effective registration statement pursuant
to which either (A) the Corporation may issue Conversion Shares or (B) the Holders are permitted to utilize the prospectus thereunder
to resell all of the shares of Common Stock issuable pursuant to the Transaction Documents (and the Corporation believes, in good faith,
that such effectiveness will continue uninterrupted for the foreseeable future), (ii) all of the Conversion Shares issuable pursuant
to the Transaction Documents (and shares issuable in lieu of cash payments of dividends) may be resold pursuant to Rule 144 without volume
or manner-of-sale restrictions or current public information requirements as determined by the counsel to the Corporation as set forth
in a written opinion letter to such effect, addressed and reasonably acceptable to the Transfer Agent and the affected Holder, or (iii)
all of the Conversion Shares may be issued to the Holder pursuant to Section 3(a)(9) of the Securities Act and immediately resold without
restriction, (c) the Common Stock is trading on a Trading Market and all of the shares of Common Stock issuable upon conversion of the
Series B Preferred Stock are listed or quoted for trading on such Trading Market (and the Corporation believes, in good faith, that trading
of the Common Stock on a Trading Market will continue uninterrupted for the foreseeable future), (d) there is a sufficient number of
authorized, but unissued and otherwise unreserved, shares of Common Stock for the issuance of all of the shares then issuable pursuant
to the Transaction Documents, (e) Authorized Stockholder Approval shall have been received and be effective, (f) the issuance of the
shares in question to the applicable Holder would not violate the limitations set forth in Section 6(d) herein, (g) <FONT STYLE="font-weight: normal; color: Black">the
shares of Common Stock have traded on the applicable Trading Market during a consecutive ten (10) day period at an average market price
per share greater than $2.00 (as adjusted for stock splits) and the average daily trading volume during such period is equal to or greater
than $2,000,000, (h)</FONT> there has been no public announcement of a pending or proposed Fundamental Transaction or Change of Control
Transaction that has not been consummated, (i) the applicable Holder is not in possession of any information provided by the Corporation,
any of its Subsidiaries, or any of their officers, directors, employees, agents or Affiliates, that constitutes, or may constitute, material
non-public information and (j) the Corporation shall have duly honored all conversions scheduled to occur or occurring by virtue of one
or more Notices of Conversion of the applicable Holder on or prior to the dates so requested or required, if any.</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Forced
Conversion Date</U>&rdquo; shall have the meaning set forth in Section 8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Forced
Conversion Notice</U>&rdquo; shall have the meaning set forth in Section 8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Forced
Conversion Notice Date</U>&rdquo; shall have the meaning set forth in Section 8(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Fundamental
Transaction</U>&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
shall have the meaning given such term in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liquidation</U>&rdquo;
shall have the meaning set forth in Section 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Mandatory
Conversion</U>&rdquo; shall have the meaning set forth in Section 8(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Mandatory
Conversion Date</U>&rdquo; shall have the meaning set forth in Section 8(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Notice
of Conversion</U>&rdquo; shall have the meaning set forth in Section 6(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Original
Issue Date</U>&rdquo; means the date of the first issuance of any shares of the Series B Preferred Stock regardless of the number of
transfers of any particular shares of Series B Preferred Stock and regardless of the number of certificates which may be issued to evidence
such Series B Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Preferred Stock Purchase Agreement, dated as of April 29, 2022, among the Corporation and the original
Holders, as amended, modified or supplemented from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reverse
Stock Split</U>&rdquo; means the reverse stock split of the Corporation&rsquo;s Common Stock that is effected by the Corporation&rsquo;s
filing of the Amendment with and acceptance by the Secretary of State of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reverse
Stock Split Date</U>&rdquo; means the date on which the Amendment to effectuate the Reverse Stock Split is filed and accepted by the
Secretary of State of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
A Preferred Stock Certificate of Designation</U>&rdquo; means the Certificate of Designation of Preferences, Rights and Limitations of
the Series A Convertible Redeemable Preferred Stock of the Corporation, dated as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
B Preferred Stock</U>&rdquo; shall have the meaning set forth in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Share
Delivery Date</U>&rdquo; shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stated
Value</U>&rdquo; shall have the meaning set forth in Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; shall mean, as to each Holder, the aggregate amount to be paid for the Series B Preferred Stock purchased pursuant
to the Purchase Agreement as specified below such Holder&rsquo;s name on the signature page of the Purchase Agreement and next to the
heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Corporation as set forth on <U>Schedule 3.1(a)</U> of the Purchase Agreement and shall, where applicable,
also include any direct or indirect subsidiary of the Corporation formed or acquired after the date of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Successor
Entity</U>&rdquo; shall have the meaning set forth in Section 7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Certificate of Designation, the Series B Preferred Stock Certificate of Designation, the Purchase Agreement,
the Registration Rights Agreement, the Escrow Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated pursuant to the Purchase Agreement, in each case as amended, modified or supplemented
from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust Company, and any successor transfer agent of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Designation, Amount and Par Value</U>. The series of preferred stock shall be designated as &ldquo;Series B Convertible Redeemable
Preferred Stock&rdquo; (the &ldquo;<U>Series B Preferred Stock</U>&rdquo;) and the number of shares of such series shall be <B>250,000
</B>(which shall not be subject to increase without the written consent of the holders of a majority of the then outstanding shares of
the Series B Preferred Stock (each, a &ldquo;<U>Holder</U>&rdquo; and collectively, the &ldquo;<U>Holders</U>&rdquo;)). Each share of
Series B Preferred Stock shall have a par value of $0.01 per share and a stated value equal to $20.00 (the &ldquo;<U>Stated Value</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Dividends</U>. Except for stock dividends or distributions for which adjustments are to be made pursuant to Section 7, Holders
shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock
basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares
of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid on shares
of Series B Preferred Stock. The Corporation shall not pay any dividends on the Common Stock unless the Corporation simultaneously complies
with this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Voting Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Solely for purposes of determining the presence of a quorum at any meeting of the stockholders of the Corporation at which the shares
of Series B Preferred Stock are entitled to vote, the number of shares of Series B Preferred Stock and votes represented by such shares
shall be counted on an as converted to Common Stock basis, disregarding, for such purposes, any limitations on conversion set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Each share of Series B Preferred Stock shall entitle the holder thereof (a) to vote exclusively with respect to the Amendment and the
Reverse Stock Split (and the Series B Preferred Stock shall not be entitled to vote on any other matter except to the extent required
under the Delaware General Corporation Law or provided herein) and (b) to 15,000 votes per each share of Series B Preferred Stock and
shall, except as required by law, vote together with the Common Stock and any other issued and outstanding shares of preferred stock
of the Corporation that are entitled to vote thereon, as a single class; provided, that all votes cast by the Series B Preferred Stock
with regards to any proposal for the approval of the Amendment and the Reverse Stock Split, when properly cast by the Holder, shall be
voted, without further action of such Holder, in the same proportion as shares of Common Stock and any other shares of capital stock
that are entitled to vote thereon are voted (excluding any shares of Common Stock that are not voted) on the Amendment and Reverse Stock
Split. Notwithstanding the foregoing, in addition, as long as any shares of Series B Preferred Stock are outstanding, the Corporation
shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series B Preferred Stock,
(a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend this Certificate
of Designation, (b) amend its certificate of incorporation or other charter documents in a manner adverse to the Holders, (c) increase
the number of authorized shares of Series B Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Liquidation</U>. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &ldquo;<U>Liquidation</U>&rdquo;),
prior and in preference to the Common Stock, the Holders shall be entitled to receive o<FONT STYLE="color: Black">ut of the assets available
for distribution to stockholders an amount in cash equal to 105% of the Stated Value and no more. <FONT STYLE="font-weight: normal">The
preference set forth in this Section 5 with respect to distributions to the Series B Preferred Stock upon a Liquidation shall apply <I>mutatis
mutandis </I>to any distributions to be made upon the consummation of a Fundamental Transaction or Change of Control Transaction.</FONT>
The Corporation shall mail written notice of any such Liquidation, <FONT STYLE="font-weight: normal">Fundamental Transaction or Change
of Control Transaction</FONT> not</FONT> less than 45 days prior to the payment date stated therein, to each Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
6</U>. <U>Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Conversions at Option of Holder</U>. Subject to Section 6(d), each share of Series B Preferred Stock shall be convertible, at any
time and from time to time only after the Reverse Stock Split Date, at the option of the Holder thereof, into that number of shares of
Common Stock determined by dividing the Stated Value of such share of Series B Preferred Stock by the Conversion Price. Holders shall
effect conversions by delivering to the Corporation a conversion notice in the form attached hereto as <U>Annex A</U> (a &ldquo;<U>Notice
of Conversion</U>&rdquo;). Each Notice of Conversion shall specify the number of shares of Series B Preferred Stock to be converted,
the number of shares of Series B Preferred Stock owned prior to the conversion at issue, the number of shares of Series B Preferred Stock
owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the
date the applicable Holder delivers such Notice of Conversion to the Corporation (such date, the &ldquo;<U>Conversion Date</U>&rdquo;).
If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be as of the close of business on the Business
Day that such Notice of Conversion is delivered to the Corporation, or if such day is not a Business day or if the Notice of Conversion
is delivered after regular business hours, the next Business Day. No ink-original Notice of Conversion shall be required, nor shall any
medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. The calculations and entries
set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. From and after the Conversion Date,
until presented for transfer or exchange, certificates that previously represented shares of Series B Preferred Stock shall represent,
in lieu of the number of shares of Series B Preferred Stock previously represented by such certificate, the number of shares of Series
B Preferred Stock, if any, previously represented by such certificate that were not converted pursuant to the Notice of Conversion, plus
the number of shares of Conversion Shares into which the shares of Series B Preferred Stock previously represented by such certificate
were converted. To effect conversions of shares of Series B Preferred Stock, a Holder shall not be required to surrender the certificate(s),
if any, representing the shares of Series B Preferred Stock to the Corporation unless all of the shares of Series B Preferred Stock represented
thereby are so converted, in which case such Holder shall deliver the certificate representing such shares of Series B Preferred Stock
promptly following the Conversion Date at issue. Shares of Series B Preferred Stock converted into Common Stock shall be canceled and
shall not be reissued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Conversion Price</U>. The conversion price for the Series B Preferred Stock shall equal $0.45, subject to adjustment herein (the &ldquo;<U>Conversion
Price</U>&rdquo;). In no event shall the Conversion Price be less than the Minimum Price defined in Nasdaq Listing Rule 5635(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Mechanics of Conversion</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
    of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days
    comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;<U>Share Delivery Date</U>&rdquo;),
    the Corporation shall deliver, or cause to be delivered, to the converting Holder the number of Conversion Shares being acquired
    upon the conversion of the Series B Preferred Stock, which Conversion Shares shall be free of restrictive legends and trading restrictions.
    The Corporation shall use its reasonable best efforts to deliver the Conversion Shares required to be delivered by the Corporation
    under this Section 6 electronically through the Depository Trust Company or another established clearing corporation performing similar
    functions. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
    of Trading Days, on the Corporation&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
    of the Notice of Conversion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Failure
    to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as
    directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation
    at any time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall
    promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly
    return to the Corporation the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Obligation
    Absolute; Partial Liquidated Damages</U>. Subject to Section 6(d), the Corporation&rsquo;s obligation to issue and deliver the Conversion
    Shares upon conversion of Series B Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective
    of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery
    of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination,
    or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged
    violation of law by such Holder or any other Person, and irrespective of any other circumstance, which might otherwise limit such
    obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares; <U>provided</U>, <U>however</U>,
    that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such
    Holder. In the event a Holder shall elect to convert any or all of the Stated Value of its Series B Preferred Stock, the Corporation
    may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged
    in any violation of law, agreement or for any other reason, other than pursuant to Section 6(d), unless an injunction from a court,
    on notice to Holder, restraining and/or enjoining conversion of all or part of the Series B Preferred Stock of such Holder shall
    have been sought and obtained, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the
    Stated Value of the Series B Preferred Stock which is subject to the injunction, which bond shall remain in effect until the completion
    of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains
    judgment. In the absence of such injunction, subject to Section 6(d), the Corporation shall issue Conversion Shares and, if applicable,
    cash, upon a properly noticed conversion. If the Corporation fails to deliver to a Holder such Conversion Shares pursuant to Section
    6(c)(i) by the Share Delivery Date applicable to such conversion, other than pursuant to Section 6(d), the Corporation shall pay
    to such Holder, in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated Value of Series B Preferred Stock
    being converted, $50 per Trading Day (increasing to $100 per Trading Day on the third Trading Day after the Share Delivery Date and
    increasing to $200 per Trading Day on the sixth Trading Day after the Share Delivery Date) for each Trading Day after the Share Delivery
    Date until such Conversion Shares are delivered or Holder rescinds such conversion. Nothing herein shall limit a Holder&rsquo;s right
    to pursue actual damages for the Corporation&rsquo;s failure to deliver Conversion Shares within the period specified herein and
    such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation,
    a decree of specific performance and/or injunctive relief. The exercise of any such rights shall not prohibit a Holder from seeking
    to enforce damages pursuant to any other Section hereof or under applicable law.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation
    for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the Holder,
    if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant
    to Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market
    transaction or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
    of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such
    Share Delivery Date (a &ldquo;<U>Buy-In</U>&rdquo;), then the Corporation shall (A) pay in cash to such Holder (in addition to any
    other remedies available to or elected by such Holder) the amount, if any, by which (x) such Holder&rsquo;s total purchase price
    (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares
    of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at
    which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option
    of such Holder, either reissue (if surrendered) the shares of Series B Preferred Stock equal to the number of shares of Series B
    Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the
    number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements
    under Section 6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover
    a Buy-In with respect to an attempted conversion of shares of Series B Preferred Stock with respect to which the actual sale price
    of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under
    clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide
    the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the Corporation,
    evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to
    it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
    to the Corporation&rsquo;s failure to timely deliver the Conversion Shares upon conversion of the shares of Series B Preferred Stock
    as required pursuant to the terms hereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation
    of Shares Issuable Upon Conversion</U>. From and after the Reverse Stock Split Date and until no shares of Series B Preferred Stock
    remain outstanding, the Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued
    shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Preferred Stock as herein provided, free
    from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of
    the Series B Preferred Stock), not less than the aggregate number of shares of the Common Stock as shall (subject to the terms and
    conditions set forth in the Purchase Agreement) be issuable (taking into account any adjustments under Section 7) upon the conversion
    of the then outstanding shares of Series B Preferred Stock. The Corporation covenants that all shares of Common Stock that shall
    be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fractional
    Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series B Preferred
    Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation
    shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
    by the Conversion Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent
    with the provisions of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from converting
    fractional shares of Series B Preferred Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transfer
    Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of the Series B Preferred Stock shall be made without charge
    to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion
    Shares, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved
    in the issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares
    of Series B Preferred Stock and the Corporation shall not be required to issue or deliver such Conversion Shares unless or until
    the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established
    to the satisfaction of the Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for
    same-day processing of any Notice of Conversion and all fees to the Depository Trust Company (or another established clearing corporation
    performing similar functions) required for same-day electronic delivery of the Conversion Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Beneficial Ownership Limitation</U>. Notwithstanding anything to the contrary set forth herein, the Corporation shall not effect any
conversion of the Series B Preferred Stock, and a Holder shall not have the right to convert any portion of the Series B Preferred Stock,
to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with
such Holder&rsquo;s Affiliates, and any Persons acting as a group together with such Holder or any of such Holder&rsquo;s Affiliates
(such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)) would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series B Preferred
Stock with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable
upon (i) conversion of the remaining, unconverted Series B Preferred Stock beneficially owned by such Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation
subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, the Series
B Preferred Stock) beneficially owned by such Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding
sentence, for purposes of this Section 6(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(d) applies, the
determination of whether the Series B Preferred Stock is convertible (in relation to other securities owned by such Holder together with
any Affiliates and Attribution Parties) and of how many shares of Series B Preferred Stock are convertible shall be in the sole discretion
of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&rsquo;s determination of whether the shares
of Series B Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates and Attribution
Parties) and how many shares of the Series B Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation.
To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice
of Conversion that such Notice of Conversion has not violated the restrictions set forth in this Section 6(d) and the Corporation shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation&rsquo;s most recent periodic or
annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or (iii) a more
recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the
written or oral request (which may be via email) of a Holder, the Corporation shall within one (1) Trading Day confirm orally and in
writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Series B
Preferred Stock, by such Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder
prior to the issuance of any shares of Series B Preferred Stock, 9.99%) of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon conversion of Series B Preferred Stock held by the applicable
Holder. A Holder, upon notice to the Corporation, may increase or decrease the Beneficial Ownership Limitation provisions of this Section
6(d) applicable to its Series B Preferred Stock; provided, that the Beneficial Ownership Limitation shall not in any event exceed 9.99%
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
conversion of this Series B Preferred Stock held by the Holder and the provisions of this Section 6(d) shall continue to apply. Any such
increase will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Corporation and shall only apply to
such Holder and no other Holder. The Beneficial Ownership Limitation shall not be waived by the Corporation or the Holder and upon issuance
of the Series B Preferred Stock by the Corporation, and the purchase thereof by the Holder, in accordance with the Purchase Agreement,
each of the Corporation and the Purchaser shall be deemed to acknowledge such limitation and to agree not to waive it. The provisions
of this Section 6(d) shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section
6(d) to correct this Section (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this Section shall apply to a successor holder of Series B Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
7</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while the Series B Preferred Stock is outstanding: (i) pays
a stock dividend or otherwise makes a distribution or distributions that is payable in shares of Common Stock on shares of Common Stock
or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation
upon conversion of, or payment of a dividend on, the Series B Preferred Stock), (ii) subdivides outstanding shares of Common Stock into
a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller
number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the
Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. Notwithstanding
the foregoing in no event may the Conversion Price be less than the par value per share of Series B Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of Common Stock or any class thereof (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete conversion of such Holder&rsquo;s Series B Preferred Stock (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Distributions</U>. During such time as the Series B Preferred Stock is outstanding, if the Corporation declares or makes any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of the Series B
Preferred Stock (without regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be
held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while the Series B Preferred Stock is outstanding, (i) the Corporation, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation
(and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders
of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by
the holders of at least 50% of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly
or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent conversion
of the Series B Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable
upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section
6(d) on the conversion of the Series B Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation
or of the Corporation, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which the Series B Preferred
Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion
of the Series B Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of
Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall
be given the same choice as to the Alternate Consideration it receives upon any conversion of the Series B Preferred Stock following
such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving
entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the
Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&rsquo; right to convert such preferred
stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation
is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Corporation under
this Certificate of Designation and the other Transaction Documents in accordance with the provisions of this Section 7(d) pursuant to
written agreements in customary form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for the Series
B Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
the Series B Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of the Series B Preferred Stock
(without regard to any limitations on the conversion of the Series B Preferred Stock) prior to such Fundamental Transaction, and with
a conversion price which applies the conversion price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such conversion price being for the purpose of protecting the economic value of the Series B Preferred
Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for
(so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other Transaction
Documents referring to the &ldquo;Corporation&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation and the other Transaction
Documents with the same effect as if such Successor Entity had been named as the Corporation herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice of Holders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustment
    to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation shall
    promptly deliver to each Holder by facsimile or email a notice setting forth the Conversion Price after such adjustment and setting
    forth a brief statement of the facts requiring such adjustment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
    to Allow Conversion by Holder</U>. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on
    the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
    (C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase
    any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required
    in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any
    sale or transfer of all or substantially all of the assets of the Corporation (and all of its Subsidiaries, taken as a whole), or
    any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation
    shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each
    case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of the Preferred
    Stock, and shall cause to be delivered by email to each Holder at its last email address as it shall appear upon the stock books
    of the Corporation, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a
    notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
    warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
    dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
    merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
    of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property
    deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver
    such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be
    specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
    regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file such notice with the Commission pursuant
    to a Current Report on Form 8-K. The Holder shall remain entitled to convert the Conversion Amount of the Preferred Stock (or any
    part hereof) during the 20-day period commencing on the date of such notice through the effective date of the event triggering such
    notice except as may otherwise be expressly set forth herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
8</U>. <U>Mandatory Conversion and Forced Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Mandatory Conversion</U>. Notwithstanding anything herein to the contrary, subject to Section 8(c), on the Reverse Stock Split Date
or, if all of the Equity Conditions are not satisfied on the Reverse Stock Split Date, on the first such date after the Reverse Stock
Split Date, if and only if such date is within and no later than fifteen (15) Trading Days after the Reverse Stock Split Date, that all
of the Equity Conditions are satisfied (unless waived in writing by a Holder with respect to such Holder) (the &ldquo;<U>Mandatory Conversion
Date</U>&rdquo;), the Corporation may deliver written notice of the Mandatory Conversion to all Holders on the Mandatory Conversion Date
and, on such Mandatory Conversion Date, the Corporation shall convert all of each Holder&rsquo;s shares of Series B Preferred Stock (the
&ldquo;<U>Mandatory Conversion</U>&rdquo;) into Conversion Shares at the then effective Conversion Price on the Mandatory Conversion
Date, it being agreed that the &ldquo;Conversion Date&rdquo; for purposes of Section 6 herein shall be deemed to be the Mandatory Conversion
Date. The Mandatory Conversion hereunder shall not be effective, unless all of the Equity Conditions are met (unless waived in writing
by a Holder with respect to such Holder) on the Mandatory Conversion Date through and including the Share Delivery Date and the actual
delivery of all of the Conversion Shares to the Holders. For purposes of clarification, a Mandatory Conversion shall be subject to all
of the provisions of Section 6, including, without limitation, Section 6(d) and the provision requiring payment of liquidated damages.
If any of the Equity Conditions shall cease to be satisfied at any time on or after the Mandatory Conversion Date through and including
the actual delivery of all of the Conversion Shares to the Holders, a Holder may elect to nullify the Mandatory Conversion as to such
Holder by notice to the Corporation within three (3) Trading Days after the first day on which any such Equity Condition has not been
satisfied (provided that if, by a provision of the Transaction Documents, the Corporation is obligated to notify the Holders of the non-existence
of an Equity Condition, such notice period shall be extended to the second Trading Day after proper notice from the Corporation) in which
case the Mandatory Conversion shall be null and void, ab initio. Subject to the other terms hereof, the Corporation covenants and agrees
that the Corporation will honor all Notices of Conversion that are tendered by the Holder on or after the Mandatory Conversion Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Forced Conversion</U>. At any time after 120 days following the Mandatory Conversion Date, the Corporation may deliver a written notice
to all Holders (a &ldquo;<U>Forced Conversion Notice</U>&rdquo; and the date such notice is delivered to all Holders, the &ldquo;<U>Forced
Conversion Notice Date</U>&rdquo;) to cause each Holder to convert all or part of such Holder&rsquo;s Series B Preferred Stock (as specified
in such Forced Conversion Notice) pursuant to Section 6 (a &ldquo;<U>Forced Conversion</U>&rdquo;), it being agreed that the &ldquo;Conversion
Date&rdquo; for purposes of Section 6 shall be deemed to be the Forced Conversion Notice Date (such date, the &ldquo;<U>Forced Conversion
Date</U>&rdquo;), provided that the Corporation shall not deliver a Forced Conversion Notice more than once in any 60 day period. The
Corporation may not deliver a Forced Conversion Notice, and any Forced Conversion Notice delivered by the Corporation shall not be effective,
unless all of the Equity Conditions have been met on the Forced Conversion Notice Date through and including the later of the Forced
Conversion Date and the Trading Day after the date that the Conversion Shares issuable pursuant to such conversion are actually delivered
to the Holders pursuant to the Forced Conversion Notice. Any Forced Conversion Notices shall be applied ratably to all of the Holders
based on each Holder&rsquo;s initial purchases of Series B Preferred Stock hereunder, provided that any voluntary conversions by a Holder
shall be applied against such Holder&rsquo;s <U>pro rata</U> allocation, thereby decreasing the aggregate amount forcibly converted hereunder
if less than all shares of the Series B Preferred Stock are forcibly converted. For purposes of clarification, a Forced Conversion shall
be subject to all of the provisions of Section 6, including, without limitation, the provisions requiring payment of liquidated damages
and Section 6(d) on Beneficial Ownership Limitation on conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Notwithstanding the terms of Sections 8(a) and 8(b) above, if the Corporation exercises its right to cause the conversion of Series B
Preferred Stock pursuant to Sections 8(a) or 8(b), then, within two (2) Trading Days following the receipt of a Mandatory Conversion
Notice or Forced Conversion Notice, each such Holder shall be entitled to Deliver a Redemption Notice to the Corporation to cause the
Corporation to redeem its shares of Series B Preferred Stock otherwise subject to conversion, only to the extent the right to cause such
redemption would otherwise be available to such Holder, pursuant to the terms of Section 9 below. In the event a Holder delivers a Redemption
Notice pursuant to this Section 8(c), any conversion contemplated by the applicable Mandatory Conversion Notice or Forced Conversion
Notice shall be null and void, ab initio, and the Corporation shall be obligated to redeem such Holder&rsquo;s Series B Preferred Stock
pursuant to Section 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
9</U>. <U>Redemption</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
(i) After the earlier of (1) the receipt of Authorized Stockholder Approval and (2) the date that is 60 days following the Original Issue
Date and (ii) before the date that is 90 days after the Original Issue Date (the &ldquo;<U>Redemption Period</U>&rdquo;), each Holder
shall have the right to cause the Corporation to redeem all or part of such Holder&rsquo;s shares of Series B Preferred Stock at a price
per share equal to 105% of the Stated Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Subject to the terms of Section 9(a) above, to cause the Corporation to redeem all or part of its shares of Series B Preferred Stock,
each Holder shall deliver written notice to the Corporation (each, a &ldquo;<U>Redemption Notice</U>&rdquo;) setting forth the number
of shares of Series B Preferred Stock that each such Holder wishes to redeem. The Corporation shall redeem the shares of Series B Preferred
Stock in accordance with the Redemption Notice, no later than 5 days after the date on which the Redemption Notice is delivered to the
Corporation. Upon receipt of full payment in cash for a complete redemption, each Holder will promptly submit to the Corporation such
Holder&rsquo;s Series B Preferred Stock certificates, if any, and such redeemed shares shall no longer be deemed to be outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
10</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Conversion, shall be in writing and delivered personally, by facsimile or email attachment, or sent by a nationally
recognized overnight courier service, addressed to the Corporation, at 1330 Avenue of the Americas, 33<SUP>rd</SUP> Floor, New York,
NY 10019, Attention: Joseph Vazzano, Chief Financial Officer, email address jvazzano@abeonatherapeutics.com, or such other email address
or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 10. Any
and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally,
by email attachment, or sent by a nationally recognized overnight courier service addressed to each Holder at the email address or address
of such Holder appearing on the books of the Corporation, or if no such email address or address appears on the books of the Corporation,
at the principal place of business of such Holder, as set forth in the Purchase Agreement. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered
via email attachment at the email address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next
Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address set
forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt
by the party to whom such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Lost or Mutilated Preferred Stock Certificate</U>. If a Holder&rsquo;s Series B Preferred Stock certificate shall be mutilated, lost,
stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated
certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series
B Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such
certificate, and of the ownership hereof reasonably satisfactory to the Corporation (which shall not include the posting of any bond).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Severability</U>. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate
of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain
applicable to all other Persons and circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Next Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Headings</U>. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Status of Converted or Redeemed Preferred Stock</U>. Shares of Series B Preferred Stock may only be issued pursuant to the Purchase
Agreement. If any shares of Series B Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares may not
be reissued and shall automatically be retired and cancelled and shall resume the status of authorized but unissued shares of preferred
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*********************</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have executed this Certificate this ___ day of April 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Vazzano</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNEX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF CONVERSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(To
be Executed by the Registered Holder in order to Convert Shares of SERIES B Preferred Stock)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby elects to convert the number of shares of Series B Convertible Redeemable Preferred Stock indicated below into shares
of common stock, par value $0.01 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of Abeona Therapeutics Inc., a Delaware corporation
(the &ldquo;<U>Corporation</U>&rdquo;), according to the conditions hereof, as of the date written below. If shares of Common Stock are
to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto.
No fee will be charged to the Holders for any conversion, except for any such transfer taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
calculations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date to Effect Conversion: _______________________________________________</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Preferred Stock owned prior to Conversion: _______________</FONT>____</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Preferred Stock to be Converted: ________________________</FONT>____</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stated Value of shares of Preferred Stock to be Converted: ____________________</FONT>____</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Common Stock to be Issued: ___________________________</FONT>____</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable Conversion Price:____________________________________________</FONT>____</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of Preferred Stock subsequent to Conversion: ________________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Delivery: ______________________</FONT>____ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Or</U></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DWAC Instructions:</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker no: _________</FONT>____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account no: ___________</FONT>____</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOLDER</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
PURCHASE AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of April 29, 2022, between Abeona Therapeutics Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Recitals
</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. The
Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), and/or Rule 506 of Regulation
D as promulgated by the United States Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) under the Securities Act; and;
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. The
Purchasers wish to purchase from the Company, and the Company wishes to sell and issue to the Purchasers, upon the terms and subject
to the conditions stated in this Agreement, shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s preferred stock, par value
$0.01 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;), that are convertible into shares of the Company&rsquo;s common stock, $0.01
par value per share (the &ldquo;<U>Common Stock</U>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. Contemporaneously
with the sale of the Shares hereunder, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached
hereto as <U>Exhibit A</U> (the &ldquo;<U>Registration Rights Agreement</U>&rdquo;), pursuant to which the Company will agree to provide
certain registration rights in respect of the Shares under the Securities Act, and the rules and regulations promulgated thereunder,
and applicable state securities laws. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I. </B><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1 <U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Ballard</U>&rdquo;
means Ballard Spahr LLP, with offices located at 1735 Market Street, 51st Floor, Philadelphia, PA 19103-7599.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading Day
following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Morgan, Lewis &amp; Bockius LLP, with offices located at One Federal Street, Boston, Massachusetts 02110.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the disclosure schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading
Day, no later than 9:01 a.m. (New York City time) on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Escrow
Agent</U>&rdquo; means Wilmington Trust, National Association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Escrow
Agreement</U>&rdquo; means the escrow agreement entered into prior to the date hereof, by and among the Company, the Escrow Agent, and
holder representative pursuant to which the Purchasers shall deposit Subscription Amounts and the Company shall deposit the difference
between the Subscription Amounts and the aggregate Redemption Consideration (as defined in the Series A Certificate of Designation and
Series B Certificate of Designation) with the Escrow Agent to be applied to the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options or other awards to employees, officers, service providers
or directors of the Company pursuant to any stock or option plan or arrangement duly adopted for such purpose, by a majority of the non-employee
members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose
for services rendered to the Company (or shares of Common Stock issued upon exercise of any such options or awards), (b) securities upon
the exercise or exchange of or conversion of any Shares issued hereunder and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities (other than in connection with stock splits or combinations), (c) securities in connection with the acquisition
or license by the Company of the securities, business, property, technology or other assets of another person or business entity or pursuant
to any employee benefit plan assumed by the Company in connection with any such acquisition, and (d) securities in connection with any
merger, joint venture, strategic alliance, commercial or other collaborative transaction; provided that, in the case of immediately preceding
clauses (c) and (d), the aggregate number of securities issued in connection with all such acquisitions and other transactions does not
exceed 10% of the number of shares outstanding on a fully diluted basis after giving effect to the consummation of the offering pursuant
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(gg).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(gg).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(ll).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Issuer
Covered Person</U>&rdquo; means the Company, any of its predecessors, any affiliated issuer, nor, to its knowledge, any director, executive
officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405
under the Securities Act) connected with the Company in any capacity at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Material
Permits&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals, with respect to each share of Series A Stock and each share of Series B Stock, $19.00 per share,
subject, in each case, to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(gg).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means A.G.P./Alliance Global Partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent Agreement</U>&rdquo; means that certain placement agent agreement dated as of the date hereof between the Company and the Placement
Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Stock</U>&rdquo; means the Series A Stock and Series B Stock of the Company, each par value $0.01 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition) pending or, to the Company&rsquo;s knowledge, threatened in writing against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Price</U>&rdquo; means, as to each Purchaser, the aggregate dollar amount to be paid for Shares purchased hereunder as specified below
such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Purchase Price,&rdquo; in United States
dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; shall have the meaning ascribed to such term in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Minimum</U>&rdquo; means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable
in the future pursuant to the Transaction Documents, including the conversion in full of all shares of Preferred Stock, ignoring any
conversion or exercise limits set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reverse
Stock Split</U>&rdquo; means a reverse stock split of the outstanding shares of Common Stock that is effected by the Company&rsquo;s
filing of an amendment to its certificate of incorporation with the Secretary of State of the State of Delaware and the acceptance thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reverse
Stock Split Amendment</U>&rdquo; means the amendment to the Company&rsquo;s certificate of incorporation that effects the Reverse Stock
Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reverse
Stock Split Date</U>&rdquo; means the date on which the Reverse Stock Split Amendment is filed with the State of Delaware and that Reverse
Stock Split is consummated and deemed effective by the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
A Certificate of Designation</U>&rdquo; means the certificate of designation for the Series A Stock to be filed with the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
A Stock</U>&rdquo; means the Company&rsquo;s Series A Convertible Redeemable Preferred Stock, stated value $20.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
B Certificate of Designation</U>&rdquo; means the certificate of designation for the Series B Stock to be filed with the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Series
B Stock</U>&rdquo; means the Company&rsquo;s Series B Convertible Redeemable Preferred Stock, stated value $20.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Preferred Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&ldquo;Stockholder
Approval</U>&rdquo; means the Company&rsquo;s stockholders approval of the Reverse Stock Split, pursuant to the Delaware General Corporation
Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate dollar amount of Shares purchased hereunder as specified below such Purchaser&rsquo;s
name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and
in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Registration Rights Agreement, the Escrow Agreement, the Series A Certificate of Designation,
the Series B Certificate of Designation, and all exhibits and schedules thereto and hereto and any other documents or agreements executed
in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing address
of 6201 15th Avenue, Brooklyn, New York 11219, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II. </B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to issue and sell, and the Purchasers,
severally and not jointly, agree to purchase, 1,000,006 shares of Series A Stock and 250,005 shares of Series B Stock. The Purchase Price
as set forth on the signature page hereto executed by each Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designees as described below. The Company shall deliver to each Purchaser its Shares as determined
pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at
the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices
of Ballard or such other location as the parties shall mutually agree. Unless otherwise directed by the Placement Agent, settlement of
the Shares shall occur via &ldquo;Delivery Versus Payment (i.e., on the Closing Date, the Company shall issue the Shares registered in
the Purchasers&rsquo; names and addresses and released by the Transfer Agent or the Company directly to the account(s) at the Placement
Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares
to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the
Escrow Agent).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <U>Deliveries</U>.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) a
legal opinion of Company Counsel, in a form reasonably acceptable to the Purchaser and the Placement Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
Company shall have provided each Purchaser with the Escrow Agent&rsquo;s wire instructions, on Company letterhead and executed by the
Company&rsquo;s Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) the
Registration Rights Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) the
Escrow Agreement duly executed by the Company and the Escrow Agent; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) a
certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company, dated as of the Closing Date, in form
and substance reasonably acceptable to the Purchaser and Placement Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) a
certificate executed by the Secretary of the Company, dated as of the Closing Date, in form and substance reasonably acceptable to the
Purchaser and Placement Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii) at
the Purchaser&rsquo;s election, (a) a stock certificate in the name of the Purchaser representing the Shares or (b) a certified copy
of the Company&rsquo;s book entry ledger containing entries showing the Purchaser is recorded as the owner of the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix) evidence
of the filing with the State of Delaware of the Series A Certificate of Designation and the Series B Certificate of Designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) such
Purchaser&rsquo;s Purchase Price by wire transfer to the account specified in the Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 <U>Closing
Conditions</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed
in all material respects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) the
Company shall have filed with the State of Delaware, and the State of Delaware shall have provided evidence of acceptance of, the Series
A Certificate of Designation and the Series B Certificate of Designation; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Shares at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III. </B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or warranty otherwise made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Organization
and Qualification</U>. Each of the Company and the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material
adverse effect on the results of operations, assets, business, or financial condition of the Company and the Subsidiaries, taken as a
whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;); provided that a change in
the market price or trading volume of the Common Stock alone shall not be deemed, in and of itself, to constitute a Material Adverse
Effect. No Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. Subject
to the Stockholder Approval, the execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the
part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection
herewith or therewith other than in connection with the Required Approvals (as defined below). This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>No
Conflicts</U>. Subject to the Stockholder Approval, the execution, delivery and performance by the Company of this Agreement and the
other Transaction Documents to which it is a party, the issuance and sale of the Shares and the consummation by it of the transactions
contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s
certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a
default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon
any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution
or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals (as defined below), conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree
or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state
securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the
case of each of clauses (ii) and (iii), such as would not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filing of the
Series A Certificate of Designation and Series B Certificate of Designation, (ii) filings pursuant to applicable state and federal securities
laws, and (iii) the registration statement required to be filed by the Registration Rights Agreement (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Issuance
of the Shares</U>. The Shares have been duly authorized and, subject to the Stockholder Approval, when issued and paid for in accordance
with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens
imposed by the Company, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities
laws. Subject to the Stockholder Approval and the consummation of the Reverse Stock Split, the Company has reserved from its duly authorized
capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement. The Company is eligible to use Form S-3
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>Capitalization</U>.
The Company has an authorized and outstanding capitalization as set forth in its Annual Report on Form 10-K for the fiscal year ended
December 31, 2021 (the &ldquo;<U>Form 10-K</U>&rdquo;) as of the dates set forth therein. The Company has not issued any capital stock
since its most recently filed periodic report under the Exchange Act other than pursuant to the exercise of employee stock options under
the Company Stock Plans (as defined below). The shares of Common Stock outstanding prior to the issuance of the Shares have been duly
authorized and are validly issued, fully paid and non-assessable. Except as described in <U>Schedule 3.1(g)</U>, there are no options,
warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company or any Subsidiary of the Company
any shares of the capital stock of the Company or any Subsidiary of the Company, subject to the grant of options consistent with past
practices. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in
the transactions contemplated by the Transaction Documents. The description of the Company&rsquo;s stock option, stock bonus and other
stock plans or arrangements (the &ldquo;<U>Company Stock Plans</U>&rdquo;), and the options (the &ldquo;<U>Options</U>&rdquo;) or other
rights granted thereunder, set forth in the SEC Reports accurately and fairly presents in all material respects the information required
to be shown with respect to such plans, arrangements, options and rights. Each grant of an Option (A) was duly authorized no later than
the date on which the grant of such Option was by its terms to be effective by all necessary corporate action, including, as applicable,
approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required shareholder
approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed
and delivered by each party thereto and (B) was made in accordance with the terms of the applicable Company Stock Plan, and all applicable
laws and regulatory rules or requirements, including all applicable federal securities laws. The issuance and sale of the Shares will
not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers)
and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under
any of such securities. There are not outstanding securities or instruments of the Company or any Subsidiary that contain any redemption
or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to redeem a security of the Company or such Subsidiary. Except as disclosed in <U>Schedule 3.1(g)</U>, there are
no stockholder agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the
Company is a party or, to the Company&rsquo;s knowledge, between or among any of the Company&rsquo;s stockholders. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) <U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years
preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including all exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the
&ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of such extension. At the time of filing thereof, the SEC Reports complied in all material respects with
the requirements of the Securities Act or the Exchange Act, as applicable, and did not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light
of the circumstances under which they were made, not misleading. The Company has never been a shell corporation as defined in Rule 144(i)
under the Securities Act. The financial statements of the Company included in the SEC Reports complied in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the
notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end
audit adjustments. The agreements and documents described in the SEC Reports conform in all material aspects to the descriptions thereof
contained therein and there are no agreements or other documents required by the Securities Act and the rules and regulations thereunder
to be described in the SEC Reports, that have not been so described or filed. Each agreement or other instrument (however characterized
or described) to which the Company is a party or by which it is or may be bound or affected and that is referred to in the SEC Reports
and is material to the Company&rsquo;s business (each, a &ldquo;Material Agreement&rdquo;), has been duly authorized and validly executed
by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s
knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive
and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefore may be brought. No Material Agreement has been assigned by the Company, and neither the Company nor, to the best of the Company&rsquo;s
knowledge, any other party is in default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse
of time or the giving of notice, or both, would constitute a default thereunder that has had or that could reasonably be expected to
result in a Material Adverse Effect. To the Company&rsquo;s knowledge, performance by the Company of the material provisions of the Material
Agreements will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental
agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses, including, without limitation,
those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in
a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required
to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)
the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock
and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company equity
compensation or stock option plans. The Company does not have pending before the Commission any request for confidential treatment of
information. Except for the issuance of the Shares contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) <U>Litigation</U>.
Except as disclosed in the SEC Reports, there is no material action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the Company&rsquo;s knowledge, threatened against or affecting the Company, any Subsidiary or any of their respective
properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county,
local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in the SEC Reports adversely affects
or challenges the legality, validity or enforceability of any of the Transaction Documents or the Shares or would, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director
or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) <U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which would reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement. To the Company&rsquo;s knowledge, no executive officer of
the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality,
disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries
to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable
U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of
employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any applicable statute, rule, ordinance or regulation of any governmental authority, including
without limitation all applicable foreign, federal, state and local laws relating to taxes, environmental protection, occupational health
and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) <U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in material compliance with all applicable federal, state, local and foreign laws
relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) <U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o) <U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in
each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except
where the failure to be in compliance would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a written notice that any of, the Intellectual Property Rights has expired, terminated or
been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither
the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports,
a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights
of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company,
all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and
value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license
rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any
rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r) <U>Transactions
With Affiliates and Employees</U>. Except as disclosed in <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company or
any Subsidiary and, to the Company&rsquo;s knowledge, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the Company&rsquo;s knowledge, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with the applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely
to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t) <U>Certain
Fees</U>. Except to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company or
any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with
respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees
or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in
connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u) <U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not be or
be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) <U>Registration
Rights</U>. Except as described in <U>Schedule 3.1(v)</U> and as provided in the Registration Rights Agreement, no Person has any right
to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w) <U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as described in <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received notice from
any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with
the listing or maintenance requirements of such Trading Market. Except as disclosed in <U>Schedule 3.1(w)</U>, the Company is, and has
no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x) <U>Application
of Takeover Protections</U>. The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Shares and the Purchasers&rsquo; ownership of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y) <U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor, to the Company&rsquo;s knowledge, any other Person acting on its behalf has provided any of the Purchasers or their
agents or counsel with any information that it believes constitutes or might constitute material, nonpublic information which is not
otherwise disclosed in the SEC Reports on or prior to the Closing Date. The Company understands and confirms that the Purchasers will
rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on
behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions
contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material respects and does not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the
twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any
representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section
3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z) <U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares to
be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa) <U>Tax
Status</U>. The Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all
foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
paid all taxes and other governmental assessments and charges that are material in amount, whether or not shown or determined to be
due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of
any Subsidiary know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb) <U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the Company&rsquo;s knowledge, any agent or other person
acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of
FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc) <U>Accountants</U>.
The Company&rsquo;s independent registered public accounting firm is set forth in the SEC Reports. To the Company&rsquo;s knowledge,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) has expressed its opinion
with respect to the financial statements included in the Company&rsquo;s Annual Report for the fiscal year ended December 31,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Shares</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any
similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any
Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Shares. The Company further represents to each
Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based solely
on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee) <U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(e) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short,
securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Shares
for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without
limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement
transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and
counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently
may have a &ldquo;short&rdquo; position in the Common Stock; and (iv) each Purchaser shall not be deemed to have any affiliation
with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further
understands and acknowledges that (y) one or more Purchasers may engage in hedging activities (in material compliance with
applicable laws) at various times during the period that the Shares are outstanding, and (z) such hedging activities (if any) could
reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging
activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of
any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff) <U>Regulation
M Compliance</U>. The Company has not, and to the Company&rsquo;s knowledge no one acting on its behalf has, (i) taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation for
soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to
purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement
Agent in connection with the placement of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg) <U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested and/or distributed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested and/or distributed by the Company
in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical
practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in
compliance would not have a Material Adverse Effect. Except as set forth in <U>Schedule 3.1(gg)</U>, there is no pending, completed
or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or
regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company
or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental
entity, which (i) contests the licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or
packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval
of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional
materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any
of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to
enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any
violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the
aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being
conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not
been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing
any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh) <U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of
the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been
no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock
options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their
financial results or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) <U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj) <U>Anti-Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the
&ldquo;Anti-<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or,
to the Company&rsquo;s knowledge, threatened in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk) <U>Other
Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of
any Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll) <U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Shares hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds the
amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital
availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it
to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts
on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its
ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its
debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or
liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <U>Schedule
3.1(ll)</U> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or
for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means
(x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the
ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in
accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm) <U>Regarding
Purchaser&rsquo;s Trading Activity.</U> Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for <U>Sections
3.2(f)</U> and <U>4.13</U> hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked
by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Shares for any specified
term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short
Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may
negatively impact the market price of the Company&rsquo;s publicly-traded securities, (iii) any Purchaser, and counter-parties in
&ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently may have a
&ldquo;short&rdquo; position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control
over any arm&rsquo;s length counter-party in <U>Acknowledgment </U>any &ldquo;derivative&rdquo; transaction. The Company further
understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period
that the Shares are outstanding, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that
such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn) <U>Cybersecurity</U>.
(i) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers,
employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge
of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems
and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from
unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material
Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to
maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent
with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo) <U>Subsidiary
Rights</U>. The Company has the unrestricted right to vote, and (subject to limitations imposed by applicable law) to receive dividends
and distributions on, all capital securities of its Subsidiaries as owned by the Company or any Subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp) <U>Promotional
Stock Activities</U>. Neither the Company nor any Subsidiary of the Company and none of their respective officers, directors,
managers, affiliates or agents have engaged in any stock promotional activity that could give rise to a complaint, inquiry, or
trading suspension by the SEC alleging (i) a violation of the anti-fraud provisions of the federal securities laws, (ii) violations
of the anti-touting provisions, (iii) improper &ldquo;gun-jumping; or (iv) promotion without proper disclosure of
compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq) <U>No
Cash Payments</U>. Except as disclosed on the Disclosure Schedules, neither the Company, its officers, or any Affiliates or agents
of the Company have withdrawn or paid cash (not including a check or other similar negotiable instrument) to any vendor in an
aggregate amount that exceeds Five Thousand Dollars ($5,000) for any purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Shares or otherwise in compliance with applicable federal and state securities
laws). Such Purchaser is acquiring such Shares as principal for his, her or its own account and not with a view to or for distributing
or reselling such Shares or any part thereof in violation of the Securities Act or any applicable state securities law, has no present
intention of distributing any of such Shares in violation of the Securities Act or any applicable state securities law and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares in violation
of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&rsquo;s right
to sell such Shares pursuant to a registration statement or otherwise in compliance with applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Purchaser
Status</U>. At the time such Purchaser was offered the Shares, it was, and as of the date hereof it is, either: (i) an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &ldquo;qualified institutional
buyer&rdquo; as defined in Rule 144A(a) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Shares and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares and
the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition, results of
operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement
Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Shares
nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation
as to the Company or the quality of the Shares and the Placement Agent and any Affiliate may have acquired non-public information with
respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Shares to such
Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement. Other than to other
Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any
actions with respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities
of the Company in order for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>General
Solicitation</U>. Such Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other communication
regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any
seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) <U>No
Government Recommendation or Approval</U>. Such Purchaser understands that no United States federal or state agency, or similar agency
of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of
the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <U>No
Intent to Effect a Change of Control; Ownership</U>. Such Purchaser has no present intent to effect a &ldquo;change of control&rdquo;
of the Company as such term is understood under the rules promulgated pursuant to Section 13(d) of the Exchange Act. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) <U>No
Rule 506 Disqualifying Activities</U>. Such Purchaser has not taken any of the actions set forth in, and is not subject to, the disqualification
provisions of Rule 506(d)(1) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) <U>Residency</U>.
Such Purchaser is a resident of the jurisdiction specified below its address on the signature pages hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) <U>Restricted
Securities</U>. Such Purchaser understands that the Shares are characterized as &ldquo;restricted securities&rdquo; under the U.S. federal
securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under
such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited
circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) Legends.
It is understood that, except as provided below, certificates or book entry accounts evidencing the Shares may bear the following or
any similar legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED
UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY
BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER
MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NOTWITHSTANDING THE FOREGOING, THE SECURITIES
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV. </B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <U>Removal
of Legends</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) In
connection with any sale, assignment, transfer or other disposition of the Shares by a Purchaser pursuant to Rule 144 or pursuant to
any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Purchaser
with the requirements of this Agreement, if requested by the Purchaser, the Company shall cause the Transfer Agent to timely remove any
restrictive legends related to the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares
sold or disposed of without restrictive legends within two Business Days of the request of the Purchaser, provided that the Company has
received from the Purchaser customary representations and other documentation reasonably acceptable to the Company in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Subject
to receipt from the Purchaser by the Company and the Transfer Agent of customary representations and other customary documentation reasonably
acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of (i) the Shares being subject to an effective
registration statement covering the resale of the Shares, (ii) such time as the Shares have been sold pursuant to Rule 144, or (iii)
such time as the Shares are eligible for resale under Rule 144(c) without current information or volume limitations or any successor
provision (such earliest date, the &ldquo;<U>Effective Date</U>&rdquo;), the Company shall (A) deliver to the Transfer Agent irrevocable
instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares, and (B) cause its counsel to deliver
to the Transfer Agent, no later than two Trading Days after the Effective Date, one or more opinions to the effect that the removal of
such legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of
the legend in accordance with such irrevocable instructions and the other applicable provisions of this Agreement. The Company agrees
that following the Effective Date or at such time as such legend is no longer required under this Section, it will, no later than two
Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Shares issued with
a restrictive legend, deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all
restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge
the restrictions on transfer set forth in this Section. Shares subject to legend removal hereunder shall be transmitted by the Transfer
Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the DTC System as directed by such Purchaser.
The Company shall be responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company (i) that such Purchaser will sell any Shares
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or
an exemption therefrom, (ii) that if Shares are sold pursuant to a registration statement, they will be sold in compliance with the plan
of distribution set forth therein and (iii) that if, after the effective date of the registration statement covering the resale of the
Shares, such registration statement is not then effective and the Company has provided notice to such Purchaser to that effect, such
Purchaser will sell shares only in compliance with an exemption from the registration requirements of the Securities Act. Each Purchaser
acknowledges that the removal of the restrictive legend from certificates representing Shares as set forth in this Section is predicated
upon the Company&rsquo;s reliance upon this understanding and that any counsel to the Company will be entitled to rely on this acknowledgment
in connection with the opinion(s) described in Section 4.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Shares for purposes of the rules and regulations
of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder
approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time issue a press release disclosing the material terms of the
transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents
to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the
Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions
contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and
agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any
of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers
or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing
any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue
any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press
release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent
shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company
shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any
regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities
law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required
by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted
under this clause (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, by any other Person, that any
Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Shares under
the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5 <U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.3, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information
and agreed with the Company to keep such information confidential. The Company understands and confirms that any Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any material,
non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser
shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents,
employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to
applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously file such material non-public information with
the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that the Purchaser shall be relying on
the foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 <U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Shares hereunder as set forth on <U>Schedule 4.6</U> attached
hereto following the Closing. Except as set forth on <U>Schedule 4.6</U>, the Company shall use the net proceeds from the sale of the
Shares hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s
debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption
of any shares of Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of
FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7 <U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.7, the Company will indemnify and hold each Purchaser and its directors,
officers, managers, advisors, brokers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such
Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, managers,
advisers, brokers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of
a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser
Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and reasonable expenses,
including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that
any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties,
covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, (b) the administration, performance
or enforcement by the Investors of any of the Transaction Documents or consummation of any transaction described therein, (c) additionally,
if any taxes (excluding taxes imposed upon or measured solely by the net income of the recipient of any payment made under any Transaction
Document, but including any intangibles tax, stamp tax, recording tax or franchise tax) shall be imposed on the Company or any Purchaser
Party, whether or not lawfully payable, on account of the execution or delivery of this Agreement, or the execution, delivery, issuance
or recording of any of the other Transaction Documents, or the creation or repayment of any of obligations hereunder, by reason of any
applicable regulations now or hereafter in effect, the Company shall pay (or shall promptly reimburse such Purchaser Party for the payment
of) all such taxes, including any interest, penalties, expenses and other losses with respect thereto), and will indemnify and hold the
Purchaser Parties harmless from and against all interest, penalties, expenses and losses arising therefrom or in connection therewith,
or (d) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder
of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants
under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined
to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect of
which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the
Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party.
Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (x) the employment thereof
has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable period of time to assume such
defense and to employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material
issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for
the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under
this Agreement (1) for any settlement or compromise of, or consent to the entry of judgement in, any action, claim or proceeding by a
Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (2)
to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of
any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4.7 shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in
addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company
may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8 <U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing of the Common Stock on the Trading Market
on which it is currently listed. The Company will comply in all respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a
Trading Market, the Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust
Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust
Company or such other established clearing corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9 <U>Reservation
and Listing of Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) On
and after the Reverse Stock Split Date, the Company shall maintain a reserve, free of any preemptive rights, from its duly authorized
shares of Common Stock for issuance pursuant to the Transaction Documents in such amount as may then be required to fulfill its obligations
in full under the Transaction Documents. If, at any date after the Reverse Stock Split Date, the number of authorized but unissued (and
otherwise unreserved) shares of Common Stock is less than the Required Minimum on such date, then the Board of Directors shall use commercially
reasonable efforts to amend the Company&rsquo;s certificate or articles of incorporation to increase the number of authorized but unissued
shares of Common Stock to at least the Required Minimum at such time, as soon as possible, and in any event not later than the 90<SUP>th
</SUP>day after such date; provided, that the Company shall not be obligated to hold a meeting of its stockholders to approve such an
amendment more than once in every six (6) months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) As
soon as reasonably possible and, in any event, within four (4) days of the Closing Date, the Company will file a preliminary proxy statement
with the SEC for purposes of holding a special meeting of stockholders to approve the Reverse Stock Split Amendment. Thereafter, unless
the Company has received comments from the SEC to the preliminary proxy statement, the Company shall file a definitive proxy statement
for such purposes within fifteen (15) days of the Closing Date. In the event the Company receives comments to the preliminary proxy statement
from the SEC, the Company shall promptly and diligently respond to and use commercially reasonable efforts to resolve such comments.
The Company shall keep the Investors reasonably informed of any such comments and responses. As long as the Company has Shares outstanding,
the Company shall hold a special meeting of stockholders (which may also be at the annual meeting of stockholders) on or prior to July
31, 2022, for the purpose of obtaining the Stockholder Approval with the recommendation of the Company&rsquo;s Board of Directors that
such proposals are approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as
all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of
such proposals. The Company shall use its best efforts to obtain the Stockholder Approval. If the Company does not obtain the Stockholder
Approval at the first meeting, the Company shall call a meeting at least every one hundred twenty (120) days thereafter to seek the Stockholder
Approval until the date on which the Stockholder Approval is obtained. When the Company obtains the Stockholder Approval, the Company
shall file the Reverse Stock Split Amendment with the State of Delaware, and cause the Reverse Stock Split to become effective, as soon
as practicable, but in no event later than one (1) Business Day following the Stockholder Approval. On the Reverse Stock Split Date,
the Company shall file a Form 8-K disclosing that the Reverse Stock Split Amendment has been filed with and accepted by the State of
Delaware and that the Reverse Stock Split has become effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Company shall, if applicable: (i) in the time and manner required by the principal Trading Market, prepare and file with such Trading
Market an additional shares listing application covering a number of shares of Common Stock at least equal to the Required Minimum on
the date of such application, (ii) take all steps necessary to cause such shares of Common Stock to be approved for listing or quotation
on such Trading Market as soon as possible thereafter, (iii) provide to the Purchasers evidence of such listing or quotation and (iv)
maintain for two (2) years the listing or quotation of such Common Stock on any date at least equal to the Required Minimum on such date
on such Trading Market or another Trading Market. The Company agrees to maintain for two (2) years the eligibility of the Common Stock
for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10 <U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) To
the extent shares of Preferred Stock are outstanding, from the date hereof until sixty (60) days thereafter, neither the Company nor
any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock
or Common Stock Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) From
the date hereof until the earlier of (A) the date on which all Shares are redeemed in accordance with their terms and (B) the date that
is one hundred eighty (180) days following the Reverse Stock Split Date, the Company shall be prohibited from effecting or entering into
an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined
price. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall
be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Until
the Reverse Stock Split Date, neither the Company nor any Subsidiary shall make any issuance whatsoever of Common Stock or Common Stock
Equivalents. The Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy
shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Notwithstanding
the foregoing, this Section 4.10 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be
an Exempt Issuance. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11 <U>Restrictions
on Conversion and Voting of Preferred Stock</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) From
the date hereof up to and including the Reverse Stock Split Date, each Purchaser, severally and not jointly with the other Purchasers,
covenants that such Purchaser will not convert any shares of Preferred Stock and such Purchaser will not transfer, offer, sell, contract
to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected
to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise))
any shares of Preferred Stock. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Each
Purchaser covenants to (i) vote, and shall cause its Affiliates to vote, all shares of Series A Stock owned by such Purchaser or its
Affiliates, as applicable, in favor of any resolution presented to the shareholders of the Company for the purpose of obtaining the Stockholder
Approval, and (ii) promptly upon request by the Company, grant the Company (or its designee) an irrevocable proxy, in form and substance
reasonably satisfactory to such Purchaser, to vote all shares of Series A Stock in accordance with clause (i) above, in each case, in
accordance with the provisions of the Series A Certificate of Designations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Each
Purchaser covenants to (i) vote, and shall cause its Affiliates to vote, all shares of Series B Stock owned by such Purchaser or its
Affiliates, as applicable, on any resolution presented to the stockholders of the Company for purposes of obtaining the Stockholder Approval
and agrees that such shares of Series B Stock shall automatically and without further action of the Purchaser be voted in a manner that
&ldquo;mirrors&rdquo; the proportions on which the shares of Common Stock (excluding any shares of Common Stock that are not voted) and
Series A Stock are voted on the Reverse Stock Split Amendment, as set forth in the Series B Certificate of Designation; and (ii) promptly
upon request by the Company, grant the Company (or its designee) an irrevocable proxy to vote all shares of Series B Stock in accordance
with clause (i) above. For the avoidance of doubt, and for illustrative purposes only, if 30% of the aggregate votes cast by Common Stock
and Series A Stock voting in connection with the Reverse Stock Split Amendment are voted against such resolutions and 70% of the aggregate
votes cast by Common Stock and Series A Stock voting in connection with the Reverse Stock Split Amendment are voted in favor thereof,
then 30% of the votes cast by the shares of Series B Stock voting in connection with the Reverse Stock Split Amendment shall vote against
the approval of the Reverse Stock Split Amendment and 70% of such votes shall be cast in favor of such Reverse Stock Split Amendment,
in each case, in accordance with the provisions of the Series B Certificate of Designations. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12 <U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to such Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Shares or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13 <U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.3. Each Purchaser, severally and not jointly with the other Purchasers covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.3,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure
Schedules. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary (including Section
4.12), the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.3, (ii) no Purchaser shall be
restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws
from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release as described in Section 4.3 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.3. Notwithstanding
the foregoing, and except as set forth in Section 4.12, in the case of a Purchaser that is a multi-managed investment vehicle whereby
separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge
of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set
forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14 <U>Capital
Changes</U>. Except for the Reverse Stock Split, until the one-year anniversary of the Closing Date, the Company shall not undertake
a reverse or forward stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding
a majority in interest of the Shares, provided that no consent shall be required in the event the Company undertakes a reverse stock
split for purposes of maintaining the listing of the Common Stock on the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15 <U>Securities
Law Filings</U>. The Company covenants and agrees that all reports, schedules, forms, statements, and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereo, will conform
in all material respects to the requirements of the Securities Act and Exchange Act and the applicable rules and regulations, as applicable,
and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein,
in light of the circumstances under which they were made not misleading. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V. </B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 <FONT STYLE="font-weight: normal"><U>Termination</U>.
This Agreement may be terminated by any Purchaser, by written notice to the Company, if the Closing has not been consummated on or before
the fifth (5th) Trading Day following the date hereof.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2 <U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 <U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4 <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or email attachment at the email address as set forth below at or prior to 5:30 p.m. (New York City time) on
a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at
the facsimile number or email attachment at the email address as set forth below on a day that is not a Trading Day or later than 5:30
p.m. (New York City time) on any Trading Day, (c) the second (2nd)Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1330 Avenue of the Americas, 33rd Floor,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: &nbsp;&nbsp;&nbsp;Joseph Vazzano</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: jvazzano@abeonatherapeutics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan,
Lewis &amp; Bockius LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One Federal St</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston, MA 02110</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: John J. Concannon III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: jack.concannon@morganlewis.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Purchasers:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
the addresses set forth on the signature pages hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment prior to Closing by each individual Purchaser, and after Closing, by the Company and Purchasers which purchased
a majority in interest of the Shares based on the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and
adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6 <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7 <U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect to the transferred Shares, by the
provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8 <U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third-party beneficiary of the representations and warranties of the
Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit
of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person, except as otherwise set forth in Section 4.7 and this Section 5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9 <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section 4.7, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10 <U>Survival</U>.
The covenants, representations and warranties contained herein shall survive the Closing and the delivery of the Shares for a period
of five (5) years from the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf&rsquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rsquo; signature page were an original
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13 <U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14 <U>Replacement
of Shares</U>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall issue
or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft
or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party
costs (including customary indemnity) associated with the issuance of such replacement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15 <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to seek specific performance under the Transaction Documents. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at
law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16 <U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17 <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The Purchasers have been represented by its own separate legal counsel in its
review and negotiation of the Transaction Documents. For reasons of administrative convenience only, the Purchasers and their counsel
have chosen to communicate with the Company through the legal counsel of the Placement Agent. The legal counsel of the Placement Agent
does not represent the Purchasers and only represents the Placement Agent. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18 <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20 <B><U>WAIVER
OF JURY TRIAL</U></B>. <B><U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY</U></B>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>Signature
Pages Follow</I>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABEONA
    THERAPEUTICS INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Vazzano</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="font-variant: small-caps">REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-variant: small-caps">SIGNATURE PAGE FOR PURCHASER FOLLOWS</FONT>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile
Number of Authorized Signatory:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DWAC
for Shares:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount for Series A Stock: $</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series A Stock:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount for Series B Stock: $</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series B Stock:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
Share Purchase Price:</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
Price for Series A Stock: $</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
Price for Series B Stock: $</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Registration Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Rights Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of May 2, 2022, between Abeona Therapeutics
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each of the several purchasers signatory hereto (each such purchaser,
a &ldquo;<U>Purchaser</U>&rdquo; and, collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of April 29, 2022, between the Company and the Purchasers named
therein (the &ldquo;<U>Purchase Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and each Purchaser hereby agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the
Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Advice</U>&rdquo;
shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Date</U>&rdquo; means, with respect to the Initial Registration Statement required to be filed hereunder, the 80<SUP>th</SUP> calendar
day following the date hereof (or, in the event of a &ldquo;full review&rdquo; by the Commission, the 90<SUP>th</SUP> calendar day following
the date hereof) and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the 20<SUP>th</SUP> calendar day following the date on which an additional Registration Statement is required to be filed hereunder
(or, in the event of a &ldquo;full review&rdquo; by the Commission, the 80<SUP>th</SUP> calendar day following the date hereof); <U>provided</U>,
<U>however</U>, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will
not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall
be the fifth Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above,
provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next
succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event</U>&rdquo;
shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event
Date</U>&rdquo; shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Filing
Date</U>&rdquo; means, with respect to the Initial Registration Statement required hereunder, the later of ten (10) calendar days following
the date of the stockholder meeting held to seek approval of the Reverse Stock Split Amendment and the 70<SUP>th</SUP> calendar day following
the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related
to the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
or &ldquo;<U>Holders</U>&rdquo; means the holder or holders, as the case may be, from time to time of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Initial
Registration Statement</U>&rdquo; means the initial Registration Statement filed pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Losses</U>&rdquo;
shall have the meaning set forth in Section 5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Plan
of Distribution</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Stock</U>&rdquo; means the Series A Convertible Redeemable Preferred Stock, par value $0.01 per share, and the Series B Convertible Redeemable
Preferred Stock, par value $0.01 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registrable
Securities</U>&rdquo; means, as of any date of determination, (a) the shares of Common Stock issuable upon conversion of the Preferred
Stock, and (b) any securities issued or then issuable upon any share split, dividend or other distribution, recapitalization or similar
event with respect to the foregoing; <U>provided, however</U>, that any such Registrable Securities shall cease to be Registrable Securities
(and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect
thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by
the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective
Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities
become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144
as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders
(assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which,
such securities were issued or are issuable, were at no time held by any Affiliate of the Company, as reasonably determined by the Company,
upon the advice of counsel to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
415</U>&rdquo; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Selling
Shareholder Questionnaire</U>&rdquo; shall have the meaning set forth in Section 3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Guidance</U>&rdquo; means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Shelf
Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) On
or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of
all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a
continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not
then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate
form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain substantially the &ldquo;<U>Plan of Distribution</U>&rdquo;
attached hereto as <U>Annex A</U> and substantially the &ldquo;<U>Selling Shareholder</U>&rdquo; section attached hereto as <U>Annex
B</U>; <U>provided</U>, <U>however</U>, that no Holder shall be required to be named as an &ldquo;underwriter&rdquo; without such Holder&rsquo;s
express prior written consent. Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration
Statement filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities
Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use
its best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all Registrable
Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without
volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current
public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such
effect, addressed and acceptable to the Transfer Agent and the affected Holders (the &ldquo;<U>Effectiveness Period</U>&rdquo;). The
Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day.
The Company shall immediately notify the Holders via facsimile or by e-mail of the effectiveness of a Registration Statement on the same
Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness
of such Registration Statement. The Company shall, by 9:30 a.m. (New York City time) on the Trading Day after the effective date of such
Registration Statement, file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holder within one
(1) Trading Day of such notification of effectiveness or failure to file a final Prospectus as foresaid shall be deemed an Event under
Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Notwithstanding
the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities
cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement,
the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the
Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered
by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering,
subject to the provisions of Section 2(e); with respect to filing on Form S-3 or other appropriate form, and subject to the provisions
of Section 2(d) with respect to the payment of liquidated damages; <U>provided</U>, <U>however</U>, that prior to filing such amendment,
the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration of all of the Registrable
Securities in accordance with the SEC Guidance, including without limitation, Securities Act Rules Compliance and Disclosure Interpretation
Question 612.09.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Notwithstanding
any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the Commission or
any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration
Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the
registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable
Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) First,
the Company shall reduce or eliminate any securities to be included other than Registrable Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Second,
the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be registered,
to the Holders on a pro rata basis based on the total number of unregistered Warrant Shares held by such Holders); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Third,
the Company shall reduce Registrable Securities represented by Shares (applied, in the case that some Shares may be registered, to the
Holders on a pro rata basis based on the total number of unregistered Shares held by such Holders).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the
calculations as to such Holder&rsquo;s allotment. In the event the Company amends the Initial Registration Statement in accordance with
the foregoing, the Company will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance
provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form
available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement,
as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) If:
(i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration Statement
without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall
be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration of
a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five (5) Trading
Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement
will not be &ldquo;reviewed&rdquo; or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement,
the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of
such Registration Statement within ten (10) calendar days after the receipt of comments by or notice from the Commission that such amendment
is required in order for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale
all of the Registrable Securities, subject to the cutback limitations set forth in Section 2(c) of this Agreement, is not declared effective
by the Commission by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a Registration
Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included
in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable
Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not
be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an &ldquo;<U>Event</U>&rdquo;,
and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such
five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded,
and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred
to as &ldquo;<U>Event Date</U>&rdquo;), then, in addition to any other rights the Holders may have hereunder or under applicable law,
on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by
such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated damages
and not as a penalty, equal to the product of 2.0% multiplied by the aggregate Subscription Amount paid by such Holder pursuant to the
Purchase Agreement. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after
the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to
be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus
all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata
basis for any portion of a month prior to the cure of an Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) If
Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the
resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3
as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect
until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) Notwithstanding
anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate of a Holder as
any Underwriter without the prior written consent of such Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <U>Registration
Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&rsquo;s registration obligations hereunder, the Company shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Not
less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the
filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed
to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed,
which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders,
and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall
be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning
of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto
to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is
notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration
Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements
thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as <U>Annex B
</U>(a &ldquo;<U>Selling Shareholder Questionnaire</U>&rdquo;) on a date that is not less than two (2) Trading Days prior to the Filing
Date or by the end of the fourth (4<SUP>th</SUP>) Trading Day following the date on which such Holder receives draft materials in accordance
with this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) (i)
Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus
used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable
Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to
register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented
by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant
to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration
Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence
from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein
which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material
respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable
Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with
the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus
as so supplemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) If
during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock
then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to
the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such
Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Notify
the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by
an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and,
in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such
notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective
amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a &ldquo;review&rdquo;
of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to
a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or
any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional
information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings
for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration
Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated
or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement,
Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading, and (vi) of the occurrence or existence of any pending
corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company,
makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; <U>provided</U>,
<U>however</U>, that in no event shall any such notice contain any information which would constitute material, non-public information
regarding the Company or any of its Subsidiaries and the Company agrees that the Holders shall not have any duty of confidentiality to
the Company or any of its Subsidiaries and shall not have any duty to the Company or any of its Subsidiaries not to trade on the basis
of such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Use
its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness
of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable
Securities for sale in any jurisdiction, at the earliest practicable moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) Furnish
to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including
financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested
by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference)
promptly after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or
successor thereto) need not be furnished in physical form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) Subject
to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by
each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any
amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) The
Company shall cooperate with any broker-dealer through which a Holder proposes to resell its Registrable Securities in effecting a filing
with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110, as requested by any such Holder, and the Company shall pay
the filing fee required by such filing within two (2) Business Days of receipt of a request therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Prior
to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with
the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification) of such
Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States
as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the
Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions
of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally
to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction
where it is not then so subject or file a general consent to service of process in any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) If
requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted
by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered
in such names as any such Holder may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) Upon
the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account
the Company&rsquo;s good faith assessment of any adverse consequences to the Company and its shareholders of the premature disclosure
of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to
the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document
so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section
3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
suspend use of such Prospectus. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly
as is practicable. The Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration
Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period
not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) Otherwise
use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and
the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement
or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at
any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions
as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) The
Company shall use its reasonable best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the registration
of the resale of the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) The
Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially
owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the
shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable
Securities solely because any Holder fails to furnish such information within three Trading Days of the Company&rsquo;s request, any
liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely
because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <U>Registration
Expenses</U>. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by
the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to
in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees
and expenses of the Company&rsquo;s counsel and independent registered public accountants) (A) with respect to filings made with the
Commission, (B) with respect to filings required to be made with any Trading Market on which the shares of Common Stock are then listed
for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including,
without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the
Registrable Securities), and (D) if not previously paid by the Company with respect to any filing that may be required to be made by
any broker through which a Holder intends to make sales of Registrable Securities with FINRA pursuant to FINRA Rule 5110, so long as
the broker is receiving no more than a customary brokerage commission in connection with such sale, (ii) printing expenses (including,
without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses,
(iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance,
and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated
by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation
of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees
performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing
of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any
broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other
costs of the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Indemnification
by the Company</U>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the
officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as
a result of a pledge or any failure to perform under a margin call), investment advisors and employees (and any other Persons with a
functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them,
each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and
the officers, directors, members, shareholders, partners, agents and employees (and any other Persons with a functionally equivalent
role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the
fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without
limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;<U>Losses</U>&rdquo;), as incurred in investigating,
preparing or defending against any litigation, commence or threatened, or any claim, arising out of or relating to (1) any untrue or
alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any
amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of
a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement
thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company
of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance
of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are
based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or
to the extent that such information relates to such Holder or such Holder&rsquo;s proposed method of distribution of Registrable Securities
and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in
any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (ii) in the
case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or
otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or
otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). The
Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with
the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by
any of the Holders in accordance with Section 6(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Indemnification
by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents
and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law,
from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of
a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information
so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii)
to the extent, but only to the extent, that such information relates to such Holder&rsquo;s information provided in the Selling Shareholder
Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by
such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this purpose),
such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than
the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and
the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by
such Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Conduct
of Indemnification Proceedings</U>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder
(an &ldquo;<U>Indemnified Party</U>&rdquo;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the
&ldquo;<U>Indemnifying Party</U>&rdquo;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including
the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection
with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party
of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by
a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially
and adversely prejudiced the Indemnifying Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such
Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to
any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to
the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent
such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing
that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to
assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified
Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section)
shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided
that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such
actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) not to be entitled to indemnification hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Contribution</U>.
If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party
harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such
proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions,
statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such
Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made
by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party
as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&rsquo;
or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified
for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the
dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the
amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Remedies</U>.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the
Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including
recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder
agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach,
it shall not assert or shall waive the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>No
Piggyback on Registrations; Prohibition on Filing Other Registration Statements</U>. Neither the Company nor any of its security holders
(other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other
than the Registrable Securities. The Company shall not file any other registration statements until all Registrable Securities are registered
pursuant to a Registration Statement that is declared effective by the Commission, provided that this Section 6(b) shall not prohibit
the Company from filing amendments to registration statements filed prior to the date of this Agreement so long as no new securities
are registered on any such existing registration statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Discontinued
Disposition</U>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of
the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition
of such Registrable Securities under a Registration Statement until it is advised in writing (the &ldquo;<U>Advice</U>&rdquo;) by the
Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use
its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges
that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be
subject to the provisions of Section 2(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Piggy
Back Registrations</U>. If, at any time during the Effectiveness Period, there is not an effective Registration Statement covering all
of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating
to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form
S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely
in connection with any acquisition of any entity or business or equity securities issuable in connection with the Company&rsquo;s stock
option or other employee benefit plans, then the Company shall deliver to the Holder a written notice of such determination and, if within
fifteen (15) days after the date of the delivery of such notice, any such Holder shall so request in writing, the Company shall include
in such registration statement all or any part of such Registrable Securities such Holder requests to be registered; provided, however,
that the Company shall not be required to register any Registrable Securities pursuant to this Section 6(d) that are eligible for resale
pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Commission pursuant
to the Securities Act or that are the subject of a then effective Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Amendments
and Waivers</U>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented,
and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by
the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes
any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification or waiver
disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group
of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or
amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall
be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be
omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with
respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect
the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or
consent relates; <U>provided</U>, <U>however</U>, that the provisions of this sentence may not be amended, modified, or supplemented
except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered
to all of the parties to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth
in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <U>Successors
and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the
parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder
without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their
respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) <U>No
Inconsistent Agreements</U>. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company
or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would
have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Neither
the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with respect to any
of its securities to any Person that have not been satisfied in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <U>Execution
and Counterparts</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature
page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in
accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) <U>Cumulative
Remedies</U>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) <U>Headings</U>.
The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or
affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) <U>Independent
Nature of Holders&rsquo; Obligations and Rights</U>. The obligations of each Holder hereunder are several and not joint with the obligations
of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder
hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder
pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other
kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect
to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders
are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions.
Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement,
and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of
a single agreement with respect to the obligations of the Company contained was solely in the control of the Company, not the action
or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do
so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a
Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABEONA
    THERaPEUTICS INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE OF HOLDERS FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
PAGE OF HOLDERS TO ABEONA RRA]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 61px; width: 204px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK, NY and CLEVELAND, OH, April 29, 2022 &ndash; Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene
therapy, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,000,006
shares of Series A convertible redeemable preferred stock and 250,005 shares of Series B convertible redeemable preferred stock. Each
share of Series A and Series B preferred stock has a purchase price of $19.00, representing an original issue discount of 5% of the $20.00
stated value of each share. Each share of Series A and Series B preferred stock is convertible into shares of Abeona&rsquo;s common stock
at an initial conversion price of $0.45 per share. Shares of the Series A and Series B preferred stock are convertible at the option
of the holder at any time following the Company&rsquo;s receipt of stockholder approval for a reverse stock split of the Company&rsquo;s
common stock. Abeona will be permitted to redeem the Series A preferred stock at its option upon the fulfillment of certain conditions
and subject to certain limitations. The Company and the holders of the Series A and Series B preferred stock will also enter into a registration
rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series A and Series B preferred
stock. Total gross proceeds from the offerings, before deducting discounts, placement agent&rsquo;s fees and other estimated offering
expenses, is approximately $25 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A preferred stock permits the holders thereof to vote together with the holders of the Company&rsquo;s common stock and any other
shares of capital stock entitled to vote generally as a single class on all matters submitted to a vote of stockholders generally, including
any proposal to effectuate a reverse stock split of the Company&rsquo;s common stock at a special meeting of Company stockholders. The
Series B preferred stock permits the holders thereof to vote on a proposal to effectuate a reverse stock split of the Company&rsquo;s
common stock at a special meeting of Company stockholders, together with the holders of common stock and Series A preferred stock. The
Series B preferred stock permits the holder to cast 15,000 votes per share of Series B preferred stock on such proposal. Except as required
by law or expressly provided by the certificate of designation, holders of the Series B preferred stock will not be permitted to vote
on any other matters. The holders of the Series A and B preferred stock agreed not to transfer, offer, sell, contract to sell, hypothecate,
pledge or otherwise dispose of their shares of preferred stock until after the special meeting. The holders of the Series A preferred
stock agreed to vote their shares in favor of the reverse stock split proposal and the holders of the Series B preferred stock agreed
to vote their shares in the same proportions as the shares of common stock and Series A preferred stock are voted on that proposal. The
holders of the Series A and Series B preferred stock have the right to require the Company to redeem their shares of preferred stock
for cash at 105% of the stated value of such shares commencing after the earlier of the Company&rsquo;s stockholders&rsquo; approval
of the reverse stock split and 60 days after the closing of the issuances of the Series A and Series B preferred stock and until 90 days
after such closing. The Company has the option to redeem the Series A preferred stock for cash at 105% of the stated value commencing
90 days after the closing of the issuance of the Series A preferred stock, subject to the holders&rsquo; rights to convert the shares
prior to a redemption at the option of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the offerings is expected to occur on or about May 2, 2022, subject to the satisfaction of customary closing conditions. Additional
information regarding the securities described above and the terms of the offering are included in a Current Report on Form 8-K to be
filed with the United States Securities and Exchange Commission (&ldquo;SEC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners is acting as the sole placement agent in connection with the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A and Series B preferred stock and shares of common stock into which these preferred shares are convertible are being issued in
reliance upon the exemption from the securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the
&ldquo;1933 Act&rdquo;) and/or Rule 506 of Regulation D as promulgated by SEC under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Abeona Therapeutics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona&rsquo;s
lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa
in Phase 3 development. The Company&rsquo;s development portfolio also features AAV-based gene therapies for ophthalmic diseases with
high unmet medical need. Abeona&rsquo;s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety
of devastating diseases. Abeona&rsquo;s fully integrated cell and gene therapy cGMP manufacturing facility produces EB-101 for the pivotal
Phase 3 VIITAL&trade; study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information,
visit <U>www.abeonatherapeutics.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted
to identify forward-looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances),
which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited
to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition; continued interest in our rare
disease portfolio; our ability to potentially commercialize our EB-101 product candidate; obtaining a strategic partnership to take over
development activities for ABO-102; our ability to enroll patients in clinical trials; the outcome of any future meetings with the U.S.
Food and Drug Administration or other regulatory agencies; the impact of competition; the ability to secure licenses for any technology
that may be necessary to potentially commercialize our product candidates; the ability to achieve or obtain necessary regulatory approvals;
the impact of changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; reducing
our operating expenses and extending our cash runway; our ability to execute our operating plan and achieve important anticipated milestones;
and other risks disclosed in the Company&rsquo;s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities
and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events
or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise,
except as required by the federal securities laws.</I></B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
and Media Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greg
Gin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP,
Investor Relations and Corporate Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ir@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  ] ,P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U;4?(5-TB
MLTS*8TV%MWS?3D#ID]J@EM-55-]G=QK(VS,4XWI& .0I&"?J:R]&N5U3Q;>S
MRBY)ME*0BXM GEC.#M?J<XKJJ<X6T,XVGJ8T'B*,7TEKJ$+6+ XC:=U EYQE
M:V16!XMMT.F?:57%Q$Z[)%C1G'/0;JU=+:5M-MS<&0RE 6,@ ;/N!Q4)N]F$
M9/F<66Z**2J-!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,75?#5OJ-\FH+)+%?PIB&3>2BD="5S@XI((=:L[>$W6H64X0.9Y)(B
MF[^[C!P .YK;JC<QFZO$@<-Y*KO88.'/3!/0CU'TIN;M8S<$M49,UO?:Y:12
M3PP%$3=Y$F0DLF>^5)V]P16G(=342K;Q604(OD[G;K_$#@<#TQ6%XM\4S:%-
M#9642"1TWEV'"KT  _"C3O%4DWA2\OKO;Y\!,:E1@.Q'R\?C6?M(IM&7M8*3
MC?4O+J&JW9OAITNES&/;Y"[GR,GG?^1QCTHFO?$5O/;%]/M);81;KEHI#N#<
MY" ]>V/6N:T&_>PNKF",_P"D2Z0DT0_O.NX_UK \+>(M:_MNV6*ZGNO/D DB
M=BP8$\GVQZUV4Z3E'FTV,O;K2]]3TS1O$,&K)\T,MG+NVK#<X5V]P.XK7S6'
MJ=G9W&M6CPI =31U8O\ *9%B'4X/;G'KS6X*PE;H=<&]F%%<[XPUJ;3K".ST
M_+:E?MY-NHZKGJWX50TFYOO#?B%-)U:\ENH+U UM<2G.) /F3/\ GM5*FW&Y
M+JI2Y3L:,T=17,6]^8/'>K+<W6RUBM(F D?"*3WYX%3&/-<N4N6QU%%97_"3
MZ+G']JV>?^NHK0@N(KF,202I+&>C(P(/XBDTUN-23V9+14%S>06<9DNIHX8Q
M_%(P4?K5%?$^BL<#5;//_744*+>R!R2W9JT5'#/%<1B2&1)$/1D8$'\:9<7<
M%G&9+J:.&/\ O2,%'ZT@NMR>BLK_ (2?1<X_M6SS_P!=A5^"YANHQ);RQRQG
MHR,&'YBFXM;H%)/9DU%027MO%.(9)XTE*%PC, =HZG'I5$^)]%5MIU6SW=,>
M<*%%O9 Y);LU:*BAN(KF(202))&>C(P(/XTRZOK:Q3?=W$4"'H9'"@_G2L%U
MN6**RAXGT5FPNJV9/_745HQ31S1B2)UD1NC(<@_C3::W!23V9)5#4].>\5)+
M>X>WNHLF*1>1]&'0@U?I*6X-75CS_6M<M)W-CXGTJ1;J'[LMNW4>JD]C7.7V
MHI/;):6<30643%U1FW,S'^)CZ_RKK?B7%!_9MI*P N1-M0]RN#D?RKA;=#,\
M<2\EV"C\3BN.K=.QY.*<E/E)O$=S-8>(+-[:1HIK>T@VLO4';G^M;7AJ^U?7
M+QK>P6RL 5W7%S!;JKX_Q-<WXNF$OBS4-OW8Y!$/HJA?Z5H^#?$::!?N\R%X
M)E"R!>HQT(KZ#V?[E66MB(3M5LWI<]4TO1;724;[.K-+)S)/(=TDA]2QJW/-
M';P/-,P2.-2S,>@ ZFJFE:U9:U"TEA-YBH<,-I!4^AS6?XLTK4-<M(=/LWCB
MM99!]JD+8;8.P'?->=:\K2/6NE"\-3F]!U[2]1\0W6O:M?V\+*3#9P2/S''W
M;'J?\:TO$^J>']=TAX$UBS2YC/F6\GF<HXZ?X5T46A:9#$D:Z?:[44*,Q*3@
M?A3_ .QM-_Z!]I_WY7_"K=2/-S*^AFJ4^5Q=M3.\):^OB#18YV(^T1_NYU']
MX=_H>M8_]EVVI_$S4!>1B:*&TB<1MRI;H"1WQS6@/#USIOBU-2TD0I9W";+N
M#.T<=&48QG_Z_K4-YH>LQ^++K6=,EM@&@2-8YB<28Z@XZ=B#33BFW%VNA-2<
M4I*]F;G]AZ7MQ_9UIC_KBO\ A7/Z-!'I/C[4-/LU\NTFM4N/)7[JOG!(':K?
MVWQ;C']EZ8#Z_:6_PJ30M%O8-5N]7U>6%[VY18PD.=D2#L">M)72?,QNTI+E
M7X&'K\HN?'HBN=,GU.&UM%>.WC (5F/+$$X/I5PWL.-O_"$W)'IY$7^-7]9T
M6_.M1:QHLT*7:1>3+%.#LF3.1R.00:9]L\6]/[+TS/K]I;_"JYDTK?F3RM2=
M_P KE/PK;W-OXAOVBTNYT[39XE=8I0-HD!YP >,@TVYM(M;^)#VVH()K:QLU
MDCA?E=S'J1WZUK:+IVJQW]SJ&L7:-),H1+: GRH@/KU/O4&L:'?_ -NQ:UHL
ML*W2Q>3+%/G9*G4<CH:7,N9Z]!\CY%IU-3^P]+(Q_9MGC_KBO^%<_IMK'HGQ
M"FLK%?*M+NS\]H5^ZKAL9 [5;-YXMQ@:7I@/J;EO\*=H>B7\>LW&L:S-"]Y+
M&(4CA!V1)UQD]:2ND^9C=I-<J_ SM=T^'4_B+IMM<@M ;)V=,X#@-T/MG%=)
M_86EA-O]FVFW'3R5_P *IW&DW$OC2TU12GV:&U>%LGYMQ.1Q6WVJ93=DDRX0
M5Y-KJ<EX=MH]+\::UIUH#':>5%,L0/RHQZX]*K^(I=,_X2^W-Q;7>IW<-O\
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JIEECN6B*KM*E%=3[X/?WJ.VT:* 2%Y'D>1][, $&< < <=A1J+W[G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>abeo-20220429.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKI2bP9z5Z8eekhvWB0bfkajyAhF/g4riINRY8WYboL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:ABEO="http://abeonatherapeutics.com/20220429" elementFormDefault="qualified" targetNamespace="http://abeonatherapeutics.com/20220429">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20220429_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20220429_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abeo-20220429_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abeo-20220429_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20220429.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031121504200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 29,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA
THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0221517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1330
Avenue of the Americas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">33rd Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">813-4701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABEO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abeo-20220429.xsd" xlink:type="simple"/>
    <context id="From2022-04-29to2022-04-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-29to2022-04-29">0000318306</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-29to2022-04-29">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-04-29to2022-04-29">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2022-04-29to2022-04-29">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-29to2022-04-29">2022-04-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-04-29to2022-04-29">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-04-29to2022-04-29">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-04-29to2022-04-29">001-15771</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-04-29to2022-04-29">83-0221517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-29to2022-04-29">1330 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-04-29to2022-04-29">33rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-29to2022-04-29">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-04-29to2022-04-29">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-29to2022-04-29">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-04-29to2022-04-29">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-04-29to2022-04-29">813-4701</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-04-29to2022-04-29">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-04-29to2022-04-29">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-04-29to2022-04-29">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-04-29to2022-04-29">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-04-29to2022-04-29">Common     stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-29to2022-04-29">ABEO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-29to2022-04-29">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-04-29to2022-04-29">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%N+A_?97!*)30G10E0 (HH+B4\S6=11X_(K%&4<XKDN.Z_,Z8\:U4!$9RXC
M>*GM%USID/F+=^\:<M\MV;JHXBC7NN@AD84L)D^<:90/5VNWJ=?V*<+5*[EZ
MJ-)8&F%> 2OF9)HGR_IY@FNX+FW3ZUX/X^F7//US>![Y6MA9 CTV94EM#^$Z
MP=WX81I<++Z,'X/9^,=B,IJ3R71TA2#>E(@WYR".()T:4CF1$7\A7_EK'22N
MY,+'IWW?[2)8U*U<SCT';,%>R"0".K$2(2O*PNG,-DCV_3:,?WI->QCAD0_3
M<P@G,E0Z5;J NR1S Y. *$U&*H<^A:Y546W*&]3OQQADY=+4.P<RB"+-L^SR
M<$"^P7/D0=:3X9+4]]V+X)G+'-JY(F;#"9BFAO1D&')5!2CNXRCR8JMJD7%)
MW]<1^+E2&B.L2@3%/?XMX<B>0<H7:BMKZ7"Y*=]>/,%*"&.KR@;%W?XM6SD>
M9UH]"QG69QS7G#YA:%75H+C1OT6;J<R Y_PITM.3!%>DX-8W&%M5.2AN^T4*
M U@EGT;!!=YW.]T/&$I5-"CN]M^4+:JSC9)8%6L0Z5._W>FY6!6C58V@N+7_
MU,(8+J%KDB27>Q_.:JEPH:;%D5>5!P_W\KF*12B,D&OR'0:X%BRNXVE0:>2I
MBH&'V_5,\W8(W<-AANW6L+",A 7RPVI5G[\&O4:RHW4Z;M?_(YMD60YDC8"X
M;"-@Y?<>;LX+8>*BDE#O_?(#F?,PA_%6NP)I4++C4\D+ A_8AH6_+LEO[I5+
M20KKTV<6YRAOY?X>;M<+S2([[N:OR5+5C[J&+08LYS"2RNL]W)</747&+^&&
MR34_N;YL$)H&\_O@=XRI,GGO+),?PXI@;7OI,RB8C;6.E,GZI.*")P>:<[2'
MMO]'?&?VC1F)^0J$W*L>M%GOMOB[$Z/28EN]5 8VZ<7AAC.8!/8!N+]2RAQ.
M[$Z]_*-E^"]02P,$%     @ P(FB5)^@&_"Q @  X@P   T   !X;"]S='EL
M97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNG
MLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[
MSC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPK
MH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP
M'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ
M#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#
MA\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VP
MI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\
MR-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+V
MH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;
M^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN
M1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB
M*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z
M6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBI
MN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &
MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ P(FB5)>*NQS     $P(
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M_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ P(FB5"0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( ,")HE1ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " # B:)4S:+&Q.X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " # B:)4
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( ,")HE0N:^X#;00  '01   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " # B:)4
MGZ ;\+$"  #B#   #0              @ &P#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( ,")HE27BKL<P    !,"   +              "  8P/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,")HE2JQ"(6,P$  "("   /
M      "  740  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " # B:)4)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " # B:)499!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>abeo-20220429.xsd</File>
    <File>abeo-20220429_lab.xml</File>
    <File>abeo-20220429_pre.xml</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex3-1.htm</File>
    <File>ex3-2.htm</File>
    <File>ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abeo-20220429_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abeo-20220429_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abeo-20220429.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABEO",
   "nsuri": "http://abeonatherapeutics.com/20220429",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-04-29to2022-04-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abeonatherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-04-29to2022-04-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-22-011829-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-011829-xbrl.zip
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M:->$I"4,"A3('0A+$:"9R4.\ O,O@L4P7&I*/["TK-I1J60!@F)ZZ\-$Z;U
M,ML*T7 -SSBPU-E-V1ZSU?U90!<$*#WF6G=M"WD#%$\ST"7+DFROGJ>[V6Y6
M1%@:UY:X8@,RIYDPRX-@ 3!E,E#(D-*A0NBEY_5= I:IAQC!YI@RMP38338I
M:&H"(L%J#*#AH,V?*?5"Q$R.3 +3.8O)[F>R!]O5TKEE K#9A,(0!42%W1F
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M!@&=JU[NM*E[W"H*HO>[G)DDE%K4%#O&8L%I$B59PM:_R)-/D6!;JVPB5T#
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M>BFJ5X!6ZAFQL@KTNZH$Y;78?K^\ONE:?I*;]2;YUPJG1&[Y+U!+ P04
M" # B:)4?(\U^%L'  #I5P  %0   &%B96\M,C R,C T,CE?<')E+GAM;,V<
M77/:.!2&[W=F_X.7O08"Z7XD3;:3T-!AFC;9D+:[>],1M@!-9(F1Y #_?B4;
M4SXL^>3&)[E(B#F2SOL<6?:Q)%^\6Z4\>J9*,RDN6[W.22NB(I8)$[/+UI=Q
M^VH\&(U:D39$)(1+02];0K;>_?7S3Y']N?BEW8Z&C/+D/'HOX_9(3.7;Z#-)
MZ7GT@0JJB)'J;?25\,P=D4/&J8H&,EUP:JC]HFCX//JMTSLE4;L-J/<K%8E4
M7QY&VWKGQBST>;>[7"X[0CZ3I51/NA/+%%;AV!"3Z6UM)ZN3S4]1_((S\73N
M?DV(II'E)?3Y2K/+EFMWT^SRM"/5K-L_.>EU__ET.X[G-"5M)ARWF+;*4JZ6
MJG*]L[.S;OYM:7IDN9HH7K9QVBW=V=9LOV4!^QU/-#O7N7NW,B8F#WMM,Y'7
MPOW7+LW:[E"[UV^?]CHKG;1*^#E!)3E]H-/(_;71V[9*)E0*8N:VLRQH9EB<
MAZ[KS+H#:;NF]3FO8*[H]++ES&T[_?[)F_Z9:^77/2.S7M@NJIGK8:VHN^?!
M0E%-A<E%W]H#>T7HRMB.19.R(M?^RWTTS+ABFP[4B]JNMV6I;=5^+"PW+I5.
M<1GO^<%=5.2!Z+*'Y^PUC3LS^=Q-*.LZ$.Y#3B2G8?_YGC=T-=%&D=B4-7$K
M@N?U?[<V!R;=!KPJ23S:&JN=VK<X]&DW?%<JCJ1*J+*LR[J(BO>"=MQ9-Q;=
M!5&VHG8\9WP;[ZF2J8_.AH3T.+H+RC;1#,TKVW[B?!AR,JO&>6 "Y-G# %JI
M!HOH>ZICQ1:.2PW8/4L@WSXJWPIM#6,NSYT'.F/.7^>*NP13=S \+GB* ,&?
M8HX40;5($;@2(B/\@2ZDJ@&_;PGD_0:3=Y4V),Q_9T09JO@:0OK(& C[-TS8
M'H5(O!\5$9HY/A#@Q]9 XK^CWGAX-"(A'\\IYRZM(P+4RZOL@=C_P,3NU_D*
MP-\\N^N[O;3 V>\4 >+_\[7@/U*+%(%[JIA,["5= =@?&0.IGV%2]RA$Y7TC
M$BCMK2DX_\&'?2 /"?60Z9CPPJ.A/:;#N"O,H<A1<LY:F:C8_Z5$@:'O&$.1
MHZ2A-1(;!C[(E-IS)CBJ^*VAR%$2T#J1#3._$8:9M9L'^)REDQ\/3O=9'UM!
M&:,DG3Y1*&S+)PW"N.F-$-]#2RACE%PS) Z%\\#J482/1$)7'^DZ!/K(%$H:
M)<<,RD-!?:]82M1ZS.+Z0>/8%@H;);,,"T2A_4A6H\2J8E-63!#60_<6@;)'
M22M!<E%",!*Q5 NY\[AX(#-[/JX',@D.Z34%H>% R3=?(!TE*%=)8G'IS9];
M)F@O%(I*<_ <$5X  C)?"?;^R[#WX=A1\M!:F:\$^^G+L)_"L:/DHK4R,;$/
M[,<[]2B7GAEHKS$4.4HN6B,1$WA^I;E3]TH^LV*=5!WUHQ)0](@I:E@L:H<O
M+O*0WEY:0GDCIJO5XC YWTMM"/^/+>KN)*OMH<P1$]>0T*8?,!9Q=P\M?$N)
M#DR@?%%RU4HY32-U$5:4^+OOO@44*$H"6B6F89ZWTLU]S*4(/H\]MH)R1<DD
M?:*:'GC=DF+M/?5WO@:O8$,95@]E-(SQFV+&>C"0:9J)S3,:SZR8QQ2*%R7]
M"\IK&/58<A8SP\3LD[U#5(SP:LY5=E#(*,F>7UC#A.\5=9&F]K8[7\?E]ARH
MN^G4-_*&[*'$47*]>J&XY$=:9U2]E']%*6@44-(^J.BFQQD:9W;86_?ZDT>W
M8\8SRAQ905FCI'P^40VS_2P?%7'[]\;K="*Y?WM(I2&4,$J"%Y#6,.0]/ZKQ
M'IA P:)D=I5RD,:$FU4\)V)&_:L7JBVA@%$RO9 XM+%W!AI[9R\<>U$R/I\H
M)+;%VG![1MU-.)L1_TZR8 'P/AM,X@&I3>_?R[?\N)W=*LW]&-H/U=@]IE#@
M.%LD0_*:1ITES-"D<&G(!!&Q3:FV^]H\V7E]*6@ </90 D6C/-[_1CG_*.12
MC"G14M"DN-4//>'W%H%& 7$.L48N2@B^2IY92BI?"*H\YX#'%(H<<>[0(P]G
M[66QJ'E[[2E>X1$B[BL!!8\XB1@6B[0^S5#G,WNF[XDA&P]#_'TEH/P1)Q3#
M8M'6SZN!O?#,9'C._, 02AMQ*6RE-!3(XY1P?IUI)J@.CBT'AE#(B&M>*Z6A
M0+Y)J9K90>V#DDLSW^SM#,'V%(!"1US9&I2* W_U8Q]YL?\M2+["&OQV D3L
M7I%8K]V(8[>0HKB2BX0H#_60/90[ZL9*O]"&R=^Y-W?MWC_ESHQLWA9:]%!?
M"AH%E'05*AKGVKJSDS]X:=VS@_)&3$RKA.'LF<HFG,5#+DGPOGS/#,H7,0NM
MD(6"]YJ()Y4M3+R^5S*FU$V?Z.W9!DB(@!5 0X*8G[X(!<[C IFF;C.1C)_&
M<RM:WV4F?Z.I]2_XT"!8#AH:S$V< .%(=T'ZQT8OFERO'^B4*K=,X9&NS+5M
MZ"E\4P0H#HT/ZAN%P!@JPG31/=)U:P^X=]86W[A?[KVL]LC_4$L#!!0    (
M ,")HE1/!VDU::@  ,XT!  *    97@Q,"TQ+FAT;>R]:W/;1K8N_)U5_ ]X
MI_;9157!&LN79#+.F2I:EA/5<6P=2=YSYB-(-"7$(,#!13+SZ]]UZ^[5 $C)
MCIT,9>ZJ/;%(L-&7U=WK\JQG_?CSY2]O_C$>_?CSR?05_#?"__OQ\O3RS<D_
M?OPK_Q>^_:M\_>/+=Z_^%5U<_NO-R?_^RZ(LFK]'1X]73729+4T=O36WT7FY
M3(J8/XBC"U-EB[_ #^&G9_9WC?G8/$KR[*KX>S0W16.J%]%]VWH1+9/J*BL>
M->7J[Q$\[CZ8E4U3+NFSO_SCOXM9O7KQXU_/.J^^_VMT)ZOLZKJYYYM_?/F/
MDX_7V2QKX#6'1S_^]>4_OE0W[%S=KQ^OW[V]U.][M$B66;[^^UUOI&?K[#?#
M'?1SB0UN',NLS-,OM7Q#H_Z2 [HX.7Y_?GIY>G(Q'IV]/S_^>7IQ$DU_.C\Y
M^>7D[>67'2@-*'K\M8=TKS7ZQ%Z'??ZUK9MLL98/LR(UV.3CP^=9\24'<GF=
MU>/1A9FW5=9D\-.SMII?)[6)IE>5,4MX:S1IX*'HO_/TWVWYXL?W_W#?_/C7
M]__X[XH^/HC@D31I3!HE=50NHNFJRO+HR0]Q].3QDR=Q-#/-K3%%-)V9LDBB
MRVM3)2O3-MF\CDZ+^6$\'B71*Y,GMTEEHGE9K<HJ:;*RP-<;]?;C<KE*BK5^
M=QPE11J99'X=K:3[593AC&6+#'H$C6 ;-4QLTK30_"JY@J%"%TQ31A/\81QE
MQ3QOTZRX&H^RIH[J=CXW=5U6-36>U/AKF,A$=<7.5:4Z0T_/RSPW\R:[,?DZ
M"KOO?E/K$1Q^65'J;H _2)B^QLGUAVQH:;VIDJ)>E!4<B^UJ9:HYK--?_G%N
MYEF3Y#5>RP]K9 _F%)L>XH$R'LG90'L0MYW?;!&>*N8CG',-;'%Z(#4Y;- *
M_Z0#SA]X61%5\&52S U,EYP>\./EB@ZD154NH]H?F96YRNI&3JMD =.<FG0\
MFJVAOW/Z\-DD.9@\.<!S$9M2Q^UTWN"G1S\\?1KCR9E !^#7W4,O_$7O[/MK
M647G;6ZBYX^_P^;.S56;4W_&HU?8[ JZW.97=#[/^$AZ7V3XUT4#']:Z2S@W
M)Q]AWHHK$\&,+C,X^_KG,-SJP?G?0K^K@>'1B?CBSLWS@$ZXW1C*2]DS:H_<
M9O5U!#>BO419TG%)96/%;F?9G88_@=?"CVJ3Y_0UB$MK\)-P!\9^*\$)MV0Y
MJ]O9K[!'QB-Y?%X6:89R"Q=P0]*:%9W=&4?U-6SFNB>/]&D@DK+=I*__7=7X
M,6X&LS!5!8W733G_$(,Z4$4W2=[";/S7X\/'1Q&<D/R6[DO.W$\O\*?A1FRN
MDR9B[:6 @Z7)9K CLP+GAGN\H3]SV&,P,](9ZL%XY/JTN3/'_+M>3VC'/0@9
M?4#;[?@0UAWN]B7JM84IVSI?CT>W67/-NFD"LF*O!Y865$_I4(WI4Q (.E)%
M:[W-8+OQA6;T=08*ZKF^C\[1E@ZV3\:;$+6!*&D:4'[QMI)FX:X R;(6]13%
MJBMV6YL/=P0<)'6;P(V*';[.YM>=LP-/#/PE'3I5>0,Z^W@TAZV3T!6LWE/Q
M>^CC>F7XUE23M>GV\2=6!?<C'SJ5NQW#B['Q,P[&""K]JU6>S1/<QG0:Z4L?
M#)7Z,'H0HOF =MDI*#QP^M8@2"(X(B;+MFF3G)8[JZ')99(:VDH@4;C4L!NB
M$@4@NBK+E#["TY?6/FB0-V-EYB:#4?(=MEAD\\P4\S6^C>0<Y*?B]D';2N8?
MBO(V-^F520?W,N\!V'H+L!O+V_KO#V(M_@BQLBZZ<"1?=AP_OOS']/SR]/C-
MR7ATBEO^)7QT#J-Y=?+Z].WIY>F[MQ>[/\H'8PL>'1[A%?;*++*"54F\DPYA
M[6"GIZQ=6NV4%=$4'X7SW^2UN<4M.:1TX@&1P'T%5]JJK*TR%S[#URIN83(J
MJ?'KY,;P"622 CZNQZ/:--@<W/SV/=9.A+[O]_[FH=C_Q][^.</R/M#YO]NL
M(F_A&1@W9:%=@*"M@Z1T5QX.^'F5S5#1*-&]>$T2@C+@W 2'S[^X(_#/GK&O
M(@A_]J"4&.#"J;6'W?V9B__T\&CRZY=W!/_94_7 UQ]4OSP#TR 0 5QS-#76
M$9\-Y!F(HS0#M;')04NL8.'=7\UU5;97UU%9&/QF6=(%A.)ATBRI,NP)J*!-
M5>8U_;2V?^;LS>//V (27X(\( 9F8ON1U%[VV"7:UNQCX:A% ?96"Q]P6^11
M?/;X^4;CZIL05AC6__?H4?0Z,WGZ]^@LN3(OH(%_MZ#OXP]?1._(*US_'5\D
MF_E%]#_HNH&OHT>/),K_XZO3_[&]O"LH^QU^-D,_<N4^>YF#'0$:PG.8HKK,
MLQ1&?CE]^>8D.CYY\^9L^NK5Z=N?_O=?'O^%_KXXFQ[;O^6ETA[&II)5#9VS
M_WH!EGC:7.,L//Y?0PKPY;EM@]Q:\R2W"P,C"%<J-POZQ:MMX /U.GA6S:Z=
MUQ?1Y7H%[Y]6R2R;OXC>)DO#<_^VQ!D]TC_ZJ_T5?O/C7R]?X?^<X__@[,!_
M8>('UF!6F>3#HYD!30S:7M&ZZG7Y;F.D_RQ<QAX$(GBC[B@.@ 7B:^EU^Z/[
MWD?W2[BFDRH=.+CEF^ABE5Q7$>RM.*)CM$0['UT_Y9P#W4UT]/W3Y]$O2?4!
M5/J+!@P!..:?']5-]#HORRJ.SJZS/$E-OKK.$OAK&AW]</3XZ:/OG__PPS=Q
M>.[\H+RXE" 2XQ%8?:_HXBZ# '[$DH-7Y P?1.LPM<]U_/[[A=^%0?F%;^NL
M,#78[:^2=7_)4<M+DW5D/LX-.037T06"3."SF/\"[<G^&Q]D/S@H;$FT,.A5
MS.'2O(+_O<9+'1X0_WP8GT7O S< ,EA(([.D^("V109Z6]:T[-&6G]/O4/)P
MS/\JJP^D[B5M<UU6,,X46ZP,&K&L1.;);:1\H'#1%^C4@'XE<^LRF>=E;?;B
MNPN#\D%"6#.0D8%KCN*M_*T]H5S@E_S:_9"4CN=8N_7)X=%>)'9A4%V1P ,M
M,%S5)799)0B%B^#(B]QQ@WX-D8=+Q!/)P?"JG+=X5(BO<X8H/PE,ICHRZ:$G
M*JXFD9#QJ.%8",?K\$T*"K#"< M."\K=)#OH( LDD!Z5,YA0B>MA0#'AMUVT
M,_2],'9GNBS;@N,VDTQ:ZL3CX8 -&[*15;\1*(A*>$,$4L5JX#7\K&;0817=
M)O"[-(YF+6&*BC(R-SB*'.8=FTL$EVAPK-'D29$>Z)D?CY0S&9Y#>"6%C,K%
M?L?MPJ "I :CJ#:<PY\*QMJO_RX,JH/4&8^Z4!UUXFH04,=@4 "EJ(-/DN,2
M-$-6W.9Y4I.]H9 *A$#B$QR=?QA_<M\MX8S$$R59X(DTH\ V-I'9(XPE+]W+
MVRX,:EC>HA/0\D%Z\(H>ME^40(22AQ)@K]!,G-$B2K=EFZ<10NR;G",=8+^(
MFQAO*+PX$PJ2F?$H8<.H@?Y'&K6F4/?L8RGAILRS9=8(UH)L'C-KXCYHCQ!!
M<52N^,G;I*I0,W4V3$;.;,+S$C /\QQT/WH@/?@EJ"W5/*M),Z$_6?SI[P7Z
M<VSKMQDHR3+X>L/H"2-R UM4CWB_D79A4-UD$T26MT5M\O[^^:6LKK#)-^86
MDV22Y>I%]!(6.FOK[:[#=X6)7HL#P+H.7Y8@W-#8+W $@W;9UJ8!M?KQDZ.C
MQWO!V85!.<%YE=5H6[=X^ET@PA+1A\,W?^H>C6K[9/<<]B84'%MP6%?0_YRO
M;I2OO7#LPJ &A0-_U).+F*S<K(LP0J\AIJ%Q2EM"[D2YV\"XA+LMM-NKB-6Z
M'_[^^'&4'"X/HXES!AYG#=^#!ZA!CD<<!XN665K@O3K\)+X4A%&]),;&C[8T
M+HA_W:]L28'M!G/C @-W/%(6;NQM]&WS8-,*MW<<F[IC%L*QD;,W1HM=V>KW
M&^K>2M^Q0;EM>5+/J_)V/)I>A4!V.:O_F>5+$ VXH$%*H&]Q]):T5+B_IW5=
MSC/Z:[_FNS"H@37O)S"H.]K08PS4IA.(D P$G:'4A0P-I;*[_V-T>)*!#OK_
M56C2XQ_\\HCD+>9S6,R(RH"]4V/\!9.(-^11J,PM!IVE9E7663/D\:Q[F5OA
M3U@168")A4@*O _X7-W@0/7-)5<P)Y@_$9V#,BL9DL<!!'^2>(RMC4X9,B6G
MT3&:8* ;2[#JE>$D;<JDQ/F0!U]N>? @<EDT>D)QKF;B:V;8'2%^O>.:8530
MY9Q4<I?\\4WLX.VHIB=[ -/7!3 ]V0.8]@"FWWMU48*2)'EW(GF_!X1<[T'(
M.S$H+PCBI@0M9KY!?U$1)1=-\M0#SS3UP.=E3'YQD?GS<ST>>@K+"1%:C$>G
M->J6\PU(@$R^15&9) <JE5V[M<DQSCAH[X%'*I^4(NBH9)5K@_UB3RC2 8#B
M>@/_M(F_%0;>JXVHN4 ')OTU?&\$:EQ!/@^, URQEIZV.2C@*3QA.,63#CU)
MX6+M');GU[)"*U[>5Y3%(]M?#-$N9\9WYJ4%][WRW:P&&E$_2RBTES6-H3G4
MS:O!FKI)9CF2*?0[BCB RDX7THW@AO,JK9V@25EM6AVB9$B9@$%B'-09FD=\
MDUH[7K6#.)K,#G1D"'],, W5@@^18&L8+J2@2BV)MP1_XQY)#]QY85E+6%+4
M:^X(P?B74.1F/.KP*PP-&T^PLFU@A@MR0FE'S4 6G\ACRJXUFA[5/[I3T=E&
M< \Y,\>C.L,]LKE97"QX!%2VFA\K6I00"M5VWL"F9&K4PV[&P=*<@^"Z6:>_
MPXD?C^3#?LL3GFUR9F64)%+(O4\6%.^H&NREIN8VE[.,;2R2A_E!&%;N-4#V
M(,;\ZHS5$F@DA[X4T'.!_KC XL)"7Z0]1,DPT))68 4+C%:RF5\795Y>K=6Q
M4M>FX:U5\"<KSFZ!)VP;')NC']ES@SA&\-5N]\U, 59IPR<'M-HN/43)]G-@
ME&[3J*&*MS*]:X8HEK0TU16R.OQ:@O!&B AJ,9)/7 ?F*ILC_(G(AV(Z.G#I
MD]R/GZR>&;&CW00&[8M0=!W3 V*4<+JTXY4A5>3IG.=)BPFMN+XRBKACVBMA
M5</CW34T2M ]NS/$BH0(H#;"T]*0]WH\0@BM00:M_^7.8O]>V>'A-DZB19O#
M:-(L)[39+*D16$M>[ZOL!I\RBP6R17A^&5CF9:*I 4KT>N"C@:2$VW>O$>_"
MH)QJ\_KX;+H!:?4:K&7H%&SPJFJANV<5"N+<*"JN[[_7^O!^Z7=A4'[I7TV_
M6#KNU=7>%-Z)0:G5/]XO_[>[_#]-IV=?;/FO]ZN_$X-RJW]:(%30I&@ ?#$I
MR/.]&.S$H)08@(6#],MMDH]'9V)+"E/=EW*2K[X-J=@>)GRZ#Q-^W3#ATWV8
M<!\F_+W'(;II*D0P,X"T3U?EC6-%\TLN.G0$KN!'1JCP^8O$DMX(UV^%0#ED
M*2WI!X[L4.#[XN..+?WVC<$T>HH"Q.(0DC][+G],#IQGJZ3A+.?07:/X4?%A
M]N:QJ^RVX,:>H"M)*'6&R7>A*\JE=%/2FS MNED'SDDX"^8M T7$?<R^)FA5
M?K0J;V4FJ#L8)BO1#X7H%_(D\S420&$LP\YXM(EBY\ ZU^ 'SL>JG)/XGWFR
M2N;8X81Q/ A'))]9DN^SM7=B4&ZSOLE,40]Q244Y?!-C.E:%&VLE&TQ$=,V$
M409!B7!#M,M9Q?YC2I)!65AD5=U$E5FT(!6434-8+5!]Y!'K7<9&JFR^AS+N
MRJ"<[/R"2.4,==YIBK$@$YV0[_M>*J_ J;>IO+-O0^7=^4&Q0'AI@ M_"??R
ME[!ZBKT([,2@?+T"U/PH!.\+.YUA>%@?"J#N)'DMF6J67AU1&TAPP)4'X 9Q
MD%V.K;N*2]T'7MK4SO\Z^N'P\6.5JSP>2;F'+GT"!F93G!N*E"^(F89/,*'F
M1DA"$)Z.Y:\TPWAGD;H/=,Q:11SK#&8R"2./1.8DZI3'#)"J5L[A6I4XXN:8
M_GXO[,*@]%ZH!PD8" U!DM1RG%U5'Z/<^P;,B?HZ6X&D<N)'5MA'.$N^+8)/
M$I\.THOR4W8S/ ,&U RLJ&:-A/5B=?&C3I#Y0\_%1 @?A"I<,=<\HH1FV&_"
MVTCF\8%7Y2P&@H$X'V",>XG=A4%YB85C<YG,J4J>^#+3]IX*W3Z^]7 &Y04B
M!VG HV!CDMKT\*?#L\._3@5!%/V4ES,XU,[D$-NO]RX,:N-Z#];9<?X[4%QL
M[9R5_2%=%HU*7-,U.COI:I%.^NJ5TNMT92])NS"H?N&RK21$ SI^J-7WF(FX
MZ.HF>J*]D.S"H)20E(C '*:+1,5SSBKM/$^R)5A<;4:Z\(V!?C)?'@%N72O1
MY$YZ'_@Y%B*#*ZK?#GK_N6:3M$<6),)*T2$JF:N4 +HR @GE*,2 GU]')9KK
MRL"I)S[X6W2VH\ITE2!E$-,FH-\LZZ;L,INK,"&M"=WLH<Q994UG2MCEJ#/N
M'&%60'#RFMWU95MANF\URQ#QBWT.^%:QV729%5+\[,8HA5\2<<IJ;:E<T8"8
M")%LS&7*$#;<%@B?1KH9:G#!J,>]OK<3@^H5BT;5/QO(T"&<JO74N'3P+GH[
MQ?AWA4GHK4N+7B49)YIX9E?Z<9"B44<HT,P%-S,YYLG3_G-O<KNK2##D-%1F
M>R 5 J^5 F;0;M5KP^0@,N[0417; <-6#5@2QR,>%[MYX%L-;T]NDBSGG!$8
MRU[MW8E!]6ND@]S#);#^$@;OL\/OOPDIV([8>;9'['Q=Q,ZS/6)GC]CYG<>?
M+K ['FVIL/O)AZ&4+@7].]_?B3LQ*"447*MA/)JN,,T/5O!+^8'-WBS8B4$-
MR,(O8"8NV^6P82"!GY1,0I**Y",^/9S8.9Q"#3\K;*8GVN1E@U&E!),NB1E
M<K"Y]&G+6K]*U-]8*T Q_]K$3)LX#JUA5B=U'Q-)7<><#\N1!U\5)4$!*:U6
MYYY7/F6:_ U@R;BBJPV7?=[+_"X,2LD\(0(LI_4%P@ &V*P=<D"A!5RBKT)Z
M;A1W9M/DK.%>.KA'C2("ENNF),("X++\0=CF(5F9#PX'J?(7F.+?)!6YD%R]
MGJ!XSRN3(Q^#\71K<RPSE C9P)YD<E<&M56.HZD5H&&W?"!?0\[-K?)&,LT"
MS<U)%UCDH2/8A;T4[<*@MDO1YG(^C%\J%'=D( -=*<03$ XX#3G?="*!: WV
MA8O4,M>"*P-DD&"#)1'=VG*V]IK>R^(N#,K+8HLZX-&S9WW9H_P&^"8@#?-7
MJA2SZ6F,80I$[,H64W-8LF1F+#L#UU(&JV8%5REJQ MX$V= 8&/PW]C6SK,8
M0*0U4[$4[( O@6+)HOJ=!-N*%(=VADJ$Z,#D[T;?MU U,2R2)'P\TMW>R_0N
M#*HCT\^>;))I^&8OTWN9WH5!.9F^.#D>C\X-Z(5?+@UZSY&P&X/R0N".H?NQ
MA7J2T*?_@22A?_:T/G19J5A.MI"O;RAF%SZ?*E;WA2TI%D+-&)5PE]&Q%Z!=
M&-2  &W!''9]&4XPCE6!-JPM8)8$Z.AY@0GSE%H XI/'0=+17F)V85 ]B=E6
M[^'W'CDO]T?.IX%&GN]!(U\7-/)\#QK9@T:^V,GYZ7?MR_U=^RU*#(5 -]#D
M;HRZ*S" !0#T$<@=[]<^:7K7!J6$I*R:\>@B&2Q?BHXC>;;&!XERR#%-)'VN
MHR=P7H!,G7LWY<7/[R)/?A04)YG,VD:\4P41[H]'$D-B,OV\30U7U&4,"!44
M +6@XHJ2PR'^O<-J%P8%DB=R18O&5?$\].U^MUOM?UIC'3CZJ858# 1 XY[3
MW@4[?S(%%6H^]G'U\>A-<KL7IET8E#_-5"5#D"9*B/DB234(X/F41)IH.(]F
M//J2B30#=1LW9M-$*IF& 'W[;)H='U0@])RR.)C5N:;P'S_0)6!,-&X2A A;
MDQ+E%/Y)#K!)#@;011U'MRCV7'5SCB(#7^:UOZX](R1'.?G?Q RTH0^8'LKZ
M)E43046T0\RSQ\'MSJ"<5.I"VT,X3JQM'B"65A7(4+:"2]@6$_\EJ3X8@AJ5
M*R-N/OYJ+PN[,*B^+/"*#HB#KQCE*\8OZ>%:5PFK0Y'I% .+\JP6PB9HVY:$
M$Y'15<'H OQWB^GH)7H%X>.W_[HX08!<!:=:P;K VZ1.DW]'Q\D*\VE$&H.O
MA'QE\S<7!GG*PP>,5)87=*:SB"86\M'.A8W75L)S,P.J20E#V9LX.S$H+?XV
M00*.0YLA,63CA(7JV(SQN6)1-U6L4V4\^-2'V38&6F(N]^>=A)N?Y"KG8*B;
MC]?9+)/ZX+7H"C5C $A<62^6?Y+T$E=9:H=-%[WM:BV<T89UTJ%Z<_N"W@]D
M4.%V6)"YOX'C2HYA.=CM\]%_)\O5"_@3.NQ).]Z\.6:!G[=511!Z^S@S(W4)
M;;B '4P-)W@D:0I6'7-%?O?D\5%T]!R^G]Z8H@75]F55EA_R-8S.'=M'1T^.
M?HB==+O3>OM[]R+ZZ3$B&WX+1_*%_5 O_S$]OSP]?G,R'IV>'D8__O4E?'8.
MPSE[?W[\\Q25@K>OHHOIFY/='^S76+0_1?J>'!ZAJ7J<E[5P&1V.1^^$UXP_
MI&2)F"OBTC5BJJ5<6LQ1JRI&IE+ TIO"G$$8A[8R7EJDDU&$A-LR:!(["C7K
M[JF1R C]CX2W)2].V3#[9XX\0]@2-F1]27%T%#]^_!C^_SOEU>X@J+"9)\_Q
MH>?]AR0J>!A=7G>9@!G3JZW\ =^3W-GV-D8H<2?BPW[Z&6*9T<SW'B,X^N1L
M?V7R# :]COX'IJ"MH[-DC9>\+]-DFB9GSU:OU $Z"YI:8!TXSQ1<L!!5\JGQ
MX.P/N#\IOW(@0H6MB<N.FD(!P%#%>*2=P!;K^N3PR20Y\$NIV?$&)\*]&/,.
M2</)0#/1$ZV0M-"Z_0'-6=*PYB6R>AB]1S&M0=6J%Y)(*]?'O(2;*"E$WQJ4
M5?^>FEY$<G+X- YV W=::(\;6V<#RV+2S?<R0>=@&MG"U#PB#KU@&5;VOQ-A
M%\PG-[9LL0!3+AL#QE#D6)B7?GJ+B;GL^O&X=,<P&-&]C\4-G#R4"]%%><5T
M=V^RY X!BR;9H3F,K6B')T#3DQG>ONIM%>G85#PEDQ+8?BN+ZY88D'@51&5P
MJ-C<D#M81NFT%29T%&B2[0'/"8+P2YONB6[;27U@EZ5'"8G\UXVXEKN[\@4?
M<%CK-ULUKB0TCRL>FG69 \3OKK ?9*!698$H&2RT*V*MFI%JN=KGI[WF. <K
M60>R A9E][ 87G\R>"F9%B:0LKP76;4\P*=O89:\/L6O!TO9VCGPXR]O O_G
MJ%';P5K?[<%:7Q>L]=T>K+6K8*T_21E]@LJHW$T9PRA 'WT0@_LZZV3__T\S
M7T'7B]X5Q/"YJK*R<GGW=Z@.]GK$&@))6QO!&,O'#%SIJ(N!3_OO>S? _<7C
MZ,\2CNR 7+&H@#E6[19U)64=*=GX.IZZ/VOT7]'Y^.<M**QH,A[EY@KQ0:NL
M$ O+;NYCT,'!E*>R-0D%I$&E3NJR &5W;2E9! @96 =]]G163Q_6_#U,D:!=
M;K!NIC[A*4T6D609)FIWSG+GM="FB(.CD=6"%--5R^8X6:2V^1R,75,A@H>=
M"N%9XKKA6CN^SLPB.K$E-:-WMH1F)5^]SHJDH'*8\M7#6J$'*70W(G-;HWK[
MRV:7AS2Q:]P-RVY=5G>1Z)/E1?2@9N9!+C9K%CHYL;?"GWR0]V*6W9HNH9F2
M$31J.1Y)=*-F^KA/T&#VVLMN#0G$[FZY"]@'/UV<HOM+TWBT%Z=='A**$\I3
MTXE].%V4@@0$ T+'26(K&"KA$X981K<O.D=,95:5J3&*(62P$G>!$W RP_:D
M)8,1KM5:U^T,5.)967[ HH<5:M/IE:D(#Y1D1&>#GW-PBM&#81<RC/+,T4F=
MVFB6*R+O>_0"Q?=!+>U#E-;LXT%DJ"PL!K<M.)+A/%OX#.U*WXV+<\K8/9!Q
M7P?8\Q\E+MOC4=_OXU%?-Q[U_3X>M:OQJ#\[RC&[3Y1C*[QE6Z!#FZ_[*,=N
M'?3WBG&$.8Q[Y6A'HE>PM+ARRBIS&G2(#-P$M;&H))74*OI]UZ?U#6@_NQFW
M?W+X5"%D,;I@D8.$3OCBCL4'M%Y_]J4-%O8E^E3*62[%4NMNRJS//-^0-&-O
M>+1[.GAGGU^GT*0S0PEWIME?W?_QI]3$!BX3A,<F\S5%K1&0"^I<A6YDJ5-;
M(\+2U<N%/N$E[WPQ5K*J"*SC"LFA$= *\O+O%L9CX::VS:PAB/8O]A73E-DU
M3H@V.J;L+>R#??4!YHD7@A4':WH FFN%NMLC?%QUJ>M-JJW31S+ X,63EJ''
M"8.9$WMOS3E]O)'',ILZ.L<;$#Y=>YPJSR4\S%Y1TGSPQP</2W8>Y'9 UV6>
M!P=FW '.JX1#6-V.Q5-)M2U;.==40DF0--$VTTDC!F8&I-W]\@7%8A[4-#],
MR;%':6H3"_IY+W+^;,_N0$N[1]^R5X[_X]4#7#=2ME1I]P&]2UT^>]7K/T!@
M]JK7'ZEZ6:MCB]Y%^5M[O>O;V@N?K'=I8?KR2I?;"+W-^+ F_F'*TI F%N0'
MWTL-2P;4L(<U50]R]6\V0['OHN_W*=O]B/\@HEN  U39U==:+1>:-6=[291/
M@0?L(9S_Z4,2O&X%XM>]6HIRD];% BGW2S<6"G<55^_5[(7[Z-D.#(G@O%B,
MCX%P:ODV) @*M9Q$QP(Z.L]K[06J;D%@J )@OU1?2!3@"6,WT2+2P1>CND3Q
M]VQIMJ8R^I[6OOC7%;,>YT0$6E'E..[;R[PLL7#\5?3F\.R0QS(>;1H,O)2*
ML&/9,/CWDFO68W?FCLLA_*VI$3^:U=>&[!/5I=MKK$B(W16;2'>+PYI@A]]
MR_0N.HW7O:DI' =!$LV2X@.9V,CK7%89],QW)#7S/$$UU&1$>2'K$E+G0F.*
MM8^LE;:Y+FV9-?\R.D>X=>*N("[3PIMR6*&<H#C$:5C/$^%(!_F"83=9SG.
MXZ+>\!V"OY."D>X#_.F2+,.%S,HRN8).(P4KFER-+7$>(6I3F 5=-Q(YS(1Y
M$)ENB(G5 =&9>I'--D($DU,,[;?8"KL#!!O8G>F58_$(00,Q-/4!AH05@Y>K
M"LE-F$&"1@3]R&H+)+9D.!HA*IP8EB?E01TVGX&U^]L>:_=UL79_VV/M=A5K
M]V=SQP7D<><G9^<G%R=O+Z>7I^_>7A"'W#^GY^?3MY>G)Q>[/_0'A)1YREQR
MYZ$KE).I_KG)%\H@FI./:#^&).IR.[[*ZCE<6LBO9@G5ZUC<H$/?>8^H5$!)
MB&UK/!+UTQ&PBX]X';$337=:.937BH:+','BB@T=TC*FU/?'NWAE'/.R0BL'
MPQ4((ZI-P$XV/,HN4H5\V:@$A#&0.YS//2:-+QX?^<^Y]7<]U(-^-UV(P)/@
M3//<BQE5!<!EMF4!?&6"@7 #>7#N+DX0L@*6M^B$=BQKJ@1!OHYA4_ONS(76
MFW.9G,J-;NEFS=HV6"D>+^"K+("%:#BT0LQEY$F"5[_)#-46$:)DZ[#D:EH4
MB&D;3*:3G>08'#L=Z;\.)^(&%C2% :GF\.-%B\;;*LE2M'F*1PG2TK%&C8]0
M1Z'%%;I"5Q3=I(/$%I6GQ'/B=ZNYE,B,^1S+RFOCWC;;<]CNP* PH@T;Y5UU
ME139;PESCN.B_U^.+3*CH]Q?*&C=76=]FWIG9G@Z8X8=;@V"B6?%7"HEL?WO
MKYN2WXR^ "NTYF-6-R3UO/FCJ[),([L75'6P/+EUQ\"O('5UFKG[!DU:_U:Y
M[DHUS-A[B2FX5(,)'ZW*6TE*M2;[FN0=S@GZ%%,;L.555:X,LUO2P["/)(0%
M#\_A5J)B%?CDK 535**>0CF=4VPT;9'L\A#6BET)>E8+L<#]KAZ/,AQ/=).5
MX@3 9U*S2-J\L4>*3 4YKVL+2,!.*+A"4!<7WH)V5,XG2S!=<31;\_S:HTY/
M7I)3F@AL^:K1;.V?)B0D&CZ(C5/'\Z)F#26@[@L!EIZG"@>P6<:C[C+ST<SR
M9[T1@8!DNBQ$P<2VTFGW:K=&'&"D!:<;@YU+62-J"GDP_JVWRWA4&&3YAG6+
ML18%:GU<!X=4FB3+\7T<R:Q+-0-T_X0CC6W^*47#E\D:?@2B6[9YZIUD9:43
MKF>HL:V(2Y6$%U8?A02/'$0D)'W'CO/]\+9"WB.8.MF1 B@P!4SWW( AG(LC
M23QIEFX_LJ4*XHB#O>X]L)$'7\0=(]G#V;4Q8=Y-L5L)<DAY9Y,#P]Q'S$"]
MA$4B2MID/+J]+G-V!'((\<ZIZ*84V]&C_XD#R03IT,XRZ^5'5R/Y67%%DAJ%
M&(?J@]_CD50#VS"-T43V-"R:3*GM.,Q1Y GR-P0=%%'^P0L?T6JNT0?L?7GL
MNQ8/'OE@(U4%Y:;,6Y^C'7BLD[PL3%"/48P1YL5"#89.'Y,O8MG;<*PW+?I#
M>X&2\8@[#>=A&9U5Y=P8>C_H%.QYS>R/4SOCM.^"75V9F_(#[1GR+U,5EPI/
MW4;8^]'S:@RY=VE?P.-&'E9/BE-RX"[@4C%JIW\3.LYV)^,/>R?CUW4R_K!W
M,NZJD_'/5N[GI-Q/^?ABS>T%G+1\D^,=T[>(KT7=\#JQT]P'3T3TNZ"@HPE<
M.@T8COIVN114W^::/.,1!=!Z12R-4B)9F1NZ(%D[]*:$5[W;IGO9ZNJ;K";8
M8D"H+OQ*-0?%VZ4JS$:VP&PL?C B91)(AX,>#1?BO.\80N 2VSSL2I,YQ,=9
MWY36MI<XFJW]"&=K';M$;5L6[C?68>GJMJIJ9$L)%(RN08?BD(I5E-$"+DH<
MD?R"V%($GQ<.A^?M94G% A;1*W*M8*FRX?!U6*(W0$RS:Y-,-OZM_4.,IZ38
MA+ ^MUVSBUF#9N5+45.MB /<!!N6L+MVOB872AR;$1F5'60G[-HK+4A93XS[
M3E9N,PT9.;B3Y"UF=*Y/I$?E9X[,- G1F?BZ5U2P1+E_&_YWS*]4RA<^38H]
M/3;+V*#R>Z6[YD[Q1R_158**6/ ]JI"^2SSON/NH1\[^(<NCMH%_'*F@"=B%
M1JT+=B&W5K4O((!!^:I=-?,U*I>@$=S '0C_AA%JDWX\4E%[=S@X/X%]HS3,
M.YG43F8$<L<B^=E@MC.455O1@=U?'@1AS9Q@4/@J3 ] (YVU3$J0YO(GSG)R
MP&<Q(G#B<&"_M@5;Z=  4KV%;D::B0HU;.MW8"L&)V214%EAO$J6A3)$I0Q(
M4V4S/KF4<X"-2=U[->/YOICU3@QJDM(=_[:DI.T%+%\C.=L783;)/:ZUV)]3
M5*;#"^<@O+9W7M*UL>VN&SXO8^?YIE>1RSG)/0.38#L^Z5Y$G]#VBS$MR6JE
M,%(F)BP>4G.9Q<C>->QRXU+%;O=T#DEW@?4<=QZ9]:4\;]&0X\TZ-3K]IX^U
MX8V(:?89<OW0R-QP)99$!@S3("X ,I=HG @6@P_ ,+@6S]/,S,LEVO'2V@%[
M96/O:^*U K/#7BDVYD$7(AY,VE]IG:G8)_:E=BZAWKS2R*[PK$3W+$X3EX65
M4QI_3A6<9$K!IBI2=DYAP/!1FN4MGY#H$Y  1Y+BII7Y1+1O;KQ3<8["F8OS
M=6*% _^+ZB9/6SP\:0>$%W9%P;@;?+]$BV1.UT*,*S-K_*(S,S0[@@2%3(Y/
M/24JZA/\&-7A ]\4K8USG;I-N'5^R>%L%9J2D&[\*]D&X@V5];ISN7"[S\JV
MX,+==.<*_(_OL$[JF]79QJ-M2EO<WZQ>_A+E*Q?Q@UT%$MJB"[ R5VTNLD&N
M@MC!TOQ%S"<B+)0A,>')Q#!?Y>,,G.G45C3Y5R4<G@4V@EJ&MI&&9[PS0782
M)EP=G6H<F915EH)<PEB+6*$?Z9C@JE)V./5!_'G+===BO;":7";V 3FD;?P1
M%:8<F9]JT8JL=A*SGP[6[KX^ZTB[K =<A>+>W&LG.S"HB2'MY#6Y7[',(>@H
MM3/=W=[NNR%  E%2=-I7.4.LB6PX:@5LFP35E=B9M2K2EU(R=LQW! ?5Z&9K
MRIAV,P9O!,9J?<.5IEGGZS/8WGP R):,>3_&5/8N]U]O. /<]V<@PQ2!(A6E
M9ZU^KC)FAE6N6!G('/YI//LE_W \NB_'Y3T26,0HXA?4D:Z=J(R+FE'1"#F0
M\\T?:N,1GFJQLF_8':66AGZ^Y!S9("V0LW]D>K:3YD_0(<PQT5PT4!]1&;A^
M=#3EFSAZMGO]CQ[OW?Y?U^U_]'CO]]_[_3_OUEW0K7LJ%K4C/69+VE^V8EEO
M=A&3 [*^CQ^!O)0*;888,\*&;?)7JMM@P\5%5CD&E5LIBAR"VF*%9A._=.'Q
M;/$0Z@[:(]0=V#;+55D/>*M%Q5V4@9Y?DT_<DA[VP+O#O@X<NW^+OOPZ5]V]
M/#7#[@]9UW/#BC''Y2_@34T'5DOY6I@(95)*6./BR>%JHT:OH84,"_A(N5E%
MB^E=Y+IT0,0 #$#>&_+AJAN_PV_35?! O;G*))L'@56O$4YQ\>BI!4;07'AC
M9[K7^7=B4),K.GV.69A$)Q=\;S?2F!2=XT:C7BW4U:KU7> \RO"T*%J0V'/*
M^L-M2D)T]/C1_Z%-S,HN9LY%:SP%* %Q/'IEYH8$^NE1'#UY_.0HFH0*H&M%
MJWVJ!$9*B7Z^-PT#YONA5#1BW+&X#L&[8,I3ZB^.8UG6#=5E)G@@Z[&@\F=E
MFLTEIU$!'T\^"GQGBD C'P$+-Q\9$]4\$S-]N<K+M3$6.+SBDXT:E?+BTF_>
MT6<YG&H;(F5FTS&@5R](+W7>W="I&UX]XU%'&/I0YJ%37\&8=9*%+P>?]<'@
M5P0&CR4%$]]3E'9.P#Z4Q (T0QPE2<R!E&3>*->LN!L19(BH5=+0='(B.E#F
M9$SPN;O=21:Z9=A)ZF>ZZ</0[_*Z=4NY=.[R*QPDP^]<-+FF88A';974#>84
M4R*FJ1F=Q08L;U]QN&(;BZPB&5ZT-6H$"D1.C\3^22H,CTG*UO_&>"X-,Z=)
M=(]YG-KFV+>NI]Z]C%EF62!6 S'.,/XLLQ'+7[.R:!74 '8M?;RB_4&._ KW
M(M_ZG7-D8$OI$\6S4=@%Z/S^W<J1\+I3R,K>>&0CDKB*1H,:XKZ2<G%R+*=D
M[5B41*]:)%F%6XK3:^K-)%6TD0MR0PC>SIK)@F6]1IQTE^N P70X]#B8J]@-
MFCR8-!;!#SNYA#.-IR":3 ^BVZ2GM."VQ?7G U#EX9<:X>O:H[Y(B]@:Q8\D
M5"T^! : HMCV !(>"9.(=]@Y:@FFZY4\S!VQFIL(YLR"(%(/@@BW+T5D>( ^
M9)-JO,UO5/)FN<R:QA@;X6=G:T"21&<&:Y#]COCQ>*WNII3$]=L*VRZLAZWV
M$HH<*8JA2?Q<>-#3I/(43S+RB*NELM@&#D5['(-E3N0  PU%\$.3E_QS2D0+
MS(>H@W:0^5.Z=7^_^0P;_QCKW=IQ7L)L5)185SJ"3Q%2[XL/&QEP746LSE_>
M(YJ)Q@TS) CPPMQQDL/DT VX\>:U-Y+J#DWHVA[8$Z4HX+L\2^$!+XX+@VKO
MNSNT2:-AHT25PNV\C0)H@>I!MR::)[1?C%5<V,!RB&/10L2;20*E$HEP1MTM
MW01*AGI_J6-F=P<0.>8I&8RR?5*ZL3I108^8<)O!JPQ.)8AE8XK4!"&W_C7A
MPC-WQ^#(5;VV$5<.RU"$!,'62%[,,]"]ZPGKW :988%RQ*F8]U2.4%(U-BO0
MBN#LH-VAN-N<+-K JO]N"Q..NX4[=JB*GGG.IR Z&6]JZ4-1WE+MKQ@FL+E%
M11-G&;;-E<Z8V09#^_+D]_^)1N<=WMZCO;?W*WM[C_;>WKVW]_/\+=><37UR
MC(6B2<-_H8K$7MA@V4"4%6TX]C4P(RS]&(P'GYR/RGX=^XB;,H0\^*@3AAN/
M@CB<?1F[+T*'GM,NM4=#ZUS:HV&9&X^>$G%C%1T]1_2; [I:AT]S6Y*WA]BP
M0-E-;7U'3= UL?<C&"T$I6)OB\VVLYV^34)L,VAX$BD6O 5V#(?+C5F;Z8 -
M.=R(5R6ELMIO>AJE^7B=S3*VKIP.[*<VR)R=H9*R@,>$,8Y(&I@16H<S^2%9
M#WF*QS4>>=M2682A?=E+7(,!LP=Y;K(;(IM@_##Q0E@T'(V?44\+&V#&H2@9
MLTE;6E1#-Y'YN,HJY]NFA]U+#J,IJY:=E[CU[YJYH#"!LBZ8Z4&#%I41MAFU
MSN]+/P:B6O9];UVKC]<N8Y2+5BU;T!);HP+75'?"=6B18/X!JDV8B88V<V,1
MA\$SW7@W/98Z28 &O'%'?Z=<I(FP#MAYM8_)O))?.I:N'+5]%R^:9Q6((5?T
M%4^A5\5@;Z!VB,W$--YE5N>&L@8'W* 8H6!''VBLUX80Z3YG5SD9H2/GJ(<>
M/7LVR0ZVA +H'3XK5(VLHPCS=O,<)9\C(LKLDV)73$FBA,:>9&Q&=D!9.H%2
M"/Q"1=CN?78E<@YJ,B3NA^/1!6Z+P9$KFF,XS)->O@"_-&2K4Z1^Q&^*&]4/
M44/R5SQ5=#YX1^%XQ(=$"HLCYRP?I3B4&T3J@TGO3YV?IM.ST 5FG%$B@'2?
MT1,4%*LW#IMW)IG3)CQ'I6TR]=HB@5,7QS?8"+X\V+8@#HNR;+A1?0?@$.(!
MSYD(D3_K0\^9?^NJK#<F,&<->V%1'Z;-'23-<P2"7BW'$4<BFC#QPV96TT[V
MJ=4<#DUJF,:\O*U=&W:]&@SB4HC$>8K=R6#1?GX6_=R1^56@6S"'YY=V^#'=
MPH^@073L(]A5 6QY_RK#,+SV N=]?]<6+O5:;]K$SC9?)LK?ZV:(<>',662/
MS9Y1/V3*#B@[OG#ZD$8S? YX'ZUUFFX;:<R22]N:4ZR12+-4OZ',^!QY),AQ
MZMUS@SCBZ_*6#F*$C\-U8B3N2TP2TN+!,%IU QB8<?S.1=%'C<IT) TGB7FU
MI#]8H?NH_7IN,.H=0\,$/8@J%]XC1>TT^%/&Y60-8!P4\XAU5G:! <Q!@;&G
MB+*$^'3A<WKCW2'CN2N!BE 6PV,=CY0'@^($M*84&?%'73QTR@^D8'VD$"9K
M52&;0S\5:$/&%>8VZ72$2#G*V*GJ\JGNDT"UIAX-4TMT<IDDD\%E,J%R;Y,Q
M.MWW.D,//MWUU@K.\+<#%E(^.Y<FW9BFQ8OJ,K58: 486HI36F=K41Z7]*\3
M??./@?(#.JY-<I'3*X,=:?0UP3A4-N]#=+>P)9 J6_'W=D-690NS3H&[_O;P
MNR*I$<(Y@(BA&.LP18T3VIFINY#R00$FCYL3X+5L*IN0XH_&;3M"N_3@J.;T
M%1R&8]#%A53D/N008I564C(H(I3=" +69FY(KH;E5@G8*@:Z* <SZEPI-TK>
M9/SI1E@[U0VZ$]<>7=XY\+O!P.XP"LF \"O[7E7+MQ[V_?<2*"PS4R=1<"BI
MPF=3"!2[DE0*VY;&2<,NNL+CA?<X2'D,]^T2I KV7EE9GA\\Q&G50JZGFXYD
MBAM=J(]L.E'EK@U3!W$[F\%#AX=-(VV(5EJG<9KB)JM*B^L>2KSX)L!)=_B)
MG^S]Q%_93_QD[R?>^XD_NQJ98HL:CX[)CU6_B-X7/AQX<L,6W9N,U3&)K+Z"
MBS8O5\J/?!&6K9#+!;$8H QLM;2=0P:/7@OLT?:=I*D0-W[M:FO051_;>[[@
M)-74]VOX2K[=?B7[^PX+DFTJFL9)+?J2<=B^8HBW/U>3-T&E%2X1;91)?J:/
MQR.ZA8H8(.W&&N]5H4"8SRO$#F*/24%T[Q/["4XVF.**DY380M<$=CTP5V2Q
M7 YJH?NJ4ZZL?0KZ9,ZSE0USH@VNL?;;H[^$UDK'G&V&$+DA?35$YQ^+.?DG
M1";:64_RALDPT&]CX+).I3Z/N*WPQS?#"^8J.)#1FK*3-<THP3:57GJV!.);
MK:]5^J?+I40;MNDPEI2>"#6-)43?>97R+71P@C:B'V#^R!T4@D9IX3:,3D%-
MA9FV#P<I%V#2($;, I'PY=,%+@CELXFUJ%?0Z7V.$X0:1V?*$@73FX(*/\>8
MK] 7G)8B95QER3"(0TR:CH/4(IKP/%FP\;? 56K(-8"9Y:Z(A *E.9"#=6YM
M0)[VL8,:JQZK \=N$#"&T <?!VYQ?1Z)(\4?2(%9@A2*.(T,5*GUD:3/(WK>
M/;RU<!"V \T%#L*2L;Q9I3D_M>8+\LO>B5CEW<<#_(N;2!?5J3HSW8"$V^)=
M#XK8Y(-I$*)-*V\W+4:'K3R3LX+FF+:51##DT'?^L54[@W?D:]T9>"8W>/P=
MN=HOKY)U&'N2(I34CXVO_R:4_%T?U.17TG3>@'1=Z>R##?"G :<KZAZ4@JR<
MRP+YK-N,O.(H]^O8\64LO+4<*Y<,H])NT)2]$DH>>^K=#[;47.-)9] U8WV'
MSKUJXRW*61.BOYTEW#T2R'EF23?D^&6_KDMX1K#N+&N(3BD.LYJQW13+-G%Z
M+>97._-= 2I]\O.DFS--%S5Z$UWRM-CX!]W$7%".?/!H.K>KZ5)QH[?(0BIG
M^U2 X=O1SZS;H1>89K&V5,;P6M2'68_]! [<;?G7UM\DMPXB;/'H! %:B)A1
M%!5&V1:+Y*:L&)\*6DK&6M"7X4JX)\MT[#ZSN@%K/JPQ^$B[QP30B4N19?%M
MRIQ,+<\R1@"9MP3TKFP9;!3*/*C\!2N7A'7:DCX1^FP%N4M :=<>FK-,00'Z
M03MG.I2V65O<J+X=8NUB==NLER>A3H F\ALVT!IBQJL&NWN@4)N?@@$GE3""
MRP988IQ)*65VWL/>.8U*WC >#6A_H(BMO.?-T@CAGU*'S7;(P=W)9)#5VY!M
M/PCK&4"M;DI4^F93^N[PFCW=>\V^LM?LZ=YKMO>:?9XN^8%UR62&E^&Y$6<_
M^\#>8O+1C)T&*PP5.0LOOON.P>@7G.&%\\\H,T^I%39OLXMKPBQ%B@'>V\.U
M53]06M0 IUW7SK0A7=<YH0M;&IM1E,!E[LQ%"J2P!X*CS_(S]XK*SNMUM@J\
M01M2&3;&);F\IHK_] J3V(RCDE!,5M6,9B!SH%X'F0SW"<6AGX I>U!/<Q=V
MZ+<:4+0RINPC%>,V6*\9%\WL!=\\+,)42Q>1HYFDV]FFHL2!IT2HY7SEK9)]
M6# ?#<,$?3Y?@![!Q%IR[S19^*5+V&2MPKZ6/M4-L"(A) I8>01,B")!P!BZ
M_U#7M8, >[M*+1>D(CH  X><GWZ,EFY,D*'=>7?N)1=IWQ@7U')!KD[\SFNB
M6S:D _7BBC24(:)=7!;$%>*V*L/TQ @W]!B-;EK:^\.+PPW\4H+Y0AMI,/H8
M!BO]C!%.Q?_I4GECR:$3@EAV[M0DN9U?WR97XHV^1A_SG15-.N.TK&\QE=:Z
M 0V=P(9,#=(0!@RDYHJ&Z@^Q\:ASBI$=M">#V^5!37(FAG#"(6Z9^]FFS%X6
M0D;8T&!1"L[+B1"5;X"'A Y#(I'#>(<'CMS!@AJ[2]=?K;9/=YE'W.D#-K6O
M.^D&I21!JL<=ZMY[FJSMR[BZ9M.DA%_K^8D=P*K TD=XQB0,L&)24G>.D_GO
MS_K@?%? P@T\Z!VD8'@ *P>4HYN<P)DBIJH<X_!+&1=UQ0_".1]X]6R%G/Y8
MZ9T>C6)!*)XB<-CE=1>A'W5'^+=#;\C0^SO<=RT==BW7(DK)R6XZ:24#*!G_
M<@5@84JE$,#2RU2V^)GP:J$SG6\7NE$"UO+D(V[E$/4"2]88<8/B?F("!_CB
MVB0YP>0IV7EAL(?P,)7RHGHYS3KRWW7O).H&J=%RH;HK1E<2_Q0*T;#LU?[:
MV.E!399T;9QH41R/WH#$]A/:!I4O*CW "IC3H;=K8O?4P4*B_Q48$ZT-A/JM
M@COYNH6!RBZQ;C"UM33A;[*<9;0I,F3Q:*M%@EW$;L?1586GI/R1TX;B!SA?
M'<8LSY/O+CG0J6:]'6[$?4CU3VM$A%_A*L CL*6,.*Y=[,%_O(CFU_#;.:6R
M\9@3QXZ3(.,V_D4]:LJ/#."[3GY+JK1LB>+8YA.A+SRI&X9(:)>_]_?_['YG
M-W"8JD8U9SJ3&0<HBWXM!EB)%N.X=.]1H :F 2$#.O ?(R%9[*/,Q 53)6CP
MH:E?$L,-<=$P[Q0.L4@MJ>I M]%9#.<7)CYAREB>AY2U-'TISC_?3_0/Z&G*
M5B+_.\J-'(^>H+KV2,L:0]5S@HG8L%0M%RGJ#?;'N#(IM;)"@G0*!%LJ&V5/
MQ(YPB9QP^ ^8K&6;7]D:GLPK$O#.Z$2?8+]&=KNZ@G3C$=W7=([[Q$*8%^F5
M&XN_B!-'!>ZBSFR2+?O1Y?[;=7G)?CC,A\A?1)YY=HO9ML%Z\DF./ ZW)G[&
MH#]L.KG;C8BSJ<R?S(IBS^[85W7)O5GK$/P@D !G]CXVU[=].=[AF7^V]\Q_
M9<_\L[UG?N^9_SR]L""]\-P!#L:C,[X[AO5"BCUJO1"N\9IJ#&,VLF<TKSMT
M\GS*VVM)8JQBY=.)OJH0..=T1B2("XGAK<XX@(T@U*7+V=YR12D05X_<L =@
M8?,) P0#+CH[;'5+:<OJ=P42M +@@<9J64+FNPV)15V/24@^X*G\D4K0(6TZ
M]BLE<MV4+G<,2X.E*IF,;VHW#.[B-W'E[?J@)B7M^\NL09<YK/64\(KWW/2D
M<%*%;?R:RQZ3QMA@>X1,1H[4#'0LVBU,C,+.CTX%<-(\L15LCIT?0^V)4EN3
MIV1#*S9#MIOZZK#< YGBW:'%!&+W_I(M!-@!T36:Q_0IG2M<%<OVPX&DZ&TW
MJ HY8@XW%,[<[OP.HSSP[P5!G&Q KZV-14*G]'N"X''8@,&=W;;[%1$'QBWJ
MLAV&2VM/UN+#7'0]7\ZF$#\7_D0R*M6)+I39FE?!LV;TR,UYF 1VY_Q%WP4*
MJX@?M':G'I(A%JCO-'3HJ>S0E0%98>J[*471M.0P\<#<8O:O02$1^X=,]/M,
M&0@KXJ+PEU8"N04"NU'R?VTS_=!7IQ*8Q0U 8^VGB0]NN9X5=<<%M3F&M.5R
MVL>'=GY0DQ67+8!S@]Q!+>D.(O:?<+S'[(^QQ,.U\,O'?!*C0XN<'O0/70NT
MCCD'!P]Q_>_P&2S 5=V@^J&?BXJ$QL9_U.C$8?)0#$!9!\]JS1WRCAK%II6I
M8?O-+B,@7Y_F1X8M[-7&LO(>$3R6\)@=+H;[N2HE!X+==O>;%69#]AYOTNW;
M<'O5';WPD5UWJ=PSB/D-E,@0<7&G%NF8;FU9*+R!.3S%_=K6&VJ+N*K0+V8+
M#9);# /7F$\_@ZY!+U.+\M!G%?^2/*SVIQ0K,_IGG!Q'9&:3)P=,:.8YQ'W.
M75ABX>UG3 :<]U\JEZ]GBF!676>F50!3>VH=H;A'3#E*AJUK8>MSTGV\0!(B
MPT67R0:0S2+Z/E/A:LZA3ZE*YYZZ.WE_(^P+)@1.(5)RMHX*+\V .,21U'!>
M@DO)LF,F/8, _$&=L1"C/GRVRCOO$4JAT3?)!U/X:3*>@G8)G[45 [TD L+@
M<#P/D4FD@TS"EXQ'3JW$F7')"D/G(6E[ ?Q$J0TI>4?_(+S)0*&'<,WQ\T7"
MW$\N80KI"'&[8#2<MK(0&C"=GEP*CM<=X_&DNK,I(2;!-JFYHUL6$(#^1XZ_
M2(F=EM<Q*+*GN^&N*ZG4@@NU57KY-*W,L&\#Q<K>/=^$9G:'E_GYWLO\E;W,
MS_=>YKV7^?.,DG^+40(7F\*LW6F(L-&+MR'9V/Q/KOD ET!Y51#YF->I4"W'
M?'W!G]I</U(4\K*VMD*5U1^$6*P W9M*ZRXQF8Y4>'SIJFI3BZJ9PQS!*)D-
M5/N3B$G@4^QW4UR!+*8!<\Z,ZUZ/1Y9W"YG(?'4+,FT8F%OS^,F81Q@P1M*_
MB8-_UP<UJ=C7JJKNC$?_1&/2$0;P0I_81 "VT^]9:*"20@.%RCYP(E-6FTNE
M#. D[\T9YE^U*;5B +29U9;E$UVB+H> >Z&*$@TF+W3:TH4XT%P7?P+M8->E
MV$\$DPK+3 2@'D8N"NP?2;1Z[(^JZ@13@7%5<?&0+MJJR.IK@:VX?J >B-#-
MN/.32M)_%^R1+*L!OS;."8:\0+OM_IP.H+*JREMYX1+68LV*,"J9-LW2?L'=
M\ 8B^SB(E9;=JK:GU,(@M84 HU3*R3W3KBFW LR49NT/RL$W^/)5P5O(F+5H
MIX:B8.0/-YR_G5'INX'&F@HVMC&QYA6)75H-$^<5^%$ C:3R8W.)$_S7T9/'
M\>/'CZ..F*&?7[O$ZR07YQ'5E,P;KC=OZE H*R2$)3\'N=@KDRUG2#7#&:%$
M5-'EIL$\6'.=Y(NAL 4C:Z2"E9NOF2G,(@OK[01D(HHWQ7($KOMT(]U4V0=V
M'#_,.Z;F^@5)-4M -WGT[F-NUB_&(S0P*SQ;IIZ.^A@/NW*H8/S](@_;>;YM
M2-^"R#2_MR^B&_23$YL7T9/'CY]XJ]?7$ M+1D8V@=Y6[.K7IMK &ZRP=YI:
MQ2:9*PC>?3O![_97'US23(O2F'O,[!+44_04H'^O7L.111EIF5TRQ2 ^ER6#
MPQ"/NTSR!?AJ,-J-E-161\0Q2+5Z7>^/1B44O8.%A4'<DBLA_I4S7=AF*8?0
MTKEVH9?,[M5]$ZKI%;HVDPY$@S$30K'NX 1.E1?\A_6/6K9JEU5F(X1,S)\)
MVSC&L.VT.;XA02'.Z6@G>GABYD%EA/I +N<B7P\$(I&%_-,GP\92A5[*3T'0
M,3KV?5]P>Q&EEMM#GB>4'B+^';70)"8$Y"095!%74:*@478R#J7AI=E"2F ,
M>"R'X_UPZ\*+0=/!W:-R(9UL2CQZ#JHINB]UU5.8VH#%X)SVY]'3Y-'1\XEA
MK.;1\Y3_.G"*SO9S"=V>J1'*7<YRN;M7Q$)*3[ C;Z 28Y>&J1L,%C-0*KU$
M6<.U6FI.L9T1%&@#>P-1(K$X.-PT$\4OX39Q5-K<M Y@6%(GRS(?D/J'YYAG
M#?:G(+$J!POMZX01:&O-2J,HR[S>Z%*VI3'Z%!=T$MX]W]TLWN&E="T2?QS_
M4VK)D*GK%^'S:_R.1Q,6$O):AU&S$QXKL<[ UV&@3&\/L5]XWC^_YO!X-!6O
M/LP;J&H!M_#0BB0SS$[Z/0LQ0SZ]B*^YK+*KR\:HG__.1&B&RLY7EM_%PSJP
MDA^S85JA=%>9=(IYAK6_!N<'!PJ'A7AB*#$["XZ.[DH>;*KY$ B59_WO 7%\
M1%'%J?+L@\$81E/V?Q!_XG#NT;]O0JV^PV?_W=YG_Y5]]M_M??9[G_WG690-
M)YJ#().)\KKKEQ3_SQEL-_9C3*\LZ>>L*C^0?UKX+V$[>:9;PYK2W"DL;"FH
M2*JP]_:SP'O^2M%F^7VQ.HJ3]":K.0%9'#,)]HW[0LE:TNF$.\T$9!S^3PIJ
M#/_K?8""!&"KH,,E^GOJJ?L"PDA8"^.7.C6VI'&_RA4/>4%\,31I_2\)&")4
MGS/R3@7>)#TB=E0MQ'^;1 V<)^$8Z *&J])6#J1[52ICI"U7E1] 27WNK#RP
M;?0PSX96XGEVT[B2PGV?$O/_L4TL7(!)X2,?#H&6+9<FQ4](Z<)BD@2M6I%G
MR$* K6'(3)"QK[B!%<\(-C;4N%7TU2:?6RN(OM!FUM(DA5+A_!C=B,1;=?3#
ML\=<NW!)Y;Z^C1K'NSXH)/WFA"='SC@>>7AD$'736,YNU.V&HF[6_R>..&>M
MZ.8MG"?DQ9;[Q.+U*JX9B?@>RF/='OQ")X;/* B()C>5>G1IM:K6^QWQNOU1
MO .#FMP*33/Y"CF!YA=TB!HF1#E7[O?@<%Z"L%Q0Z(?,8!0A\K,,%@M^,IEQ
ML> GDRMG?7>*N(ICQW'($2T/.2"Q&B WY-QUB')PZ2)2!<!C[+):K'$'(O2>
M#\86"^37$K &6T"5"<7-S8/<X) ;X@_J9<FYA#>'I=74M%JYH?ZHOI%'0W<N
M)-#>=L#<2EA?]TP8EUP]R:,G&.5MKBFN/ERC.>YQ'V&@EQ5IR^+^"R5<H8X8
M@%D""='D/#G*"M$7P.4I4$^U0'J6E HP0 + KL%<_-S$7>,EMUM-F.8R[/*]
M,1)#DYE)TM,UNIZ*4EQ![/S-,W/CH9Y.RY!I1T.X-@PI7K2-];HAT9[B'APB
M/& DDLH*VC1@CXX*5D&HCI&E $Z93'B)X ^8]ZHLLCEKW0L2=:I:1QU^9:A:
M*N;,7F)L/#SSV1Q0[GU&S'+<R=47YJ.ELZR6>AF&Z[.T>(Z,<35$-[[>U0^_
M7Q<.!FT-Q@ST9V!_?>W H+"<)G+2^^0@BA%?PKU!SM4S1P&TA:CH99E4%#9X
MY:!."F./^\Z''FT%@HS4(=JHKL(WHS3@(TTGZ>!!9<XE9: )V*=<?#C6A8*6
M,SKVJ79!F>%9LL*#8Q)"C8+2.(+"<!E*5D4\\(X'R5C"CC39H\9.C*_;Z6^V
MX= .Y>-S8%F7"Z>])]E02%S4Z/J\!Y9@B9GB%U*E!QJBY0E;LGFWY&MA/A68
MC  $8'U%WME!T!Y)AI<C0W_;.6H6;0XFG:U4GR$DR;E'Z,7FHZF0[=\^8&?4
M3\Z@MT$C988HX/J=[,PQ4O8.EL:Q(_"#LG2_F+1<$4=O\(MOXKBZ(Q[P_3X>
M\)7C =_OXP'[>,#GW=1KNJE?N4AS6 ]HJ,960+8]Q//U^6[B4)6GC#AX!=//
M.FZ K DJ+-^!5 W\_ D7!BHYR"^N\VOMZ5$)@>KBXFL3+R@*+-A+L:A-+E9
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ML78C;1WDG$\*5AE_;8OM]6X&WXWJ](VM_D&IG;#,AH/-, 4!,,B>+/:*(9O
MWS#WOJ+CR-6NA:-9LFL'*T-BXJLK#7F?<K8V7\_7IG24&H1"AX]MQE>X/IYX
MFEQQUKU& 5/VKVU.A1RH.=ZYO+==S-(1.)4&[4Z)O7!2KM<<\!!S'D+\@VB%
M8.#7V2S3CG@ZPW&+N1+'.+U2CY@TRB#+0);97L.V(CR1R9%S^L;D,(NIO:DY
M8X5?U5?3-"$6=M*#; 0 -X>#%Z]/E&\Z?.1,<(0]"]>Z$)+YOK$2YGJD]HZ#
ML[OOPGY]$Q;3=B?ED\=[)^77=5(^>;QW4NZ=E)_G++B^Y@),&$P:C]YQ-:VS
M/+&\52=DXNI26U>8,=H_@#?3.?4+==W".6R;(93E0#D?5D>1GF%#9+??K$-9
M"F.%95>R#DFXPS"OOL$PF8<=@8%F#WX7:7.YKI[%3G \E$U/-GOP_ELAD"+-
M*:.::6Z$/#.N\D]X66,]^\'YM0GL]QNZ A_-/Z1)+T@G5SS9=G"7@>8CKW'N
M%F<M"K<@-4<$@ZZ&"'HSUWSYL16-4]AI,0XZ5SMNCC@LY^=_-2]+1+U8%S U
M0K2)+)&V'5S26.P#(D=0>0F"R2V*$A13Y[94.7VZ5LX00P9J@5T;T#.B!'5:
MV[RQNC/K9-_$#;_K@Z)3 8ZY=Y0\2/:6I--@%CV6LI+B<I^22O,I)#VJ8J2M
M^\@,_JH,(@%F/ /X'0D: :NF<N?B8^2ZK9/"%C03#XRN1\0S$?F)0#>QGHG
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MIP.O@9Z-1]"MBW=O7@6MGK^'UQP]>Q;CO,)/X;?X(IC2,YA(Z!XNY/')Z?]
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MR_ R<(8PU!C\ H@3 $,K0EO!11Y5$-T;+&+"6ST&IJ\@,3MFE1$C&Z)7J:.
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MYL\L\9U=0,A36BP450.\^>#5DVH\6$[("ASP,<?-]M1+&MJFVV4;JR4)4=B
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MUP6K'CE8]5T7K.J"5?<[^U[3V;<0Y \>.Q0\HA.//?^QED'.=;4 IZ#D1./
MDW'VYN8F.B-7=Y85);!@&NN9$E.;^7IVS9:_0OT)*D0Q6OPQJHSS90!^BZ=I
M+,S[E&0ZI\03'@ (()R0V1\#-F%&Q/LVV;91 ?IS&\U'-D.VZ[,D7@:6X] ]
MG>^M4R@7B(+4#'+KF(3!N3D34$Z'A=N)70M@B9*PLYZ\Z;9I0 %\_5E>%VQB
M]].,("6-IB4.#8[@DIWK,R<]D)8<\[NQ@7SD4Q;6(_I7*/Z%Y-3<G4-AP,#7
MAQR/2ER/S:HUZRZ'_),Y0%-S?=R$K'(V)LE>E_A1.E.LL6X7("^@-3XFGV=7
M=EE7Y 3RKXFE:!SY"4R*R\'5K9QQ^,Z6,<!MFA"T'@-C@A9!9* I%ZN%/H#2
M3B+;DV@.E9S,EEQ# ]:=5936.(^]%A5Q#/H_\1BVAL=,[,1(6E2OSS0&&D(;
M?"W,TKB$=<_MZ_<$YPR1@(DYAV$'8JPC+2)EJJYQ7WN\R[3;!"<!IS'U5+O4
M%57%EN9Z$!!N+=?B2/:]%?:!8(JF(=+X#16%I!0$(:<HC@KW\'ARC32-@-ZB
MZ[H:CVZ'/[&NF!V.Y2C'T35Y J=Q&0P@_L\(80%HE39:KK<:ZVO"L2%@?OYG
M8='Q]FY7U=IM6L"(4>OWU*V6PB@(7G,W7(7,+RU4*^3C&],*]?8PZHLA!$X_
MSX-9Y:J8*B=D%][YQ)> FAQ7+89(.17=JP2UIGFT!.9A;HCQ(\Q#,.@68N@Q
M@G$.Q=BQE":JP5]D.6OL82MR)016<JG=%/H\P;1B1/%1AQ*&$%?&'_;OO8%Q
M!HHRIK?&5-V6U[#'$AU(T3!K[G4BC[8AC<AQKY]'Z>=\N2C';,P)M0<:; S:
MP]^.25P,G@IC;?I4HI-!7A\,\)@=,XP.E-[R4W:(]$BSW%DBG1[)_4F3+ 1.
M%P/#:1C)"P/4E0+(K+"4DS%@4$I(-M?%@E6.Q$R.2Y+(JKN,)DXS O62!*96
M66MF$633J?U\-J8CH;.23ZPKQDIBL=7(O& 1XUOZO4/*=WDEL9(..U('-RP6
MC";JH@LE&6A3HQ8@0#L?;%QVE3J)4L(YL^P#Q\-@'ZP2TQ$\W)U&PXU M*W@
M'8;JP>D@@?+)/$D3<U&@U$&]X+!2@.'*);@U_1YV8PR91]RUCO=70<6M/NTE
MH7+A=WZGQ+OS:U)HS.[RR7[/1BKM:#8U'J]I]A-%\TO78NFNUR[$PJ93V'B3
MZ!H@\:?FI()_!>\A#HC_BLNQC6+@"HL*<BL6"Y"3-YMK$EU;$'@9?5::( YI
M2,?.(LD]>#A!3371/-]A"&EL,XAR#0CVEH7QV8V[CR3@+N+-+Q+)(H1BR"%!
M+W'H#G1'+,$!TJUC:1(A._4;NH/CB77%+%FL^-E7!3P*'=9PK5277%0Y_X;6
MHE^9)D80C2X= .RQ@"L!N(L%<#HLTX1H!> C++7<?FL, XEU<7*=M+=0U)*+
M<YQ@CCAFE ^W*)IH?IY<+$DT,\ICZZP6V0Q]*BY[P9MC'DU+AUYFU07>.%RS
M8N^Z]REL8G_6$FQ8I12$_DC@@L,)Z,EAI(&]<\SF(+%%CM5)0F1?4(C3O-G3
MQTW2]JN,=2E5<034G+ <]A3/8-+KQ>*6NE8Q6#CZ3Z17,1TJ0OZ[.6#/60U-
M8[ EMZA+F!J%?7'*T.%4>@TB.] I;S_IKNQNO=P.?MH#4;Q/@]%OPY-^[^A=
M\.O'D]^#LY/1X  L#$@?;O&'1H?!X/#W8+!_-CHZ-(_].#H+@Z.3X/CD:'\X
MA&19P!\QSQB=OAWA!X.]DZ./O[P_"_9^Q[\=#T[.S+]^&8P.3\_P-T=G[X<G
M]'O3YO=#<V\']<7A:3 <[+\/_NOPZ)-Y]@%\_:UYP]GP$)X[.#B CQ_!-X)?
M3H:#LZ%YWO"?\.?@>'CR871V-GR+;ST^/ACM8V+O8/#)G/'#DR'\>N_TZ.#C
MV1 >\_%P_^CP[<@]=W1R,OSM"+[T>[\'[QW^\_AD>'IJ6H%C=1J\.S*?,.W&
MH8+7P,"I(7NH%=*>TZQQ3E$V\(&%,&7![SV<ON!7[=+&3Z.?3P5F:)8:TON]
M0]F4G[X9_;RY'KW\*TGV[[LD^R,GV;_ODNSW.>H>F!;_JQRRH\-^[]/H[-"<
M'<$G.'F.WH5-T$T*?$#XTA$PB&Z\1!U\SABH:%S.KAV"D0KQ?!<_6I:760ZB
M3E#F#%8O0Y&SR+ISZ*Q-D[PHD7YO3-#*\VSU5;,LE:EW%D-;B*H%N7?K/ /2
M:FC^@7M"F9.[OZ#!\/Q#=I@Q-OM'T)_#__>/E_=N_$/+7>\-C>M#+0-W;' \
M_'@VVC\U_M;^EG?X&SME.V"G28S7DQPHU<@OW_*_NB9W_^-!.>/-=QIGL'+*
MMI[:],Q[]> U=*%I[.6=TM-M_W-/:3H>5'$)O8$;9^%K-*M%/N@Y;):''(8S
MP'@\P>FY3;3H]GEB?W*]KC+/M"__77_4*LJ3"+I0S*/9[,78>!S_^/ED^&$P
M.GS+(9GCP2]#/_ 1' S?G05[!X/#_[(#LP[C<\?A.1W]<C@X^W@RI*%Y!T&H
MCR?[[P>GPQ/S7P<'1Y].>4#^YW&=V*=Q<_^AN[D_\LW]A^[FWK+R'_62_@@6
MV!J*?L\W(Z<03#X=[G\\&6'P63X8#'XY&0X_&..['K;D.<H<M$91J(R?R  >
M/802J @*(K:>= CE:2^C+U!M T8<:U(L:N?-3Q\?6)VT^]G]_/L_*6WXS+;7
M,[4*?OK/6(>!L^^G;-^O/3@FI 6MJEMG0!YS"SR71?1,U[X]$9O6?+?$NY_=
M%OW:S<8X=+='NY_=?GT6S48AYWYOP S9W;Y=YY_=COH"S7XG')']WN$2Q">Z
M3?5L?W8;Y@LTF\\>TF0XM$QE*NK9[9/N9[<GOV2SWWX:[-.&)$ZB;@]V/Y_\
MS\XR?(%F:T5Y<V]$27DLXH0OF"<-J++R3?!_UL%D=$OJ2RPI/&*(?M%?1.NP
MA)[OSV[Q/P%[NK=6]K1;6%_1JNYU5O7)_.RVP!=H]G&<]WNX#QR \AC(3+HM
MT"W^M5_\O.+[/5SRZWM'>_H_N_7^==?[.OK03_]GM^J_!'X#2DLHS]Q5!SSD
MNGUFZZ!Q^=Y<=OEZNRN[?-RRR]?;_\YEEUW5_</QVX ,\C_?C_9&9_W>0%CZ
MUJ9W,EEKU*5W63['V-M)?,&4XEG*!.BNB'.MNMPZB[<<0SL_!D<8_B[>! ?
M4MV=18]Q%NW\U;/HB^O5R4[X9N_H[>] _/+-^[,/!S__?U!+ P04    " #
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M^_XYW=#AG) BO%R2OC4X+75T?IK!G;N&%\"LF$ER31B5H(] @D9EI?^>3GZ
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M8T)#M2Z K]6#ZYMLM$C?%70R-E56DJN5+$?.=:&TU;@GI@#ZP@8]D7A:*$Q
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M! U6A <X3O%7AEZ1@=\6EMU3_ >5N8)U0$EK).G/=Y[F.RWI/,;V3E "&*E
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M'=%]Q%5<<.#R,VC++O1WN+9X*]2\^D#!PT6DMJ.E' V;]=J.LL&*_4"-0L)
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M?K7+@H\Z++ >,M>Q'<+: B. ;UMK>#K!(QDEQ^59.H#N#M#(8^ANA5<[C_N
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M4K#7<[S\J>:D1?!K93'OQ(5,;UP$F?TH<JL$: E=9J9*41SI$("4Z;9J$SM
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M&NEO[8O20"9M73OH@6*I*-&'TGZ$0+M>$P\!KDGJ(NEJ:0@QX^(J0I%V4P2
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M$ML&D-9J1. /.T3@#A&X0^+LD#BWC,2YW!Z_':(05%XYIBT*\6?-]3U0T$%
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M*S:%+>R<_-FX ?3AX#)-.@03/MG^@)71FQ\]!O:RW%OL12/--:+GF,F$,Z5
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MFICHN8UHMGPY7><.UT-(N(N\Z25<)^]A!O QG9F?.,6E0_8PL2^:*\4C8"
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MR"3*WR.II6"OI;7$L^5Q>@XY$:[YWT7YGLP\*PA$?J:_FK1DZS&+KHUKZZ(
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M0.N-%.E4]MP%T!+LFK+B"G%:&D)FCWIEC %OBE8Z)Q=JG608ODK1.=\="LD
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M\N--7@,KXCPN'%?XI#56F;2&"3RC[ 3'A=*$]:/Z1#S3Z"U)(5G3/27DQ=@
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M9DA76?6LYPB&_'L=1X G[<#T0M6Z=6R #_HQCWZR4B*U$K_J_<;5))A$G*O
MQ6I\QD2QGWK&RR[Z&D>,9]!UJ*7]F^&<K^7PZ$GU<)2A2K>/2_.&MIVZ. --
M2%0-FZ[)&9/6)_$L7A756FI4G^_W7IS]]NYE5;]XC/^EUG]6B:NJ=EG>4I!F
MSK/B3J;45!I+1MK^G%SIYXJ,SV]% [ (0@+SX:>[U;"< JPR)_'T-)GT>T(Z
M8QHS2&<TJ>B<<W1A'ZQ?-XTU' X8BZX;<%/O4@^5/KLJBM_GQ36H+Q=B8%EF
M, U0,$@7[1<ZIW"_X%[R5AO2DNWPTQ8;6*">-Y),G6)9W)Q[R5% %@R@/+&J
MD3DLBR5'I-.3O,=@6GW3QCCTLQ'R')<EW3I[4B/QBBB'$._^.'"TE&FB")L*
MATP.E05:ATX0#(BO(#:ZQ*[CA\70/'J?!*R6<WY>LY M =,F0=\JNN*)O59I
MJ?BAAG^ZP-D9MM(Z.3X<\W=E3Z-M$%56XW;R=<%@^/Y"97JOEY?U, (J'Q&2
M_'$;DMR&).]12/(+=[3_P72T!\K">IU]4T*Q;6U_CWF?M+9GY>4@I?I@Z71C
MU6_IE@ >Y<8"S0>!FB4K7>"6]LR.F 5U.0(9Q-WD91(.4 F)3G0=3M/*V*HH
M*:V_5?E79>>:]7DT^KZA@)2)%SD/'?[5I%=11O*:?1P<$(FNBG2JM/MIT4SJ
MT#$Z.%#G&IT=ZZZGH4_7W@L9C?1F+JZMR-HR)X;DK<PB/U353/B9:@T?'=5'
MX?EDF*Q8=DRD4-Q3<3&?8&MNN^8?,4DBSM8+2JD+Y&.ND*[&Z[X>-90Y@B&#
M5=]]/WG(KL:\C95N6\%FGKP[SJ*JXN8(8EOU&WAAZZSB:)$BY$"E,%[)^^5<
M@]I P[0R_DWFIX-!$CE%$J8X E:'F,6%I;@O]V0IS].( \(*::%&VZTIVQ$&
M:]+C7CM6VEZ0@DF;&*KPD9DGT%M!;NU"P]RNG.I:YK-Y*QNC5JD&Y<ZZI?&6
M3OO#*!J;J0 UVM9J]ST</D!SBSU<JHRS$UVB4U?UCS[D&8X"6&S+9DKH-I[J
MLUQK5N9[FEB["8NZO>QKYENGK=<R>>12>B<'B'N'FYR+U&J4B[:0EX@[;7(7
M48E%@PVA84J%S]=N,FSZHJ3'\QF6!*&A4P>G7"Q\ @2)^:Y5+T";73'K _FE
MNTE!+<;%L92&M@?CHL2Z5VSF3MR<[.0DRRIZHE<<%QH>SBX=JZ3I7U3RH(Y7
M7=0+L:]K2B$.8!*1:5:#W&$X,+7/+3Y6*B1UNAGLTVDU5-3.&][*'CRQ5GC5
M9C+2\S 43<#X0#RHRZV7L2Y@"J];7W<K\F*#FZ1:+2K0) WUCON!;L>U.#V/
M8ONM"?^[75OH"_+W:I C29S!.-@%]@ 4$K0\'ZC=Z5B*ZC-AE)*^S)L5;IVQ
M3T9R-@CU]U.X5Y$2*R";:E!;<RU:B+1#RQ=<,I"2VH+.^6%\ PX@E_-MC1O:
MX1GRQ9D3E9]:I-MW1*7ITZDC5IX)KYQM,&HW;"!N8G=L"#@ILYNH:9&8!UH(
M(U)QNA!9J,L^W/=+VB(L$=0L)3-5((A=_2I:MN*<N_?2<1X[-:KNU'S34G>3
M5SL<C*BMF"=#RBT]\06X([4Z_PFT7L4)#_[?B5-=3D KFG2Q<8LGR0T1Z,SU
MAUL8W\BZB3;Q<"GB34W2>'R\<N@VIA/A7A3=4PGTH;!&LNKVW;D*L=4'5BQ*
MFI@?V"8V:P '#96_:$I0&0]KFOVA#XIOBB::%*Z+M8_U;Z)6DUG.\MIU 0AN
M2U4ER((<-4!DF/4#BA'TB//0,E:E^9UE^MG."+C$JP#*:.;N-+E?0:4TAW:*
M66CT$/QVP8+,MI_55L @"PPIS&8AY8(XZGZH:Y)0!I#><\$QHZ"*+Y,YFQ#F
M8VLJJJC08,6.74A4FQ!:7:&18YJD-"[6UQD4RWHT^CBH_1Y3:#;ODQ@6W.-P
M8(TGR4S8BJ2MPP1WKL(LS<+0.DNP5&6Q1KP[I07T:*_6HIL2+U-:.L=Q*Y7$
M<1@0J=Z!2F(.F++C?20S,CD"HGT8S8-ES:>J'L[K^A6/H$_O& X^@^+1OC:V
MB!\5NC?0Q)J%HWTL\4_ZE(\EKS.YEE8.?O<AQ1#$HO I'E:;HP>KA]S'DLN]
MW6V <QO@W*K"K9K+-TT^C0B.0>K364\R#;,_*1H6^M*20VF2G=UP8HKZ"QUD
MG":+^C)G%4M>O)E8);YDUJ7G"<5OI$,G7E?MXVXKXY3S0N\C5<5M*4DAI$Z@
M:J1*ZT4E1S=B"GI'R54SI%-P'T:$.AKWKLN9,CH<0KBLI$MF:8P('<CE*SA\
MUFH5>$3(ZM.-I&E9Q@(5]ZO:DRSCQ)L);GK-E536I,6.,#L;@8I>2A*N;X-5
M\(L0^'D-]GK@E R.]8RF23E$)?_%2;^2J,^?C%0QBS\[S3V+,9<4L4;JH@:S
MXB7*5C<A%W6L!>I6A.&.XCM!G$ U.6M:\+JT5(K!S&NY$*1687E2J<1%@3U$
M,9:84=2+):RE 2+X,QQN'9@VA4YXR#70*,BW[OT(UK@>PX%-;%U;"I3P\B+*
MT_]8\16Q"/5GOOQ0<0S#P3195:@@G-G3SD'QQK1BPB801/#TJEB)[J1U0M,U
M3X7CI,MVD.[-+;>0>$DSGW/1D[%O><6:^)VFGSS725-AN+AR0EB693T<^+&_
MW4,).T?"]O$CN$Z,@>>Q>L>J9,OITGN-^J+*E[>_&0[$E5#Q/E 4K(=B>S3H
MD<D$4!':ODX 5E*OVT2XA/.Q/JC034)X)]R<%#/YN.WQTLZM[7']P[ KTG^8
ML!WKG>8X&)$_P'8B+!&A;F!$M;\DFTM'I&S0U16YN![G0Q=J0&*X5G/(-N9*
MT-M2PBJC;G>Y<)L.6%4(!5:/E4Y?T9X=6>TTP.OI9L 6ZR,WZH20]4+V F6O
MLT21L.A.=&!PBM*C4)")EE)N#H]37G&6?-Q.E.9HHNI3SEB&TT0$8"NXMI^!
MFIZC#?S:_IE-2UPME5Z1 \=GQO;M/J5HF%S8M78):<B$8/J+_UMUP%YBN3/2
M"/R4L?+Z>, :M/^C#<39R9E8G@D3+5 FE;HRAH+'$NY4*<GTGIX#-IVL*<"I
MP:OZ?JZ+9USL,11M*G,!TWF<G*.E!^#OUZR3JL7IX=T$F*VX@WIF2WI])&W*
M:-:2)P_'0U5.\CC7*P,_NE+-:]GKC%HD<\HY<"8.CL^6O9#R^CI.<46KN#V8
M>"YE<9<%+4*C'2Q5 ]F))RQ6DOY[=]3K^Z*D(GZ]]@)WYM![[+5Z=V5DR2TP
M^W2]J(3+>J;>!A<PF?S8\Y14N 8GYZ;=F"J*4-TK8:V>VA@R681E@LZ*CL";
M530JY(AEJ@A^!Z8NYN:R<DOD<I"@%679>WJ'-<:Z#:].)1P4".8)JC*RBL9>
MZ+UCI<%7/^%;/ TK;6D49<NXXH[MP@)Q>R##5"N3)MA+XN?>NQI3LR!W^\WN
M]A)KH'M<=:S@E(O4C9!#G=N56F?Z58?T*EM<$0N$39X3KU*5K6*@DOZ@*]1]
M*7VJ$Q+EQ2TY;A?;WU[9@>!-5GW52$L*RWY 06.9-J9 6.N+-&P,W+Z8XP7!
M\AX)4Y-!'B>&[]T8<,&"[Y+%'$A30"EBU7$I."8E&YO<\%!$[,BBF_&:\E6G
M[(5N1S;7#QW:[<JL&3!2$EMZRI'=B^I"'@;BH1KUKTT@NFV3)(ZJ74VINHK4
M<->AH4)Y:>[;814$Z>_^1:3=4E(HSYGKJZI%P;:.3R'JY,IRF\OVDD9HS:34
M[8JD%=^Z,36 XIPN+6%6QN48ST!K>;=LMS$<K!>=NZ5BO1ZEL2(A2"[V\-SW
M36)S##W3G@'_1.,UZ%?UG<4(L:-\+2]L;6(XT.K$DLVW_1<K+Q*.HP==-L/0
MKBQG-)F>I>C,ELYV,%:6#A::;BS *VI+>TK@R6*>QH&SW"4J>Y]!I]T?=IBK
M9SND ZR^7WV\SGMO-<"=*GM5. PMFU(KZ<LTK>Z%9(%(8I T<9XJ(?# !-*Z
MJ17LZJ@JV":>=7O_J*#RZ@EXY,C'"*SAP$@L/C,+W5!DK@/R80,)T /$1I-(
MUR2W=T8.#5.C=4YAPFTA23'!+Q?%M5!L6R";Y&\1Z[>4Y7>S,ZYZI_ ;JR#M
M8\^8(T%^#@1-GJKT'J=S)J56?!5YW2M"I7O;4.DV5+H-E:I%S3A4^EIP_DS2
MX#X97.93F\%I$Z(%E*];I* >4 >QN)SMS_8> ]'5EU(:@PJ# F :#BP$)A_T
MJ/WB-1VA#CB=E.U1;905 N#,ITC\%B@2P4:UB[E $*SM4_R(LB[_M+X*5KWI
MB[K@RV, \,07\EEJJ.E_]^[5\6T;LVT;L\$L-ZB=C $ZT(TQVCY_%G]_7"9Y
MXFD>S6$!$$4Z#&);UX1;HTRE/JGE0;2D9A1@GRUJNVUUX:!Y3FX"L#C)640Q
M?@+I0U\Q<Y\N3F WF&$J=JTR7;)Y^&'I^D4C1,&DQ![<A-.HBM?)+QS%M>KM
MH<L*S'C;-F#W>EKWYC)NVX!]X6EM4A<P!4$L+'L?(WTV?YNH3EP:^62TW\F<
M$F-%*I=L( X%.>:I6*+8$7# *^[R-<?8O&GQU$IX>[7ZG1C.QF3UO,A+#"1P
M1@:&8BU8$$YE+),I=8WVIZV%/(O1Z[YWZH;!]#W5AHJSC7)K3 2YFQ WL]I4
MJVIL=AY/L$GIA.,+;*!)CA'.904,AZF^YJ032N*3TMG1 2^#HT11IEVC-IJ#
MQ^NF#375K$DW(XN+/+=;9?I2!OO11%HIMZ7*QM6IFNV)H$; "5DAMUKA=E<L
MJG7+M!4YK;0#G-/J6>NM4W95UZWEV8TJC\Z7TMA.8UR=2XH!U$-/OK'5[]6A
MRZLB:[A?7B$=Y>1/N(5P E+&E*5PNN8PKE,VW9N%WK79+$J])*+2TZ3:3?J0
MZVJWOB@SNPP8-3JJ P%PG$E3V.@BR>.; -MN"&2?)X;1#3_Y&O&&EM/9?K5!
MWX2S85VOI1!*X]P,$W)%&9Q.2TSJH[H:D^"21*7I$\S7<5(4[TW#O,Z6Z43?
M^AI4NIM@]&1WC-X@8$\PUC2ZJ=RPBH5N('5CJ*"ZP"CL@A8=%+G@+,6:KXAG
MH;18#.'!R8X^C*T(A;=6GW;)K=BW-M]!>0D=GAY:G#4TG$ZZ[VKP":3'F?-*
MP==4K^VOGEO)77E('LLN%&,H5YR'?^I5S]P-E_96X^&EO/%MJ"H*[!2E6MQ/
M! TSP%!R_ U'*]O\!#.A/V#2EG*\M5!TL* A*Z@P0((AG2WDU$,S"H:O=&Z\
M0[/>??66KOHSY'T#42FEA\>Y^"-R3'Q+321[K1U=>S-];3V!T64-G[*\7;BK
MA=XK^@RCI.)3"M94:NETY\+:Z3R)!![-U#,8; 7Y8C(=3*VRQ(OM=ID340+T
MU=893SPG;U,7G*1,62_4A,@)D)9BF7P=!2"U0H!KH&T0G=C8.G\DR/PIX<]:
M\H83!%0,N5.:865P.(+4*Q7 [FXR$-A)T50@L"E/R]YQ3V<![1DP'6.#UQ3Z
MK8-3[DH /WJ#H>-_/?J_G/3DY#]S7R>'BE525<N^W]=)E8Z844YI7JZX&4!'
MT9BZ4T8&P(>>[')C3FJA@.K"7'*\1&XXL6*%/7Y9%LT%K[O%[64J#%0%_.OB
M(M'> H?C)[JE$7K^W?[R'[!;"6YWN]_=9V^L2?_[I,?9^J5#F$^V(<QM"/,>
M16&^2$3"!K3]EP:T_15TBHBR<EI=A('-8D:>^?2+X=QN0VNW0+KUG>>*7JFB
M[+1:IH9VVRWED/_7*$8SF07<J0">6D"ZP0%%@P5$PS+2$<NNICGI?.N2\?<Y
M,RPU]0Y]P^KWSL!NE2QI5H1U>I;SZ'!@/XO3(5<1"$>5%L3PDY7JR2/-%[ &
M4%JHSU(8&LRET=XSIU5/U?=.9[JLL&&T8NDFF T826=TZ=]@94A;;5\ZK34M
M=+EQ.Q?;1PW# 4ZO4Y#FJ'"H6:BH2JL/DZS%RS?$5::[S>?]/V5"B=!>4T9
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M=%CU2J)!@.1WNA0U*@98^@L1?J%VF#^9...C0A43K!IK5UCI=<18SS6" LN
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MA.5"]569 &EJYVU;'S'7&YGB3:8#O+[+2L6^QZZ,'C0Y%W>L9?>XE94/L@"
M8W1H5>G&(/A.-]R^R4>[S+(M02^-X2XN#^'@NJ.?#%T7%JU"_!$:GOL]Z$N3
M"VSHM5!@'3MV#]DQ5ZSFRCN>'?T[PRS &H82QFXJPV4.(H[;+R2&^">C2MG]
M)@/R?K=M@X3C%G%B')X$HV8.Z/T,08@&FL;&F8-<KE0&K9(Z:B%!?@0"Q+^
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M_6WM_*3!ZLVSL]/+R]/F^0O%L*PP_,3=KF'=>K:575TYJK,RN$$[+Q2GE[V
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MGE20:X>Q@4AW@_%0VBZ.Z;^I&8XCJA:)3>+J"G30CD^9I(1,^$Z9L^24!95
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M8VR>^,Z$]!L%GD),'V'5HT%EDN-S]9PN#9LEUI5\:28L^2*.B)\'UW#6=?"
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MX&1=P$<>,TGUMJ++S4YX6B_M,E$MT!3W<<\0]<=]KVL[ +X^M[SL,LWT\NS
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M^']02P$"% ,4    " # B:)4N3::KC #  #)"P  $0              @ $
M    86)E;RTR,#(R,#0R.2YX<V102P$"% ,4    " # B:)4O^K2D/T*  "
MA@  %0              @ %? P  86)E;RTR,#(R,#0R.5]L86(N>&UL4$L!
M A0#%     @ P(FB5'R/-?A;!P  Z5<  !4              ( !CPX  &%B
M96\M,C R,C T,CE?<')E+GAM;%!+ 0(4 Q0    ( ,")HE1/!VDU::@  ,XT
M!  *              "  1T6  !E>#$P+3$N:'1M4$L! A0#%     @ P(FB
M5#ON9AV<1   /+0!  H              ( !KKX  &5X,3 M,BYH=&U02P$"
M% ,4    " # B:)4EJD6\)53  !:+@( "0              @ %R P$ 97@S
M+3$N:'1M4$L! A0#%     @ P(FB5)G*4I(V40  U1H"  D
M ( !+E<! &5X,RTR+FAT;5!+ 0(4 Q0    ( ,")HE3@>%ID& \  % ^   *
M              "  8NH 0!E>#DY+3$N:'1M4$L! A0#%     @ P(FB5,\/
M^>OY'@  /N8   L              ( !R[<! &9O<FTX+6LN:'1M4$L%!@
0   )  D % (  .W6 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
